Dibenzodiazepinone-type mAChR ligands: radio- and fluorescence labeling enable unveiling of dualsteric M₂R binding and conjugation to short peptides as an avenue to highly selective M₂R ligands by Pegoli, Andrea
 Dibenzodiazepinone-type mAChR ligands: radio- 
and fluorescence labeling enable unveiling of 
dualsteric M2R binding and conjugation to short 
peptides as an avenue to highly selective M2R 
ligands 
 
Dissertation 
zur Erlangung des Doktorgrades der Naturwissenschaften (Dr. rer. nat.)     
an der Fakultät für Chemie und Pharmazie 
der Universität Regensburg 
 
 
 
 
 
 
 
vorgelegt von 
Andrea Pegoli 
aus Senigallia (Italy) 
2017
 
 Die vorliegende Arbeit entstand in der Zeit von Oktober 2013 bis März 2017 unter 
der Leitung von Herrn Prof. Dr. A. Buschauer und Herrn Dr. M. Keller am Institut für 
Pharmazie der Naturwissenschaftlichen Fakultät IV – Chemie und Pharmazie- der 
Universität Regensburg. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Das Promotionsgesuch wurde eingereicht im März 2017 
Tag der mündlichen Prüfung: 10.05.2017 
Prüfungsausschuss: 
Prof. Dr. B. Dick     (Vorsitzender)  
Prof. Dr. A. Buschauer    (Erstgutachter) 
Prof. Dr. G. Bernhardt    (Zweitgutachter) 
Prof. Dr. S. Elz     (Drittprüfer) 
  
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
a Laura 
 
 
 
 
 
 
 
 
 
 I 
ACKNOWLEDGMENT 
I would like to take this opportunity to thank all the people that have contributed to the 
realization of this work and have accompanied me during the period of my doctoral thesis. 
I would like to thank: 
Dr. Max Keller, for the opportunity to work on this challenging and versatile project, for the 
inspiring and useful discussion, for the support during these years and for the constructive 
critic that made this work possible,  
Prof. Dr. Armin Buschauer, for let me working in his research group, for the inspiring 
suggestions and for the scientific advice and support,  
Prof. Dr. Günther Bernhardt, for his interest in the progress of the work, for his helpful advice 
and for the critical revision of the present thesis, 
Dr. Nicholas Holliday, for his supervision during my staying at the University of Nottingham, 
for the stimulating conversations and for the constructive criticism, 
Xueke She, for the synthesis of various dibenzodiazepinone-type MRs ligands described in 
Chapter 2-4 and for the valuable ideas,  
Dr. David Wifling, for the molecular dynamics simulations of 19 and 33 at the M2R described 
in Chapter 2, for the helpful discussions, and for the critical review of my manuscript, 
Jessica Carpenter, for the help in carrying out confocal microscope experiments as well for 
her hospitality during me staying at the University of Nottingham, 
Brigitte Wenzl and Susanne Bollwein for the cultivation of CHO-Mx cells and for their 
excellent support with radioligand binding assays, 
Maria Beer-Krön and Dita Fritsch for the preparation of M2-homogenates, for the cultivation 
of CHO-Mx cells and for the help with radioligand binding assays, 
Elvira Schreiber, for the support with the investigation of fluorescent ligands at FACS, 
Peter Richthammer for many tips and advices on the reparation of lab equipment as well 
as for the help with the preparation of the student Praktikum courses, 
Karin Reindl for the friendly support with all the bureaucratic and organization matters, 
Seema Rajani, for the support with the confocal microscope experiments at the University 
of Nottingham, 
All employees of the analytical departments of the University of Regensburg for the NMR 
and mass spectra. Special thanks go to Fritz Kastner and Josef Kiermaier for the useful 
discussions and the excellent assistance, 
Prof. Dr. Peter Gmeiner and Dr. Harald Hübner for performing IP1 functional assays at the 
M2R reported in Chapter 2 and for the critical review of my manuscript, 
The GRK 1910, for the financial support and for all the interesting events organized during 
the last years, 
All the members of the GRK 1910, for the critical and helpful scientific discussions and for 
sharing their results during our retreatments, 
 II 
Frauke Antoni, Nicole Plank, Timo Littmann, and Stefanie Dukorn with whom I have shared 
office/labs in the last years, 
All my colleagues for the excellent working atmosphere and for the good time we had in 
and outside the University,  
All the PhD students and Post-Docs in the Cell Signaling group at the University of 
Nottingham for the interesting conversations and the help in the lab, 
Un ringraziamento speciale (ed in ordine sparso) va a Andrea, Matteo, Salvatore, 
Polyssena, Nadia e Valeria per tutte le serate passate insieme (e per i frequenti postumi 
del giorno dopo). Grazie per aver reso il tutto un po’ più divertente, 
Mio padre e mia madre, perchè nonostante la distanza mi sono sempre stati vicini, 
Ed infine Laura, per ogni singolo momento passato insieme. 
  
 III 
Contents 
Chapter 1 General introduction ........................................................................... 1 
1.1 Muscarinic acetylcholine receptors: an overview .................................................. 2 
1.2 Allosteric modulation of GPCRs and MRs ............................................................ 4 
1.2.1 Methods to investigate allosteric interactions ................................................ 5 
1.2.1.1 Radioligand binding assays .................................................................... 5 
1.2.1.2 Functional assays ................................................................................... 7 
1.3 Muscarinic receptor ligands (MRs ligands) ........................................................... 7 
1.3.1 MR agonists ................................................................................................... 7 
1.3.2 MR antagonists .............................................................................................. 8 
1.3.3 MR allosteric modulators ............................................................................. 10 
1.3.4 Dualsteric/bitopic MR ligands ....................................................................... 11 
1.3.5 Dimeric MR ligands ...................................................................................... 13 
1.4 Radioligands for MRs .......................................................................................... 14 
1.5 Scope and objectives .......................................................................................... 16 
1.6 References .......................................................................................................... 18 
Chapter 2 Radiolabeled dibenzodiazepinone-type muscarinic receptor ligands 
enable unveiling of dualsteric binding at the M2R ........................................... 29 
2.1 Introduction ......................................................................................................... 30 
2.2 Results and Discussion ....................................................................................... 32 
2.2.1 Chemistry ..................................................................................................... 32 
2.2.2 Synthesis of radiolabeled dibenzodiazepinone derivatives .......................... 35 
2.2.3 Equilibrium competition binding studies with [3H]NMS ................................. 37 
2.2.4 Functional studies ........................................................................................ 39 
2.2.5 Characterization of [3H]19, [3H]33 and [3H]47 .............................................. 40 
2.2.6 M2R equilibrium competition binding with [3H]19 and [3H]33 ........................ 46 
2.2.7 Schild-like analysis with 8 and 9 at the M2R using [3H]19 and [3H]33 .......... 48 
2.2.8 Molecular dynamics simulations .................................................................. 51 
2.2.9 M2R binding studies with 50 ......................................................................... 57 
2.3. Conclusion .......................................................................................................... 58 
2.4. Experimental Section .......................................................................................... 59 
2.4.1 General experimental conditions ................................................................. 59 
2.4.2 Compound characterization ......................................................................... 60 
2.4.3 Chemistry: experimental protocols and analytical data ................................ 61 
2.4.4 Investigation of the chemical stability ........................................................... 70 
 IV 
2.4.5 Synthesis of the radioligands [3H]19, [3H]33 and [3H]47. ............................. 70 
2.4.6 Cell Culture and preparation of cell homogenates ....................................... 71 
2.4.7 Radioligand binding experiments ................................................................. 72 
2.4.8 IP1 accumulation assay ............................................................................... 74 
2.4.9 Molecular dynamics simulation .................................................................... 75 
2.4.10 Data processing ........................................................................................... 77 
2.5. References .......................................................................................................... 79 
Chapter 3 Fluorescently labeled monomeric and dimeric dibenzodiazepinone-
type muscarinic M2R ligands ............................................................................. 87 
3.1 Introduction ......................................................................................................... 88 
3.2 Results and discussion ....................................................................................... 89 
3.2.1 Chemistry ..................................................................................................... 89 
3.2.2 Radioligand binding studies with [3H]NMS ................................................... 91 
3.2.3 Fluorescence properties of compounds 61, 62 and 64 ................................ 92 
3.2.4 Flow cytometric M2R saturation binding studies with 62 and 64 .................. 95 
3.2.5 Application of the fluorescent ligands 62 and 64 to high content imaging ... 95 
3.2.5.1 Saturation binding ................................................................................. 95 
3.2.5.2 Competition binding .............................................................................. 98 
3.2.5.3 M2R Saturation binding with 62 and 64 in the presence of the allosteric 
modulator 8 (Schild-like analysis) ......................................................................... 100 
3.2.6 Application of the fluorescent ligand 62 and 64 to confocal microscopy .... 102 
3.3. Summary and conclusion .................................................................................. 105 
3.4. Experimental section ......................................................................................... 106 
3.4.1 General experimental conditions ............................................................... 106 
3.4.2 Chemistry: experimental protocols and analytical data .............................. 107 
3.4.3 Compound characterization ....................................................................... 109 
3.4.4 Determination of fluorescence quantum yields .......................................... 109 
3.4.5 Investigation of the chemical stability ......................................................... 109 
3.4.6 Cell Culture ................................................................................................ 110 
3.4.7 [3H]NMS competition binding experiments ................................................. 110 
3.4.8 Flow cytometric saturation binding experiments ........................................ 110 
3.4.9 High-content imaging based saturation and competition binding assay with 62 
and 64  ................................................................................................................... 111 
3.4.10 Confocal microscopy .................................................................................. 112 
3.4.11 Data processing ......................................................................................... 112 
3.5. References ........................................................................................................ 114 
 V 
Chapter 4 Conjugation of dibenzodiazepinone-type muscarinic receptor 
antagonists to short peptides: a new avenue to highly selective M2R ligands
 ............................................................................................................................ 119 
4.1 Introduction ....................................................................................................... 120 
4.2 Results and discussion ..................................................................................... 122 
4.2.1 Chemistry. .................................................................................................. 122 
4.2.2 Equilibrium competition binding at hM1-hM5R. ........................................... 126 
4.3. Conclusion. ....................................................................................................... 132 
4.4. Experimental section ......................................................................................... 133 
4.4.1 General experimental conditions ............................................................... 133 
4.4.2 Compound characterization ....................................................................... 134 
4.4.3 Chemistry: experimental protocols and analytical data .............................. 134 
4.4.3.1 Solid-phase peptide synthesis (SPPS) ............................................... 134 
4.4.3.2 Synthesis of the DIBA-peptide conjugates 87-108 from amines 83 or 84 
and the side-chain protected peptides 72-82 ........................................................ 135 
4.4.4 Cell Culture ................................................................................................ 147 
4.4.5 Radioligand competition binding ................................................................ 147 
4.4.6 Data processing ......................................................................................... 147 
4.5 References ........................................................................................................ 149 
Chapter 5 Summary .......................................................................................... 153 
Chapter 6 Appendix .......................................................................................... 157 
6.1 NMR spectra ..................................................................................................... 158 
6.2 Chromatograms ................................................................................................ 187 
6.2.1 Chapter 2 ................................................................................................... 187 
6.2.2 Chapter 3 ................................................................................................... 188 
6.2.3 Chapter 4 ................................................................................................... 189 
6.3 Abbreviations .................................................................................................... 193 
6.4 Publications, posters, short lectures, professional training and awards. ........... 197 
6.4.1 Publications ................................................................................................ 197 
6.4.2 Poster Presentations .................................................................................. 197 
6.4.3 Short Lectures ............................................................................................ 197 
6.4.4 Professional training .................................................................................. 197 
6.4.5 Awards ....................................................................................................... 198 
6.5 Eidesstattliche Erklärung ................................................................................... 199
 1 
 
Chapter 1 
General introduction
Chapter 1 
2 
1.1 Muscarinic acetylcholine receptors: an overview 
Muscarinic acetylcholine receptors (MRs) belong to the class A of G-protein coupled 
receptors (GPCRs) and comprise five distinct subtypes, denoted M1, M2, M3, M4, and M5 
receptors.1-4 The M1, M3 and M5 subtypes preferentially couple to the Gq/11 family of G 
proteins, resulting in phospholipase C activation, hydrolysis of inositol phosphates and the 
mobilization of intracellular Ca2+. By contrast, the M2 and M4 subtypes preferentially couple 
to the pertussis toxin sensitive Gi/o family of G proteins, resulting in the inhibition of adenylyl 
cyclase activity with a decrease in cAMP formation.5 Endogenously, the neurotransmitter 
acetylcholine (ACh) exerts its physiological function, regulated by hormonal and neuronal 
mechanisms, via activation of all five muscarinic receptor subtypes. Early pharmacological 
studies suggested at least three MR subtypes6, but it lasted until the early 1990s, when all 
five subtypes had been cloned, that the diversity in the muscarinic receptor family was fully 
accepted.2 MRs are widely distributed in the human body: whereas all five MR subtypes are 
expressed in different parts of the central nervous system (CNS), the M1R, M2R, M3R and 
M5R are also located in the periphery (Table 1). Due to the broad distribution of MRs in the 
human organism and their involvement in numerous physiological processes, several 
diseases such as chronic obstructive pulmonary disease (COPD), overactive bladder, 
glaucoma and CNS related diseases like schizophrenia and Alzheimer’s disease have been 
correlated to an impaired cholinergic signaling (Table 1).7-14  
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Table 1. Overview of MR subtypes, distribution, effector proteins and associated disease. 
Subtype Distribution Effectors Associated diseases 
M1R 
o CNS15 
o stomach16 
Gq 
o Alzheimer’s disease 
o peptic ulcers 
M2R 
o CNS15 
o PNS17 
o myocardium15 
Gi (preferentially) 
Gs 
o Alzheimer’s disease 
o cardiomyopathy 
o Chagas’ disease 
M3R 
o CNS15 
o smooth muscles18 
o endocrine and 
exocrine glands19 
o urinary bladder10 
Gq 
o overacting bladder (OAB) 
o chronic obstructive 
pulmonary disease (COPD) 
o glaucoma 
M4R o CNS15 Gi o Parkinson’s disease 
M5R 
o CNS15 
o iris20 
Gq 
o schizophrenia 
o dementia 
o drug addiction 
 
All MR subtypes share a high degree of homology in the sequence constituting the 
acetylcholine (orthosteric) binding site. Therefore, the development of highly subtype 
selective, orthosterically binding MR ligands has been very challenging. The highly 
conserved Asp 1033.32 was suggested to be crucial for the activation of the receptors (as 
reported for many class A GPCRs) by agonist binding and for the binding of the majority of 
described antagonists, too.21-23 In addition to the orthosteric binding site, MRs present 
various less conserved allosteric binding sites, which can be addressed by allosteric ligands 
modulating agonist or antagonist function.24-29 The recently reported crystal structures of 
the M1R (inactive state23), M2R (inactive state21, active state29, and active state in complex 
with an allosteric modulator29), M3R (inactive state22) and M4R (inactive state23) provided 
insight into the binding of molecules to MRs, in particular for the understanding of the 
receptor subtype selectivity, ligand induced activation and binding of modulators to allosteric 
binding pockets.30 Notably, the discovery of allosteric compounds, capable of selectively 
modulating one MR subtype, led to an increased application of the dualsteric ligand 
approach to MRs. Basically, the dualsteric ligand approach consists in connecting an 
orthosteric agonist or antagonist with an allosteric modulator in order to gain affinity by the 
interaction of the orthosteric pharmacophore with the endogenous ligand binding site, and 
selectivity through the interaction of the allosterically interacting moiety with an allosteric 
binding site.24, 31-38 
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1.2 Allosteric modulation of GPCRs and MRs 
The development of the allosteric model was prompted by the observation that the activity 
of certain enzymes could be modified, in either a negative or a positive fashion, by the 
binding of ligands to sites that are topographically distinct from the substrate binding site.39, 
40 To describe this phenomenon the cooperativity factor (α) was introduced, which refers to 
the ability of an allosteric ligand to modulate the affinity of an orthosteric binder at the 
orthosteric binding site. The simplest allosteric GPCR model assumes that the binding of 
an allosteric ligand to its site modulates only the affinity of the orthosteric ligand and not the 
interaction between receptor and G-protein; this model is referred to as the allosteric ternary 
complex model (ATCM) (Figure 1A), first reported by Lefkowitz and coworkers.41 In the 
ATCM, the crosstalk between the orthosteric and the allosteric ligand is governed by the 
ligand concentration, the equilibrium dissociation constants (KA and KB, respectively, cf. 
Figure 1A) and the cooperativity factor α (Figure 1A). Values of α between 0 and 1 indicate 
a negative cooperativity, whereas values higher that 1 indicate a positive cooperativity.5 The 
allosteric two state model42 (ATSM) (Figure 1B) is an extension of the classic ATCM in 
which additional parameters like the constitutive interconversion between an active and an 
inactive receptor state (R* and R, respectively) governed by the isomerization constant L 
(cf. Figure 1B), the ability of the orthosteric and the allosteric ligand to modulate the 
transition of the receptor between different states (governed by the parameters α and β, cf. 
Figure 1B), the ability of each ligand to allosterically modulate the affinity of other 
compounds (termed as “binding cooperativity”, γ, cf. Figure 1B) and the ability of either 
ligands to modulate the transition to an active receptor state when both ligands are bound, 
termed as “activation cooperativity” (δ, cf. Figure 1B), are taken into account.5  
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Figure 1. Allosteric GPCR models. A) The simple allosteric ternary complex model (ATCM), 
which describes the interaction between an orthosteric ligand, A, and allosteric modulator, 
B, in terms of their equilibrium dissociation constants (KA, KB) and the cooperativity factor, 
α, which describes the magnitude and direction of the allosteric effect on ligand binding 
affinity. B) The allosteric two state model (ATSM), which describes allosteric modulator 
effects on affinity, efficacy and the receptor equilibrium between active (R*) and inactive (R) 
states. L: isomerization constant; α and β: cooperativity factors; γ: “binding cooperativity”; 
δ: “activation cooperativity” (cf. section 1.2) (adapted from Gregory et al.5). 
 
1.2.1 Methods to investigate allosteric interactions 
1.2.1.1 Radioligand binding assays  
Several approaches are described for studying allosteric mechanisms at GPCRs. One of 
the first evidences of a non-competitive interaction came from the observation that 
gallamine and hexamethonium-type compounds (i.e. W84, Figure 5) did not show a 
competitive interaction with the orthosteric antagonist [3H]N-methylscopolamine ([3H]NMS) 
at the muscarinic M2 receptor.43-45 Radioligand binding assays can directly provide 
represent data to deduce allosteric behavior.46 For instance, [3H]NMS saturation binding 
experiments performed at the M2R in the presence of the negative allosteric modulator 
gallamine: the modulator is able to shift the radioligand binding curves to the right, and, 
most importantly, at progressively increasing concentrations of the allosteric modulator no 
further rightward shift of the saturation isotherm is observed.47 Likewise, the negative 
allosteric modulator W84 is not able to fully “displace” [3H]NMS (when used at a 
concentration resulting in a receptor occupancy ρ > 0.80) in equilibrium binding experiments 
at the M2R (Figure 2, red curve). Moreover, allosteric modulators such as W84 cause a 
retardation of [3H]NMS dissociation from the M2R.48, 49 By contrast, the positive allosteric 
modulator alcuronium is capable of enhancing [3H]NMS binding at the M2R (Figure 2, black 
curve). Notably, whereas a positive allosteric modulation can be easily identified by using 
radioligand binding assays due to the enhanced binding of the (orthosteric) radioligand to 
the receptor, the identification of a negative allosteric modulation based on radioligand 
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equilibrium studies is more difficult, as curves, comparable to those resulting from 
competitive interactions (especially if low radioligand concentrations (ρ < 0.5) are used), are 
obtained. One of the methods of choice to investigate competitive and non-competitive 
interaction at GPCRs is based on a “Schild-like” protocol relying radioligand saturation 
binding experiments in the presence of orthosteric or allosteric ligands. Whereas a 
competitive interaction will result in a parallel rightward shift of the saturation isotherms (with 
a slope not different from unity), a non-competitive interaction will lead to a partial and 
saturable curve shift (with a slope different from unity).46, 50 Radioligand saturation binding 
studies in the presence of allosteric modulators were performed in order to prove allosteric 
binding of gallamine at the M2R (radioligand: [3H]NMS) and oleamide at the 5-HT7 receptor 
(radioligand: [3H]5-HT).47, 51. 
 
Figure 2. Concentration dependent effects of alcuronium (positive allosteric modulator, 
PAM) and W84 (negative allosteric modulator, NAM) on the equilibrium binding of [3H]NMS 
(Kd = 0.09 nM) determined at live CHO-hM2 cells. [3H]NMS concentrations applied: 0.1 nM 
(ρ = 0.53, alcuronium) and 2.0 nM (ρ = 0.96 nM, W84). W84 concentration dependent curve 
was extrapolated from Chapter 2 (Figure 8C). Alcuronium binding experiments were 
performed according to the protocol for radioligand competition binding experiments 
described in Chapter 2 (experimental section).  
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1.2.1.2 Functional assays  
Functional assays are often used to study allosterism at GPCRs. According to the simple 
ATCM (Figure 1), an allosteric modulator that effects the affinity of an orthosteric agonist, 
but not its efficacy, will cause a rightward (NAM) or leftward (PAM) saturable shift of the 
concentration-response curve of the agonist with no change in basal response, maximal 
response, curve shape and slope. In case of a positive cooperativity, the agonist curves 
would be shifted leftward relative to the agonist control curve. However, as in case of 
radioligand binding assays, negative allosteric modulation may be misinterpreted as 
competitive antagonism, particularly for modulators exhibiting a strong negative 
cooperativity.46 A straightforward method to discriminate between competitive and non-
competitive mechanisms is to perform a Schild analysis.52 Regarding the M2R, increasing 
concentrations of the allosteric modulator LY2119620 (Figure 5) caused a leftward shift of 
the concentration-response curves of a series of MR agonists (ACh, oxotremorine-M and 
iperoxo) (Figure 3) obtained from [35S]GTPγS-binding assays.53 Pitfalls related with 
functional studies of allosteric interactions include, for instance, non-equilibrium conditions 
and heterogeneous receptor populations.54 Moreover, the occurrence of saturable agonist 
removal mechanisms (i.e. extraneuronal uptake or enzymatic breakdown), can lead to a 
misinterpretation of the experimental results.46 
 
1.3 Muscarinic receptor ligands (MRs ligands) 
1.3.1 MR agonists 
The endogenous agonist for MRs and for nicotinic acetylcholine receptors (nAChRs) is 
acetylcholine (ACh) that binds to the five MRs with rather low affinity (Ki = 0.3-48 µM).55, 56 
Biochemically, acetylcholine is synthesized by various neurons that express the enzyme 
choline acetyltransferase by transferring an acetyl group from acetylCoA to choline. Due to 
the presence of a positively charged ammonium group, preventing the penetration of lipid 
membranes, and its susceptibility to hydrolytic and enzymatic cleavage, acetylcholine is not 
suited as a drug. Several MR agonists were described over the past decades with different 
MR subtype selectivity profiles. Methacholine (Figure 3), which is the β-methyl analog of 
ACh, is commercialized as a diagnostic bronchoconstrictor agent.57 Notably, methacholine 
has little effect at nAChRs.58 Pilocarpine and aceclidine (Figure 3) are M3R agonists 
therapeutically used to treat glaucoma59; the M1R and M3R agonist cevimeline (Figure 3) is 
an FDA approved drug for the management of dry mouth associated with the Sjögren's 
syndrome.60 Xanomeline (Figure 3) is a MR agonist with M1R preference, which has been 
proposed as a promising therapeutic candidate for the treatment of Alzeheimer’s disease 
Chapter 1 
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and schizophrenia.61, 62 Oxotremorine, oxotremorine-M and carbachol (CCh) (Figure 3) act 
as a non-selective MR agonists and they are common and useful pharmacological tools for 
experimental studies requiring M1R-M5R receptor activation. Iperoxo (Figure 3), structurally 
related with oxotemorine-M, exhibits an enhanced affinity compared to the parent 
compound. Moreover, at the M2R, iperoxo behaves as a “superagonist” exceeding the 
maximal effect of both, the endogenous neurotransmitter ACh and oxotremorine, in 
activating Gi/Gs signaling, when investigated in cell dynamic mass redistribution and 
[35S]GTPγS-binding assays.63 Noteworthy, iperoxo was co-crystalized in complex with the 
hM2R in the active state in the presence and in the absence of a positive allosteric modulator 
(LY2119620).29 The thieno[2,3-b]pyridine derivative VU 10010 (Figure 3) was reported to 
be able to selectively enhance M4R cholinergic signaling in animal models although an ago-
allosteric mechanism (that refers to modulators able to activate the receptor on their own 
and to enhance the binding of orthosteric agonists)64 rather than an orthosteric interaction 
seems to be involved.65 
 
Figure 3. Structures of selected MR agonists reported in literature. 
1.3.2 MR antagonists 
For centuries, traditional and popular medicine has used the naturally occurring alkaloids 
atropine and scopolamine (Figure 4) to block the cholinergic transmission, although the lack 
of MR subtype selectivity is responsible for severe side effects associated with these 
alkaloids.66 Muscarinic M1 receptors are abundantly expressed in all major forebrain areas 
including the cerebral cortex, the hippocampus, and the striatum.67 Several reports 
suggested that selective antagonism at M1 receptors in the CNS promotes cognitive decline 
and memory impairment.68 For instance, Prado-Alcalà and coworkers demonstrated that 
rats treated with the M1R antagonists trihexyphenidyl and biperiden (Figure 4) showed a 
consistent loss of memory consolidation compared to the control, confirming the pivotal role 
of central M1Rs for cognitive functions.69 Notably, due to its inability to cross the blood-brain 
barrier (BBB), the M1R antagonist pirenzepine (Figure 4) has been used for decades to treat 
peptic ulcers. Selective M2R antagonism increases cholinergic neuronal transmission, in 
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both the brain and the periphery, by reducing autoreceptor function. In the last decades, 
several authors70-74 suggested selective M2 receptor antagonists or compounds acting as 
M2R antagonists and M1R agonists as a therapeutic approach to enhance cholinergic 
function in Alzheimer’s disease, in particular at a stage where cholinergic tone is not 
completely lost.15 Several attempts have been made in order to design selective M2R 
antagonists. DIBA75 and BIBN 9976 (Figure 4) are tricyclic compounds with high affinity for 
the M2R (pKi = 9.52 and 7.52, respectively) and represent privileged scaffolds to develop 
selective M2R antagonists. Interestingly, it was shown that BIBN 99 is mainly active in the 
CNS.76 In addition, compounds structurally related to the alkaloid himbacine (Figure 4) were 
suggested as promising selective M2R antagonists, although clinical data have not yet been 
reported.77-80. Muscarinic M3 receptor blockade is one of the oldest treatments of asthma.15 
Moreover, M3R antagonism is therapeutically relevant for the treatment of diseases like 
chronic obstructive pulmonary disease (COPD), overactive bladder (OAB) and hyperactive 
smooth muscle associated disorders. For instance tolterodine (Figure 4), which was 
reported to show a selective M3 antagonism in vivo, and darifenacin (Figure 4) are approved 
drugs for the treatment of OAB. The bicyclic antagonist tiotropium (Figure 4), which was co-
crystalized in complex with the hM3R by Kobilka and coworkers22, is still a blockbuster for 
the treatment of COPD. The M4R is expressed in the corpus striatum, and it was suggested 
that M4R activation exerts an inhibitory effect on dopamine D1 receptor function.81 Therefore, 
selective M4R antagonists were developed for the treatment of Parkinson’s disease (which 
is caused by impaired dopaminergic transmission). For instance, the benzoxazine derivative 
PD 029802982 (Figure 4) was described as a promising selective M4R antagonist, although 
the poor bioavailability and the rapid metabolism in animal studies limited its use for in vivo 
research.83 The M5R is expressed by the dopamine-containing neurons of the pars 
compacta of the substantia nigra.84 Thus, M5R antagonism may be a useful approach to 
novel therapeutics for the treatment of both schizophrenia and compound addiction. 
However, only a few reports on selective M5R antagonists can be found. For instance, the 
isoxazole derivative VU0488130 (Figure 4) was described as a lead for the development of 
new M5R antagonists, showing more than 50-fold higher antagonism at the M5R compared 
to the other MR subtypes (IC50: M5R = 0.45 µM; M1-M4R > 30 µM).85  
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Figure 4. Structures of selected MR antagonists reported in the literature. 
1.3.3 MR allosteric modulators 
In the late 1960s, it was reported for the first time that a non-competitive interaction between 
the orthosteric mAchR agonist carbachol and neuromuscular blocking agents such as 
gallamine, or alkene-ammonium compounds such as W84 (Figure 5), had been observed.43, 
44 Later on, numerous negative (NAM) and positive (PAM) allosteric modulators were 
described for the five MR subtypes. BQCA (PAM) for the M1R86, W84 (NAM), LY2119620 
(PAM) and alcuronium (PAM) for the M2R43, 49, 53, 87, brucine (PAM) for the M2/M355, 88, 
LY2033298 (PAM) for the M489, and VU-0238429 (PAM) for the M5R90 (Figure 5) are only a 
few examples of numerous MR modulators reported in literature. In addition, several 
putative allosteric agonists, able to activate the receptor on their own by binding to an 
allosteric site, were identified.91 The recently reported M2R structure in the active state, co-
crystalized in complex with the agonist iperoxo and the positive allosteric modulator 
LY2119620 (Figure 5), gave, for the first time, an insight into the receptor residues involved 
in the formation of the “common” allosteric binding vestibule.29 Notably, it was suggested 
that various allosteric sites are present in MRs although their exact locations are still 
unknown.31, 92, 93 Due to the improved selectivity profiles compared to orthosteric ligands, 
and to the ability to modulate, positively or negatively, the action of the endogenous 
neurotransmitter ACh, the design of allosteric modulators emerged as an attractive 
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approach to target and regulate MRs. However, no high-affinity (Ki < 0.1 µM) MR allosteric 
modulators are reported to date.37 
 
Figure 5. Representative MR allosteric modulators reported in literature. 
1.3.4 Dualsteric/bitopic MR ligands 
The dualsteric/bitopic ligand approach, i.e. the design of compounds, which interact 
simultaneously with the orthosteric and an allosteric receptor binding site, has emerged as 
a promising strategy to design high-affinity selective GPCR ligands.31-33, 35-38 A straight 
forward method of developing dualsteric ligands is the connection of an orthosteric ligand 
to an allosteric modulator through a linker.34, 94 However, also non-dimeric ligands such as 
the M2R partial agonist McN-A-343 (Figure 6A), were recently suggested to interact with 
both the orthosteric and the “common” allosteric binding site of the M2R.95 To back this up, 
the binding of McN-A-343 was shown to be sensitive to the mutation of the key residue Asp 
1033.32 of the orthosteric site, and to the mutation of Tyr 177ECL2, which is part of the allosteric 
vestibule of the M2 receptor.96 Analogously, there is experimental evidence that the agonists 
AC-42 and 77-LH-28-1 (Figure 6A) interact dualsterically with the M1R.97-99 Regarding the 
M2R, Holzgrabe and coworkers synthesized and pharmacologically characterized a series 
of dualsteric/bitopic binders constructed by linking an orthosteric agonist (iperoxo) or 
antagonist (NMS, atropine) with an allosterically interacting phthalimide moiety (derived 
from the allosteric modulator W84) through an aliphatic carbon chain (Figure 6B).100 
Steinfeld and coworkers reported the synthesis of a potent M2R antagonist, THRX-160209 
(Figure 6B), designed by connecting the orthosterically binding moiety 3-BHP with the 
allosteric scaffold 4-ABP (Figure 6B). Data from radioligand binding experiments suggested 
that THRX-160209 is able to interact with both the orthosteric and the allosteric site at the 
M2R. Interestingly, the M2R affinity of THRX-160209 was several orders of magnitudes 
Chapter 1 
12 
higher compared to the single entities 3-BHP and 4-ABP (M2R pKi: 9.51 (THRX-160209), 
5.39 (3-BHP) and 5.70 (4-ABP)).101  
In addition, to improved selectivity and receptor affinity, it was suggested that dualsteric 
ligands can be capable of inducing biased signaling at a pleiotropic receptor. To endorse 
this hypothesis, M2R binding of iper-6-phth (Figure 6B) was shown to result in a selective 
activation of the Gi, but not the Gs signaling pathway, demonstrating functional selectivity of 
this compound.102, 103 Moreover, recently, Bock and coworkers suggested that not only the 
choice of the allosteric and orthosteric pharmacophoric groups, but also the variation of the 
linker, which directs the orientation of these pharmacophores towards each other and the 
receptor, allow the design of biased M2R ligands associated to different signaling 
phenotypes.102 The benzimidazolinone derivative TBPB (Figure 6A) was described as a 
M1R selective allosteric agonist104, before its dualsteric binding mode was unveiled by the 
use of structurally truncated analogs of this ligand.105 
 
Figure 6. (A) MR ligands reported to interact in a dualsteric manner. (B) Examples of 
rationally designed dualsteric M2R modulators obtained by connecting orthosterically 
(yellow) with allosterically binding ligands (green) through a linker. 
  
General Introduction 
13 
1.3.5 Dimeric MR ligands  
Numerous studies suggested that GPCRs can form dimers or higher ordered oligomers.106 
Regarding MRs, it was suggested that the M1, M2 and the M3 receptor can homodimerize.107-
109 The formation of MR heterodimers (e.g. M1/M2, M2/M3, M1/M3) was suggested, too.107 
Although many factors have to be considered for the design of bivalent ligands that are able 
to “bridge” GPCR dimers (choice of the pharmacophore, point of attachment and structure 
of the linker), homo- and heterobivalent GPCR ligands are considered potential tools to 
investigate receptor dimerization.106, 110-112 It should be mentioned that there is no sharp 
differentiation between a heterodimeric or heterobivalent and a dualsteric ligand (cf. section 
1.3.4). The term “dualsteric ligand” is usually preferred for compounds, which are supposed 
to address different binding sites of a single receptor protomer, in particular in the MR field. 
Homo and heterobivalent MR ligands derived from the agonist xanomeline (Figure 7) were 
reported to exhibit higher M2R affinity compared to the monomeric ligand113, 114, whereas 
the multimeric antagonist tripitramine (Figure 7) was suggested to interact with numerous 
binding sites at the MRs.115 Moreover, two DIBA-derived (cf. Figure 4) dibenzodiazepinone-
type homodimeric MR ligands (UNSW-MK250 and UNSW-MK262, Figure 7), exhibiting high 
M2R affinity, were recently reported.116 
 
Figure 7. Examples of reported homo and heterobivalent M2R ligands. 
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1.4 Radioligands for MRs  
The first GPCR radioligand binding assay was described in 1970 by Lefkowitz and 
coworkers using a [125I]-adrenocorticotropic hormone to determine its binding affinity at 
adrenocorticotropic receptors.117 Since then, 3H- or 125I-labeled ligands have been widely 
used to determine the affinity of GPCR ligands.118 Today, radioligand-based assays are still 
routinely used in many laboratories due to their robustness and reproducibility. Over the 
years, several tritium-labeled MR ligands were produced and characterized. Due to their 
high affinity at all five MR subtypes and their high stability, the radiolabeled antagonists 
[3H]N-methylscopolamine ([3H]NMS) and [3H]quinuclidin-3-yl-benzilate ([3H]QNB) (Table 2) 
have been predominantly used. Concerning MR agonists, the endogenous neurotransmitter 
ACh was recently tritium labeled to unveil the positive allosteric cooperativity between 
thiochrome and ACh at the M4R.119. The tritium-labeled MR agonist [3H]oxotremorine-M was 
used, e.g., for binding studies at solubilized MRs from rat myocardium.120, 121 The MR 
antagonist [3H]darifenacin was synthesized by Pfizer as the first M3R selective radioligand 
(Table 2).122 Several tricyclic MR antagonists were tritium labeled during the last decades. 
For instance, saturation binding studies with [3H]pirenzepine (Table 2) were performed at 
different tissue preparations to show the ability of pirenzepine to discriminate between 
different MR subtypes by selective binding to the M1R.1 Telenzepine, a bioisosteric analog 
of pirenzepine, was reported to exhibit an increased M1R affinity compared to pirenzepine 
(pKi (M1R): 9.4 vs. 7.9).123, 124 Thus, a tritiated analog of telenzepine (Table 2) was 
synthesized as a M1R selective radioligand with improved affinity. Using [3H]telenzepine, 
the two atropisomeric forms (due to the slow rotation of the exocyclic amide bond, there 
exist two stable isomers of telenzepine) were shown to exhibit different M1R affinities.124, 125 
The pyridobenzodiazepinone-type MR antagonist AF-DX 384 (Table 2) was radiolabeled in 
order to investigate its binding mode at the M2R. Based on radioligand binding studies with 
[3H]AF-DX 384, a bitopic/dualsteric binding mode of AF-DX 384 at the M2R was 
suggested.48 The synthesis of tritium-labeled analogs of allosteric MR modulators was 
reported as a useful approach to investigate allosterism at MRs. For instance, the tritiated 
versions of the allosteric modulators dimethyl-W84 and LY2119620 (Table 2) were 
synthesized in order to study allosteric modulation at the M2R.126, 127 
  
Table 2. Overview of reported tritium-labeled MR ligands. 
Radioligand Structure 
agonist/ antagonist/ 
allosteric modulator 
Radioligand Structure 
agonist/ antagonist/ 
allosteric modulator 
[3H]acetylcholine 
 
agonist [3H]4-DAMP 
 
antagonist 
[3H]oxotremorine-M 
 
agonist [3H]pirenzepine 
 
antagonist 
[3H]NMS 
 
antagonist [3H]telenzepine* 
 
antagonist 
[3H]QNB 
 
antagonist [3H]AF-DX 384 
 
antagonist 
[3H]tiotropium 
 
antagonist [3H]dimethyl W84 
 
allosteric modulator 
[3H]darifenacin 
 
antagonist [3H]LY2119620 
 
allosteric modulator 
*The position of the tritium isotopes is not specified in the literature.
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1.5 Scope and objectives 
The family of muscarinic acetylcholine receptors (MRs) comprises five different subtypes, 
named M1R-M5R, that are widely distributed in the human body, being expressed in both 
the CNS and the periphery. Various diseases such as Alzheimer’s disease, chronic 
obstructive pulmonary disease (COPD), overacting bladder (OAB) and glaucoma are 
associated with impaired cholinergic signaling. Due to the high conservation of the 
orthosteric (acetylcholine) binding pocket within the MR subtypes, the development of highly 
subtype-selective MR ligands has been extremely challenging. Thus, there is still a need 
for highly selective molecular tools and therapeutics acting at MRs. As MRs comprise 
several less conserved accessory (allosteric) binding sites, various allosteric MR ligands 
(modulators) were reported; however, allosteric modulators with high affinity are still lacking. 
The dualsteric ligand approach, that is, the design of ligands, which interact simultaneously 
with the orthosteric pocket and an allosteric site, was suggested as a promising strategy to 
develop high-affinity and selective ligands.24, 31-38 A rational design of (dualsteric) MR 
ligands is supposed to benefit from the reported crystal structures of the M1R-M4R.21-23, 29 
Recently, a series of M2 subtype-preferring dibenzodiazepinone-type MR ligands derived 
from the M2R antagonist DIBA, comprising two high-affinity homodimeric analogs, was 
synthesized and investigated in terms of MR binding.116 This class of compounds represents 
interesting MR ligands, including leads for the development of highly selective M2R 
antagonists. Therefore, this doctoral thesis was aiming at an elucidation of the M2R binding 
mode of monomeric and dimeric dibenzodiazepinone-type ligands by means of preparing 
and studying radiolabeled and fluorescently labeled derivatives. Moreover, the development 
of dibenzodiazepinone-type MR ligands with improved M2R selectivity was envisaged. 
In order to get access to radiolabeld dimeric dibenzodiazepinone-type ligands, which can 
be conveniently prepared from commercially available labeling reagents such as 
succinimidyl [3H]propionate, compounds containing a linker with a primary amino group in 
the center, had to be designed and prepared (Figure 8). Moreover, a monomeric and a 
dimeric [3H]propionylated dibenzodiazepinone derivative had to be synthesized and 
investigated by saturation binding studies (including experiments in the presence of 
reported allosteric M2R ligands), association and dissociation experiments, and equilibrium 
binding (competition binding) studies involving various orthosteric and allosteric MR ligands. 
Molecular dynamics simulations (up to 3 µs) of the M2R bound to selected compounds (for 
instance the “cold” forms of the studied radiolabeled dibenzodiazepinone derivatives) had 
been considered to investigate the M2R binding mode by computational methods.  
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In addition, a small series of fluorescently labeled dibenzodiazepinone-type MR ligands 
(including two homodimeric derivatives) had to be prepared using red-emitting cyanine 
dyes. The fluorescent ligands had to be characterized with respect to M2R binding using 
flow cytometry, high-content imaging analysis and confocal microscopy. 
 
Figure 8. Schematic representation of the scope of the thesis. (A) Structure of amino-
functionalized monomeric and homodimeric dibenzodiazepinone-type MR ligands to be 
used as precursors for radio- and fluorescence labeling. (B) General structure of 
dibenzodiazepinone-type MR ligands conjugated to short peptides. 
Finally, the dibenzodiazepinone pharmacophore had to be conjugated to various di- and 
tripeptides via two different linkers as a new approach to improve the M2R selectivity (Figure 
8). The affinity and the selectivity profile of these compounds had to be assessed by 
radioligand competition binding studies at CHO-hMxR cells (x = 1-5) using the antagonist 
[3H]NMS as orthosteric radioliganand.
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Chapter 2 
Radiolabeled dibenzodiazepinone-type muscarinic 
receptor ligands enable unveiling of dualsteric binding at 
the M2R 
Note: prior to the submission of this thesis, parts of this Chapter have already been 
submitted for publication in cooperation with partners. For detailed information on the nature 
of this collaboration see Acknowledgements and declaration of collaborations.                   
“Reprinted (adapted) with permission from Pegoli, A., She, X., Wifling, D., Huebner, H., 
Bernhardt, G., Gmeiner, P., Keller, M., Radiolabeled Dibenzodiazepinone-Type Antagonists 
Give Evidence of Dualsteric Binding at the M2 Muscarinic Acetylcholine Receptor, J. Med. 
Chem., 2017, 60, 3314-3334. Copyright 2017 American Chemical Society”.
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2.1. Introduction 
In humans, the family of muscarinic acetylcholine receptors (M receptors, MRs) comprises 
five subtypes (M1R-M5R), which belong to the GPCR superfamily class A and mediate the 
action of the neurotransmitter acetylcholine in the CNS as well as in the periphery. For 
instance, the M2R is expressed in the myocardium mediating a negative chronotropic and 
inotropic effect and it acts as a presynaptic autoreceptor in both the brain and the periphery.1 
Accordingly, selective M2R antagonism in the CNS, resulting in enhanced cholinergic 
transmission, was suggested as an approach to increase cholinergic function in Alzheimer’s 
disease.2-5 In general, MRs represent important drug targets, however, there is still a need 
for highly subtype selective pharmaceuticals acting at MRs, because the development of 
selective ligands has been highly challenging due the high conservation of the acetylcholine 
(orthosteric) binding site. As MRs exhibit several distinct allosteric binding sites, which are 
less conserved than the orthosteric site6, 7 these 7-TM receptors emerged as a prototypic 
receptor class to study allosterism at GPCRs.8, 9 Numerous allosteric MR modulators were 
reported (for instance compounds 7,10 8 (W84)11 and 9 (LY2119620),12, 13 Figure 1A), but 
allosteric ligands with high affinity are lacking.14 The linkage of an orthosteric MR ligand to 
an allosteric modulator, called the dualsteric (or bitopic15) ligand approach, was suggested 
as a promising strategy to develop subtype selective MR ligands.8, 14, 16-20 The rational 
design of dualsteric MR ligands is supposed to benefit from the recently reported crystal 
structures of the M1, M2, M3, and M4 receptor.7, 21-23 In case of the M2R, linking of non-
selective MR ligands with allosteric modulators was reported to result in dualsteric ligands 
with peculiar pharmacological profiles with respect to subtype binding, the nature of 
allosteric cooperativity and functional selectivity (for instance 12-16, Figure 1B).24-28 
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Figure 1. (A) Structures of reported M2R antagonists (1, 2, 10), agonists (3-6, 11) and 
allosteric modulators (7-9). Compounds 10 and 11 were also reported to bind to the 
allosteric vestibule of the M2R.29, 30 (B) Examples of rationally designed dualsteric M2R 
modulators obtained by connecting orthosterically (orange) with allosterically binding 
ligands (cyan) through a linker.26, 28 
 
Recently, a series of dibenzodiazepinone-type M2R subtype-preferring antagonists, derived 
from 17 (Figure 2A), including two homodimeric compounds (20 and 21, Figure 2A), were 
reported.31 Compounds 20 and 21 showed the highest M2R affinity (for Ki values see Table 
1) and their retarding effect on the dissociation of [3H]NMS from the M2R was more 
pronounced compared with monomeric derivatives (18, 19, Figure 2A) indicating an 
involvement of allosteric binding sites in the interaction of these compounds with the M2R.31 
These findings are supported by previous reports on the M2R binding profile of 10 (AF-DX 
384)32 (Figure 1A), which is structurally closely related to 17 (Figure 2A), and was suggested 
to interact with the orthosteric as well as with the allosteric binding site. It is noteworthy that 
the use of the tritiated form of 10 proved to be a valuable approach to investigate the binding 
mode.29  
The present study aims at the elucidation of the binding mode of complex ligands such as 
the dibenzodiazepinone derivatives 20 and 21 at the M2R. For this purpose we designed 
congeners of 20 and 21, which can be conveniently prepared as tritium-labeled ligands, by 
introducing a branched ring structure in the center of the molecule intended to bear the 
radiolabel (Figure 2B). For comparison, the tritium-labeled form of 19, representing the 
monomeric counterpart of the dimeric ligand 20 (Figure 2A), was synthesized and also 
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studied in saturation binding assays including experiments in the presence of allosteric 
modulators (Schild-like analysis). Moreover, kinetic investigations, equilibrium competition 
binding studies and molecular dynamics simulations were performed. 
 
 
Figure 2. (A) Structures of recently reported DIBA-derived MR antagonists, including the 
homodimeric compounds 20 and 21. (B) Schematic presentation of radiolabeled 
homodimeric DIBA derivatives, used as tools to investigate the binding mode at the M2R. 
 
2.2. Results and Discussion 
2.2.1 Chemistry  
The preparation of the homodimeric dibenzodiazepinone derivative 33, containing an 
isophthalic acid moiety in the center, is outlined in Scheme 1. The crucial building block 29, 
namely N-Boc protected aminomethylated isophthalic acid, was synthesized from 22 via 
azide 27, following reported procedures with minor modifications (Scheme 1).33, 34 Amidation 
of 29 with amine 30,31 using HBTU/HOBt as coupling reagent, and subsequent removal of 
the Boc group gave amine 31, which represents a precursor for the preparation of differently 
functionalized dimeric MR ligands (e.g. radiolabeled and fluorescence labeled compounds). 
Propionylation of 31, using succinimidyl propionate (32) afforded 33, which represents the 
‘cold’ form of a tritium-labeled dimeric MR ligand. 
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Scheme 1. Synthesis of the homodimeric MR ligand 33. Reagent and conditions: (a) H2SO4, 
MeOH, reflux, 24 h, 99%; (b) NaOHaq 1 M, MeOH, rt, 18 h, 75%; (c) (CH3)2S.BH3, THF, rt, 
24 h, 87%; (d) SOCl2, reflux, 90 min, 98%; (e) NaN3, acetone, reflux, 16 h, 96%; (f) (1) 
triphenylphosphine, H2O/THF 5:1 (v/v), rt, 10 h, (2) NaOHaq 1 M, rt, 8 h, 71%; (g) di-tert-
butyldicarbonate, triethylamine, H2O/dioxane 1:1 (v/v), rt, 12 h, 61%; (h) (1) HOBt, TBTU, 
DIPEA, DMF, 60°C, 3 h (2) triethylamine/ CH2Cl2/H2O 1:1:0.1 (v/v/v), rt, 3 h, 32%; (i) DIPEA, 
DMF, rt, 1 h, 90%. 
 
The key intermediates for the synthesis of the homodimeric MR ligand 47, containing a 
basic homopiperazine moiety in the center of the molecule, were bromide 38 and 
homopiperazine derivative 45c (Scheme 2). Compound 38 was obtained by reduction of 
the carboxylated piperazine derivative 34 to the corresponding alcohol 35, followed by N-
alkylation of 35 with chloride 36 yielding alcohol 37. The latter was converted to bromide 38 
using perbromomethane and triphenylphosphine (Scheme 2). The synthesis of 
homopiperazine 45c started with a nitro-Mannich reaction of dibenzylated ethylenediamine 
(39) and nitroethanol (40) yielding derivative 41, which was converted into homopiperazine 
42 by a retro-Henry reaction. Reduction of the nitro group in 42 using Raney-Nickel and 
hydrogen led to primary amine 43, which was Boc-protected to obtain intermediate 44 
(Scheme 2). Several attempts to debenzylate 44 by hydrogenolysis using 10% Pd/C and 
methanol or ethanol as solvent, failed due to solvent oxidation to formaldehyde and 
acetaldehyde, respectively, and formation of the cyclic aminal 45a and the N-alkylated 
derivative 45b (identified by NMR spectroscopy and mass spectrometry, data not shown). 
The use of 2,2,2-trifluoroethanol as solvent, preventing the Pd-catalyzed oxidation of the 
alcoholic solvent to the corresponding aldehyde,35 enabled a successful debenzylation of 
44, affording homopiperazine 45c without by-products. The alkylation of 45c using bromide 
38, followed by Boc-deprotection led to the amino-functionalized dimeric 
dibenzodiazepinone derivative 46, which was propionylated to give compound 47, 
representing the ‘cold’ form of a tritium-labeled dimeric ligand as well. Imidazolyl propionic 
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acid derivative 50, representing the terminal moiety of the side chain in 19 (cf. Figure 2), 
was prepared from urocanic acid derivative 48 (Scheme 2),31 which was converted to 49 by 
hydrogenolytic reduction of the ‘acrolein’ double bond under acidic conditions resulting in a 
simultaneous cleavage of the Boc group (Scheme 2). Propanoylation of 49 using 32 yielded 
compound 50. The homodimeric dibenzodiazepinone derivative 52 was prepared by 
alkylation of piperazine with chloride 36 (Scheme 2). 
 
Scheme 2. Synthesis of the homodimeric MR ligands 47 and 52 and the imidazolyl 
propionic acid derivative 50. Reagent and conditions: (a) LiAlH4, THF, 0°C/reflux, 12 h, 89%; 
(b) K2CO3, acetonitrile, reflux, 5 h, 43%; (c) CBr4, triphenylphosphine, CH2Cl2, -5°C/5°C, 5 
h, 79%; (d) paraformaldehyde, EtOH/toluene 1:1 (v/v), reflux, 6 h, 87%; (e) potassium tert-
butanolate, anhydrous THF, rt, 30 min, 95%; (f) H2, Raney-Nickel, EtOH, rt, 12 h, 44%; (g) 
di-tert-butyldicarbonate, CH3Cl, 0°C/rt, 5 h, 81%; (h) Pd/C (10%), H2, 2,2,2-trifluoroethanol, 
1 atm, rt, 12 h, 85%; (i) (1) K2CO3, DMF, 120 °C (microwave), 1.5 h (2) CH2Cl2/TFA/H2O 
1:1:0.1 (v/v/v), rt, 3 h, 37%; (j) DIPEA, DMF, rt, 1-1.5 h, 72% (47), 43% (50); (k) Pd/C (10%), 
H2, MeOH/TFA 1:1 (v/v), 7.9 atm, rt, 12 h, 90%; (l) K2CO3, acetonitrile, 130°C (microwave), 
30 min, 21%. 
 
The chemical stability of compounds 19, 33 and 47 was investigated in PBS (pH 7.4) at 23 
°C over a period of 48 h. These dibenzodiazepinone derivatives showed excellent stabilities 
(Figure 3). 
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Figure 3. HPLC analysis of 19 (A), 33 (B) and 47 (C) after incubation in PBS (pH 7.4) at 23 
°C for up to 48 h. 19, 33 and 47 showed no decomposition. For HPLC conditions see 
experimental section. 
 
2.2.2 Synthesis of radiolabeled dibenzodiazepinone derivatives  
The tritium-labeled dibenzodiazepinone derivatives [3H]19, [3H]33 and [3H]47 were obtained 
by treatment of an excess of the amine precursors 30, 31 and 46, respectively, with 
commercially available succinimidyl [3H]propionate ([3H]32) in the presence of DIPEA 
(Figure 4A). In order to facilitate the purification of [3H]47, the excess of amine precursor 46 
was ‘quenched’ by the addition of succinimidyl 4-fluorobenzoate (53), resulting in the 
formation of 54, which could be conveniently separated from [3H]47 (Figure 4B). Purification 
by RP-HPLC afforded all radioligands in high radiochemical purity (99%, Figure 4C-E). 
[3H]19, [3H]33 and [3H]47 proved to be stable upon storage in EtOH/H2O (1:1 v/v) at −20 °C 
(Figure 5) 
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Figure 4. (A) Synthesis of the MR radioligands [3H]19, [3H]33 and [3H]47 by 
[3H]propionylation of the amine precursor 30, 31 and 46, respectively, using succinimidyl 
[3H]propionate ([3H]32). Reagents and conditions: (a) DIPEA, DMF, rt, 60 min, 39% ([3H]19), 
32% ([3H]33); (b) (1) DIPEA, DMF, rt, 45 min, (2) 53, rt, 60 min, 38%. The excess of 46 was 
‘quenched’ by 4-fluorobenzoylation to facilitate the purification of [3H]47 (cf. B). (B) RP-
HPLC monitoring of the synthesis of [3H]47 before (black line) and after (blue line) addition 
of the active ester 53. (C-D) RP-HPLC analysis (conditions see experimental section) of 
[3H]19 (0.23 µM) (C), [3H]33 (0.20 µM) (D) and [3H]47 (0.20 µM) (E), each spiked with the 
‘cold’ analog (19 and 33: 5 µM; 47: 3 µM) analyzed 2 days after synthesis. 
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Figure 5. Long-term stability of the radioligands [3H]19, [3H]33 and [3H]47. (A) HPLC 
analysis of [3H]19 (0.18 µM) spiked with “cold” 19 (5 µM), analyzed 12 months after storage 
at −20 °C. (B) HPLC analysis of [3H]33 (0.17 µM) spiked with “cold” 33 (5 µM) analyzed 12 
months after storage at −20 °C. (C) HPLC analysis of [3H]47 (0.2 µM) spiked with “cold” 47 
(3 µM) analyzed 9 months after storage at −20 °C. For all the radioligands the radiochemical 
purity was >95%. HPLC conditions are provided in the experimental section. 
 
2.2.3 Equilibrium competition binding studies with [3H]NMS  
M1-M5 receptor affinities of the dimeric dibenzodiazepinone derivatives 33 and 47 were 
investigated in equilibrium competition binding experiments using [3H]NMS (structure of the 
‘cold’ analog see Figure 1A) as orthosterically binding radioligand. The MR binding 
constants (pKi values) are presented in Table 1 in comparison with previously reported M1R-
M5R affinities of 18-21. The transformation of the structures of 20 and 21 to 33 and 47, 
respectively, by the introduction of a branched central linker moiety (Figure 2, Scheme 1 
and Scheme 2) resulted only in a marginally decrease in M2R affinity (Figure 6), and in a 
MR subtype selectivity profile comparable to that of the parent compounds 20 and 21 (Table 
1). Steep curve slopes were observed for 33 at the M1R (slope = −1.8) and M2R (slope = 
−2.2) indicating a complex mechanism of binding (e.g. the involvement of more than one 
binding site). Moreover, equilibrium binding of [3H]NMS at the M2R in the presence of 
dibenzodiazepinone derivative 52 (cf. Scheme 2) and the reported M2R allosteric modulator 
9 was investigated. Compared to the homodimeric dibenzodiazepinone derivatives 33 and 
47, in which the pharmacophores are separated by complex linker moieties, the decrease 
in [3H]NMS binding caused by compound 52 was considerably less pronounced by more 
than four orders of magnitude (Figure 7A). Similarly, the allosteric modulator 9 exhibited a 
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weak inhibitory effect on [3H]NMS equilibrium binding (Figure 7B) being in agreement with 
a previously reported negative cooperativity between 9 and NMS.22 
 
Figure 6. Effect of the homodimeric ligands 20, 21, 33 and 47 on M2R equilibrium binding 
of [3H]NMS (c = 0.2 nM, Kd = 0.09 nM) determined at CHO-hM2 cells. Corresponding pKi 
values: 20: 9.7 ± 0.05, 33: 9.39 ± 0.05, 21: 9.51 ± 0.19, 47: 9.15 ± 0.01. Data represent 
mean values ± SEM from at least three independent experiments (each performed in 
triplicate). 
 
Figure 7. Effect of the homodimeric dibenzodiazepinone derivative 52 (A) and the allosteric 
M2R modulator 9 (B) on M2R equilibrium binding of [3H]NMS (c = 0.2 nM, Kd = 0.09 nM) 
determined at intact CHO-hM2 cells. (A) Mean values ± SEM from three independent 
experiments (each performed in triplicate). (B) Representative experiment performed in 
triplicate (at least two independent experiments were performed and gave comparable 
results). 
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Table 1. M1-M5 receptor affinities (pKi values) of the DIBA derivatives 18-21, 33 and 47, 
obtained from equilibrium competition binding studies with [3H]NMS at live CHO-hMxR cells 
(x = 1-5) 
compd. 
M1R M2R M3R M4R M5R 
pKi slopea pKi slopea pKi slopea pKi slopea pKi slopea 
18 
8.01 ± 
0.08 
1.13 ± 
0.10 
9.17 ± 
0.06 
-1.25 ± 
0.08 
7.11 ± 
0.08 
-0.92 ± 
0.09 
8.49 ± 
0.11 
-0.99 ± 
0.09 
6.36 ± 
0.09 
-0.97 ± 
0.14 
19 
8.07 ± 
0.06 
-1.11 ± 
0.11 
9.12 ± 
0.05 
-1.19 ± 
0.06 
7.22 ± 
0.08 
-1.09 ± 
0.08 
8.63 ± 
0.02 
-0.86 ± 
0.03 
6.75 ± 
0.08 
-0.68 ± 
0.11 
20 
8.91 ± 
0.05 
-1.56 ± 
0.08 
9.71 ± 
0.05 
-1.27 ± 
0.12 
7.88 ± 
0.03 
-1.30 ± 
0.09 
9.19 ± 
0.08 
-1.17 ± 
0.14 
7.44 ± 
0.10 
-1.46 ± 
0.18 
21 
9.00 ± 
0.04 
-1.32 ± 
0.09 
9.51 ± 
0.19 
-2.01 ± 
0.07 
8.17 ± 
0.03 
-1.05 ± 
0.14 
8.97 ± 
0.08 
-1.32 ± 
0.17 
7.64 ± 
0.08 
-1.09 ± 
0.09 
33 
8.82 ± 
0.10 
-1.81 ± 
0.16 
9.39 ± 
0.05 
-2.17 ± 
0.19 
7.81 ± 
0.01 
-1.19 ± 
0.11 
9.33 ± 
0.11 
-1.17 ± 
0.06 
7.64 ± 
0.04 
-0.95 ± 
0.13 
47 
8.15 ± 
0.06 
-1.29 ± 
0.12 
9.15 ± 
0.01 
-1.40 ± 
0.06 
6.70 ± 
0.06 
-1.15 ± 
0.06 
8.44 ± 
0.09 
-0.87 ± 
0.08 
7.11 ± 
0.18 
-1.06 ± 
0.13 
aCurve slope of the four-parameter logistic fit. Presented are mean values ± SEM from 3-9 
independent experiments (each performed in triplicate). Kd values31 / applied concentrations of 
[3H]NMS: M1: 0.12 / 0.2 nM; M2: 0.090 / 0.2 nM; M3: 0.089 / 0.2 nM; M4: 0.040 / 0.1 nM; M5: 0.24 / 
0.3 nM. Data of 18-21 were previously reported as pIC50 values by Keller et al.31 and were re-
analyzed to obtain pKi values. 
 
2.2.4 Functional studies  
The monomeric dibenzodiazepinone derivative 19 and the homodimeric congener 33 were 
investigated in an IP1 accumulation assay using HEK-293 cells transiently transfected with 
the human M2R and the hybrid G-protein Gαqi5-HA. 19 and 33 did not elicit IP1 accumulation 
when studied in agonist mode (Figure 8A), that is, they were incapable of stabilizing a G-
protein activating conformation of the M2R. In antagonist mode, 19 and 33 completely 
inhibited IP1 accumulation elicited by 3 (0.3 µM, ≈ EC80), proving these compounds to be 
M2R antagonists as previously reported for 10 (Figure 8B).29 Furthermore, 19 and 33 were 
able to fully suppress the IP1 accumulation signal elicited by increasing concentration of 
CCh suggesting a competitive interaction between the orthosteric agonist CCh and the 
dibenzodiazepione-type MR ligands 19 and 33 (Figure 8C and 8D). 
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Figure 8. Investigation of M2R agonism and antagonism of compounds 19 and 33 in an IP1 
accumulation assay using HEK-hM2-Gqi cells. (A) Concentration-dependent effect of 3, 19 
and 33 on the accumulation of IP1. 19 and 33 elicited no response. pEC50 of 3: 6.93 ± 0.09 
(mean ± SEM from 8 independent experiments performed in triplicate). (B) Concentration-
dependent inhibition of the IP1 accumulation (induced by 3, 0.3 µM) by 2, 19 and 33. 
Corresponding pKb values: 2: 8.63, 19: 7.53, 33: 7.36. Concentration-dependent inhibition 
of 19 (C) and 33 (D) on IP1 accumulation elicited by increasing concentration of CCh (0.1, 
1 and 10 µM). Data represent the means ± SEM from at least five independent experiments 
(each performed in triplicate). 
 
2.2.5 Characterization of [3H]19, [3H]33 and [3H]47 
Saturation binding experiments with the radiolabeled dibenzodiazepinone derivatives 
[3H]19, [3H]33 and [3H]47 were performed at intact adherent CHO-hM2 cells in white-
transparent 96-wells plates revealing Kd values of 0.87, 1.1 and 8.6 nM, respectively (mean 
values from at least three independent experiments performed in triplicate) (Figure 9A, 
Figure 9B and Figure 9E). Whereas unspecific binding was very low in case of the 
monomeric ligand [3H]19 (<5% at the Kd) (Figure 9A), drastically increased unspecific 
binding (>60%) was a characteristic of the dimeric ligands [3H]33 and [3H]47 (Figure 9B and 
Figure 9E). Saturation binding studies with [3H]33 and [3H]47 performed with intact CHO-
hM2 cells in suspension ([3H]33, Figure 9C) or with CHO-hM2 cell homogenates ([3H]33 and 
[3H]47, Figure 9D and Figure 9F), precluding unspecific binding of the radioligand to the 
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microplate, resulted in considerably lower unspecific binding (<15% at Kd), indicating that 
the dimeric ligands 33 and 47 strongly adsorb to polystyrene tissue-culture treated 
microplates (for experimental protocols see experimental section). The Kd values amounted 
to 0.31 nM ([3H]33, suspended cells), 0.24 nM ([3H]33, homogenates) and 6.0 nM ([3H]47, 
homogenates) (mean values from at least three independent experiments performed in 
triplicate). Worth mentioning, the maximum number of M2R binding sites per well (calculated 
from Bmax values and the specific activities of the radioligands) obtained from experiments 
performed with the monomeric radioligand [3H]19 and the dimeric radioligand [3H]33 (same 
day and same seed of cells) were not different (data not shown), indicating that one 
molecule of dimeric radioligand did not bind simultaneously to the orthosteric pockets of 
putative M2R dimers. In other words, these results suggested a ligand-receptor 
stoichiometry of 1:1 for both, the monomeric and the dimeric radioligand. In addition, 
saturation binding experiments were performed with [3H]33 at live CHO-hM4 cells resulting 
in a Kd value of 0.67 nM (mean value from four independent experiments performed in 
triplicate) (Figure 10). 
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Figure 9. Representative saturation isotherms (in red) of specific M2R binding of [3H]19 (A), 
[3H]33 (B-D) and [3H]47 (E, F) obtained from experiments either performed with live 
adherent CHO-hM2 cells (A, B, E), live CHO-hM2 cells in suspension (C) or CHO-hM2 cell 
homogenates (D, F). Unspecific binding was determined in the presence of the 
orthosterically binding MR antagonist atropine (500-fold excess). Scatchard transformations 
are depicted for the optimized binding assay conditions (A, D). Experiments were performed 
in triplicate. Specific binding data were analyzed by an equation describing a one-site 
binding. Error bars of specific binding and error bars in the Scatchard plots represent 
propagated errors calculated according to the Gaussian law of errors. Error bars of total 
and unspecific binding represent the SEM. 
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Figure 10. Saturation isotherm of specific M4R binding of [3H]33 from a representative 
experiment performed with live CHO-hM4 cells. Unspecific binding was determined in the 
presence of the orthosterically binding MR antagonist atropine (500-fold excess). Error bars 
of specific binding represent propagated errors calculated according to the Gaussian law of 
errors. Error bars of total and unspecific binding represent the SEM. 
 
Notably, as the orthosteric antagonist 2, used to determine unspecific binding, was able to 
completely prevent one-site (monophasic) specific binding of [3H]19, [3H]33 and [3H]47 to 
the M2R, these data strongly suggest that the dibenzodiazepinone derivatives 19, 33 and 
47 address the orthosteric binding site of the M2R. Due to the lower affinity and inappropriate 
physicochemical properties (high unspecific binding) of [3H]47, this radioligand was not 
considered with respect to further characterization, contrary to the monomeric radioligand 
[3H]19 and its dimerized analog [3H]33. The association of both, [3H]19 and [3H]33, to the 
M2R could be described by a monophasic fit resulting in comparable kon rates (Figure 11A, 
Figure 11C and Table 2). By contrast, the dissociation from the M2R was different: whereas 
the monomeric ligand [3H]19 completely dissociated with a half-life of 71 min (monophasic 
decline), the dissociation of the dimeric dibenzodiazepinone derivative [3H]33 was 
incomplete, reaching a plateau at 67% of initially bound radioligand (Figure 11B and Figure 
11D, respectively). This result suggests in part a (pseudo)irreversible (long lasting) binding 
of [3H]33, which might be attributed to conformational adjustments of the receptor upon 
ligand binding,36 or to an enhanced rebinding capability of the dimeric ligand by a 
simultaneous interaction with two or more binding sites.37 However, the equilibrium 
dissociation constant of [3H]33, calculated from koff and kon (Kd(kin) = koff/kon = 0.20 nM, 
(Table 2) was in good agreement with the Kd value derived from saturation binding 
experiments (Kd = 0.31 nM) indicating that [3H]33 follows (in part) the law of mass action.38 
An overview of the M2R binding characteristics of [3H]19 and [3H]33 is provided in Table 2. 
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Figure 11. Association and dissociation kinetics of [3H]19 (A, B) and [3H]33 (C, D) 
determined at intact CHO-hM2 cells at 23 °C. (A) Radioligand (c = 2 nM) association to the 
M2R as a function of time (non-linear regression: kobs = 0.042 min-1); inset: ln[B(eq)/(B(eq)-B(t))] 
versus time, kobs = slope = 0.035 min−1. (B) Radioligand (preincubation: 2 nM, 105 min) 
dissociation from the M2R as a function of time, showing complete monophasic exponential 
decline (non-linear regression (black circles): koff = 0.0091 min-1, t1/2 = 71 min); inset: 
ln[B(t)/B(0)] versus time, slope·(−1) = koff = 0.0078 min−1, t1/2 = 89 min. (C) Radioligand (c = 1 
nM) association to the M2R as a function of time (non-linear regression: kobs = 0.067 min-1);   
inset: ln[B(eq)/(B(eq)-B(t))] versus time, kobs = slope = 0.066 min−1. (D) Radioligand 
(preincubation: 1 nM, 90 min) dissociation from the M2R as a function of time, showing 
incomplete monophasic exponential decline (non-linear regression (black squares): koff = 
0.011 min-1, t1/2 = 66 min, plateau = 67%); inset: ln[(B(t)-B(plateau))/B(0)] versus time, slope·(−1) 
= koff = 0.011 min−1, t1/2 = 66 min. Data represent means ± SEM from three (B, C, D) or four 
(A) independent experiments (each performed in triplicate). 
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Table 2. M2R binding data of [3H]19, [3H]33 and [3H]47 (at 23 ± 1 °C). 
radioligand 
Ki (‘cold’ 
analog) [nM]a 
Kd(sat) 
[nM]b 
Kd(kin) 
[nM]c 
kon 
[min−1 . nM−1]d 
koff [min−1]e 
t1/2 [min]e 
[3H]19 0.76 ± 0.05 0.87 ± 0.01 
0.70 ± 
0.10 
0.013 ± 
0.003 
0.0091 ± 0.0016 
71 ± 7 
[3H]33 0.41 ± 0.05 0.31 ± 0.08 
0.20 ± 
0.04 
0.056 ± 
0.010 
0.011 ± 0.001 
66 ± 9 
[3H]47 0.71 ± 0.01 6.0 ± 1.4 n.d n.d n.d 
aDissociation constant determined by equilibrium competition binding with [3H]NMS at intact CHO-
hM2 cells; mean ± SEM from at least three independent experiments (performed in triplicate). 
bEquilibrium dissociation constant determined by saturation binding at intact CHO-hM2 cells ([3H]19 
and [3H]33) and at CHO-hM2 cell homogenates ([3H]47); mean ± SEM from at least three independent 
experiments (performed in triplicate). cKinetically derived dissociation constant ± propagated error 
(Kd(kin) = koff/kon). dAssociation rate constant ± propagated error, calculated from kobs, koff and the 
applied radioligand concentration (cf. Figure 6 and experimental section). eDissociation rate constant 
and derived half-life; mean ± SEM from three independent experiments (performed in triplicate). 
 
Binding of the monomeric dibenzodiazepinone derivative 19 to the orthosteric site was 
further supported by investigating the saturation binding of the orthosteric radioligand 
[3H]NMS in the presence of 19 (Schild-like analysis). This experiment revealed a parallel 
rightward shift of the saturation isotherms of [3H]NMS and a slope not different from unity of 
the corresponding ‘Schild’ regression, being indicative of a competitive interaction between 
19 and the orthosteric radioligand [3H]NMS (Figure 12).  
 
 
Figure 12. Saturation binding of [3H]NMS at intact CHO-hM2 cells in the presence of 
increasing concentrations of 19. Presented are saturation isotherms of specific radioligand 
binding to the M2R plotted in linear scale (left) and semi-logarithmic scale (middle), and the 
“Schild” regression (right) resulting from the rightward shift (ΔpKd) of the saturation isotherm 
(log(r−1) plotted vs. log(concentration of 19), where r = 10ΔpKd). The presence of the 
dibenzodiazepinone derivative 19 led to a parallel rightward shift of the saturation curves of 
[3H]NMS. The slope of the linear “Schild” regression was nearly equal to unity indicating a 
competitive interaction between [3H]NMS and 19. Data represent mean values ± SEM from 
at least three independent experiments (each performed in triplicate). 
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2.2.6 M2R equilibrium competition binding with [3H]19 and [3H]33  
Selected standard MR agonists (4, 5) antagonists (1, 2, 10) and allosteric modulators (7, 8) 
as well as the ‘cold’ forms of the radioligands (19, 33) were investigated by equilibrium 
competition binding with [3H]19 or [3H]33. The concentration-dependent effects of the 
investigated compounds on equilibrium binding of [3H]19 and [3H]33, analyzed by four-
parameter logistic fits, are depicted in Figure 13. The lower curve plateaus were throughout 
not significantly different from 0 (P >0.2), which either suggests a competitive mechanism 
or a strongly negative cooperativity between the studied compounds and the radiolabeled 
dibenzodiazepinone derivatives.39 Generally, the pKi values derived from this study were in 
good agreement with reported data (Table 3), although MR ligand affinities determined with 
the dimeric radioligand [3H]33 were consistently lower compared to M2R affinities obtained 
from equilibrium competition binding experiments with [3H]19. It is a matter of speculation 
whether the need for higher competitor concentrations for the displacement of the dimeric 
radioligand [3H]33 is caused by a multivalent binding mode of [3H]33 or not. Concerning this 
issue, experiments were repeated with 4 and 10, applying a preincubation period of 90 min 
with the M2R prior to the addition of [3H]33, but did not result in an increase in the apparent 
pKi of 4 and 10 (data not shown). In addition, the effect of the allosteric M2R ligand 9 on the 
equilibrium binding of [3H]19 and [3H]33 was studied (Figure 13A and Figure 13B). The 
apparent pKi values of 5.73 nM ([3H]19) and 5.24 ([3H]33) (Table 3) were in good agreement 
with the reported pKB of 9 (pKB = 5.77).22 
 
 
 
Figure 13. Concentration-dependent effects of various reported orthosteric (1-5), allosteric 
(7, 8) and dualsteric (10, 19, 33) MR ligands on M2R equilibrium binding of [3H]19 (c = 2 nM, 
Kd = 0.87 nM) (A) and [3H]33 (c = 0.5 nM, Kd = 0.24 nM except for competition binding 
experiments with compound 9 (c = 0.25 nM)) (B) determined at live CHO-hM2 cells and at 
CHO-hM2 cell homogenates, respectively. Data were analyzed by four-parameter logistic 
fits. Mean values ± SEM from at least three independent experiments (performed in 
triplicate).  
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Table 3. M2R binding data (pKi or pIC50) of various orthosteric (1-5), allosteric (7-9) and 
dualsteric (10, 19 and 33) MR ligands determined with [3H]19, [3H]33 or [3H]NMS. 
Ligand [
3H]19 
pKi ± SEMa 
[3H]33 
pKi ± SEMb 
[3H]NMS 
pKi*or pIC50** (± SEM) 
1 10.2 ± 0.10 8.92 ± 0.03 9.7*c 
2 9.09 ± 0.04 7.77 ± 0.04 7.8-9.2*d 
4 6.83 ± 0.05 5.00 ± 0.12 5.0-6.6*d 
5 6.57 ± 0.05 5.35 ± 0.03 6.5-7.4*e 
7 6.33 ± 0.04 5.43 ± 0.01 6.11 ± 0.09**f 
8 7.40 ± 0.03 5.97 ± 0.05 6.32 ± 0.18**f 
9 5.73 ± 0.03 5.24 ± 0.05 <4.5**g 
10 8.76 ± 0.07 7.63 ± 0.13 8.2*d 
19 8.96 ± 0.06 7.99 ± 0.10 9.12 ± 0.05*h 
33 9.97 ± 0.20 8.98 ± 0.05 9.39 ± 0.05*h 
aDetermined by equilibrium (competition) binding with [3H]19 (c = 2 nM) at intact CHO-hM2 cells; 
mean values ± SEM from at least 3 independent experiments (performed in triplicate). bDetermined 
by equilibrium (competition) binding with [3H]33 (c = 0.5 nM) at CHO-hM2 cell homogenates; mean 
values ± SEM from at least three independent experiments (performed in triplicate). cDei et al.40 dpKi 
values from equilibrium (competition) binding experiments reported in the literature (data taken from 
the IUPHAR/BPS database (guidetopharmacology.org, (Nov. 2016)). eJakubik et al.41 fpIC50 values 
obtained from nonlinear four-parameter logistic curve analyses of data characterizing the inhibition 
of [3H]NMS (c = 0.2 nM) equilibrium binding at live CHO-hM2 cells; mean ± SEM from at least 3 
independent experiments (performed in triplicate). gInhibitory effect on M2R equilibrium binding of 
[3H]NMS (c = 0.2 nM) at intact CHO-hM2 cells (cf. Figure 7B). hpKi values taken from Table 1. 
 
In order to verify a putative competitive mechanism of the allosteric modulator 8 with [3H]19 
and [3H]33 at the M2R, equilibrium competition binding studies were performed applying 
increasing fixed concentrations/receptor occupancies of the radioligands (Figure 14A and 
Figure 14B). In the same manner, a reference experiment was performed with 8 and the 
orthosteric radioligand [3H]NMS (Figure 14C). The control experiment with [3H]NMS 
revealed an elevation of the lower plateau of the curves and the pIC50 of 8 was unaffected, 
indicating a non-competitive mechanism as reported previously.29 By contrast, the lower 
plateau of the curves did not increase in case of [3H]19 and [3H]33, and a rightward shift of 
the pIC50 of 8 was observed (Figure 14). These data support a competitive mechanism39 
between the allosteric M2R ligand 8 and the dibenzodiazepinone-type ligands 19 and 33 
and, consequently, a dualsteric binding mode of 19 and 33 at the M2R. 
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Figure 14. Effect of the allosteric MR modulator 8 on M2R equilibrium binding of [3H]19 (Kd 
= 0.87 nM) (A), [3H]33 (Kd = 0.24 nM) (B) and [3H]NMS (Kd = 0.09 nM) (C) using various 
radioligand concentrations. Experiments were performed at intact CHO-hM2 cells (A, C) or 
at CHO-hM2 cell homogenates (B). Unspecific binding was determined in the presence of 
atropine (500-fold excess to [3H]19, [3H]33 or [3H]NMS). Data were analyzed by four-
parameter logistic fits. In case of [3H]19 and [3H]33 increasing radioligand concentrations 
resulted in a parallel rightward shift of the curves, which reached 0% specific radioligand 
binding throughout, indicating a competitive mechanism (A, B). In contrast, curves of 
[3H]NMS equilibrium binding obtained in the presence of increasing concentrations of 8 
were not rightward-shifted, instead, the lower plateau of the curve appeared to be elevated 
at increased radioligand concentrations, indicating negative allosteric cooperativity between 
8 and [3H]NMS (C). Data represent mean values ± SEM from at least three independent 
experiments (performed in triplicate). ρA = fractional receptor occupancy. 
 
2.2.7 Schild-like analysis with 8 and 9 at the M2R using [3H]19 and [3H]33  
In order to substantiate the studies on the binding mode of [3H]19 and [3H]33 at the M2R, 
saturation binding of [3H]19 and [3H]33 in the presence of the allosteric modulators 8 and 9 
were performed (Figure 15). This kind of experiment is equivalent to the Schild analysis 
used to investigate the inhibiting effect of a receptor antagonist on the response elicited by 
an agonist and is considered the experiment of choice to unveil non-competitive 
mechanisms.39, 42, 43 Increasing concentrations of 8 led to a parallel rightward shift of the 
saturation isotherms of both, the monomeric ligand [3H]19 and the homodimeric ligand 
[3H]33, resulting in linear ‘Schild’ regressions with a slope not different from unity (Figure 
15A and Figure 15C, Table 4), indicating a competitive mechanism between the allosteric 
M2R ligand 8 and the dibenzodiazepinone-type ligands 19 and 33. Likewise, the allosteric 
modulator 9, which was co-crystallized with the M2R bound to 6,22 elicited a parallel 
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rightward shift of [3H]19 saturation isotherms, again yielding a linear ‘Schild’ regression with 
a slope not different from unity (Figure 15B, Table 4). The ‘pA2’ values derived from these 
‘Schild’ regressions were in a good accordance with the pKi values from equilibrium 
competition binding studies with [3H]19 and [3H]33 as well as with reported affinities (pKA or 
pKB) of 8 and 9 (Table 4). With regard to the fact that the dibenzodiazepinone derivatives 
19 and 33 address the M2R orthosteric binding site (see above) the results of the Schild-
like analyses strongly suggested a dualsteric binding mode of 19 and 33 at the M2R, that is, 
a simultaneous binding to the orthosteric site and the allosteric vestibule. 
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Figure 15. Saturation binding of [3H]19 in the presence of increasing concentrations of 8 
(A) or 9 (B), and of [3H]33 in the presence of increasing concentrations of 8 (C). Presented 
are saturation isotherms of specific radioligand binding to the M2R in linear scale (left) and 
semi-logarithmic scale (middle), and ‘Schild’ regressions (right) resulting from the rightward 
shifts (ΔpKd) of the saturation isotherms (log(r−1) plotted vs. log(concentration allosteric 
modulator), where r = 10ΔpKd). The presence of the allosteric modulator (8, 9) led to a parallel 
rightward shift of the saturation isotherms of both, the monomeric ([3H]19) and the 
homodimeric ([3H]33) radiolabeled dibenzodiazepinone derivative. In all cases the slope of 
the linear ‘Schild’ regression was nearly equal to unity indicating a competitive interaction 
between the radioligands and the investigated allosteric ligands. Experiments were 
performed at intact CHO-hM2 cells (A, B) or at CHO-hM2 cell homogenates (C). Data 
represent mean values ± SEM from at least three independent experiments (each 
performed in triplicate). 
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Table 4. Summary of M2R binding data of the allosteric M2R modulators 8 and 9 determined 
by the use of the radiolabeled dibenzodiazepinone derivatives [3H]19 and [3H]33. 
allosteric 
ligand 
used 
radioligand 
slopea ‘pA2’b pKic pKA* or pKB** 
8 [3H]19 0.94 ± 0.04 6.81 ± 0.02 7.39 ± 0.03 6.00/6.53*d 
9 [3H]19 1.1 ± 0.1 5.45 ± 0.09 5.73 ± 0.03 5.77**e 
8 [3H]33 0.98 ± 0.06 6.58 ± 0.01 5.91 ± 0.06 6.00/6.53*d 
aSlope of the ‘Schild’ regression constructed based on radioligand binding data from saturation 
binding experiments in the presence of increasing fixed concentrations of the allosteric ligands 8 or 
9; mean values ± SEM from at least three sets of independent saturation binding experiments 
(performed in triplicate). The slope of the linear ‘Schild’ regression was not statistically different from 
unity (P >0.2). bThe ‘pA2’ value corresponds to the X-axis intercept of the linear ‘Schild’ regression 
(cf. Figure 15) and reflects the affinity of the investigated allosteric ligands. cpKi values taken from 
Table 3. dMohr et al.44 eKruse et al.22 
 
2.2.8 Molecular dynamics simulations 
Aiming at a verification of the conclusions drawn from the experimental data by 
computational methods, MD simulation of the human M2R bound to the dibenzodiazepinone 
derivative 19 or 33 (2 and 3 µs, respectively) were performed. Simulations were prepared 
by induced fit docking of 19 and 33 to the M2R in the inactive state (Figure 16).  
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Figure 16. Induced fit docking-derived binding poses of the dibenzodiazepinone derivatives 
19 (A) and 33 (B) at the human M2R (inactive state, PDB ID 3UON), which were used as 
initial coordinates for the MD simulations (cf. experimental section). 
 
The docking-derived orientation of 19 showed interactions of 19 with the lower part of the 
allosteric vestibule (Figure 16A), which was, regardless of minor conformational changes, 
persistent during the 2-µs simulation (Figure 17A and Figure 18). Amino acid residues 
reported to be involved in binding of the allosteric M2R ligand 922 appeared to be in close 
proximity to the monomeric ligand 19 and amino acid residues interacting with 19 (Figure 
17A). These data suggested a (partial) overlap of the binding sites of 9 and 19, which is 
consistent with the results of the experiments presented in Figure 15B (Schild-like analysis). 
Notably, the backbone contact between the propionamide moiety in 19 and I178ECL2 
suggested that 19 reaches the extracellular surface of the M2R. 
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Figure 17. Molecular dynamics simulation of the human M2R (inactive state, PDB ID 3UON) 
bound to the dibenzodiazepinone derivatives 19 and 33 (2 and 3 µs, respectively). (A) 
Cluster 1 binding pose of 19 (shown in purple). (B) Cluster 1 binding pose of 33 (shown in 
green). In A and B carbon atoms of amino acids constituting the D1033.32-W993.28-S762.57-
Y4307.43 cluster are highlighted in cyan (only assigned in B). Key amino acids suggested to 
interact with 19 were Y1043.33 (π-π), I178ECL2 (HB), T1905.42 (HB) and Y4036.51 (HB) (A). Key 
amino acids suggested to interact with 33 were T842.65 (HB), D1033.32 (HB), Y1043.33 (π-π), 
T170ECL2 (HB), Y4036.51 (HB), W4227.35 (HB) and Y4267.39 (HB) (B). In A, amino acids 
reported to interact with the allosteric modulator 9, that is Y802.61, E172ECL2, Y177ECL2, 
N4106.58, N4197.32, W4227.35 and Y4267.39, are surrounded by transparent cyan surface.22 
(C) Time course of the 3-µs MD simulation of the M2R bound to 33 showing superimposed 
snap shots collected every 100 ns. (D) Superimposition of the cluster 1 binding poses of 19 
(purple) and 33 (green). HB = hydrogen bonding. 
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Figure 18. Binding poses of cluster 2 (A), 3 (B), 4 (C) and 5 (D) (cf. Table 5) of the 
monomeric dibenzodiazepinone derivative 19 (shown in purple) obtained from a 2-µs MD 
simulation of the human M2R (inactive state, PDB ID 3UON) bound to 19. The poses and 
putative interactions of 19 with the M2R were comparable to that of cluster 1 (see Figure 
17A). 
 
As also observed for the monomeric compound 19, the orientation of the orthosterically 
bound part of the dimeric ligand 33 varied only marginally during the 3-µs simulation, that 
is, it remained tightly bound to the orthosteric site. By contrast, the major part of the linker 
and the second dibenzodiazepinone pharmacophore in 33, being unbound and located in 
the ‘extracellular space’ at the beginning of the simulation (cf. Figure 16B and frame 1 
(orange) in Figure 17C), showed a high flexibility over the first 2 µs (in part reflected by 
Figure 17C and Figure 19). Strikingly, in the late phase of the simulation the flexibility of the 
allosterically interacting part of 33 was much lower resulting in a persistence of the 
predominant binding pose of 33 (represented by cluster 1, Figure 17D, Table 5) over 1 µs 
(Figure 17C).  
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Figure 19. Binding poses of cluster 2 (A), 3 (B), 4 (C) and 5 (D) (cf. Table 5) of the 
homodimeric dibenzodiazepinone derivative 33 (shown in green) obtained from a 3-µs MD 
simulation of the human M2R (inactive state, PDB ID 3UON) bound to 33. Whereas the 
binding poses of 33 were mostly invariant in the region of the orthosteric binding pocket 
they markedly differed concerning the allosterically interacting part of 33 (for cluster 1 
binding pose of 33 cf. Figure 17B) 
 
Table 5. Relative occurrence of the clusters 1-5 obtained by the cluster analysis of the MD 
simulation trajectories (cf. experimental section). 
Cluster 19 33 
1 92.8 % 95 % 
2 4.2 % 2 % 
3 1.3 % 1.7 % 
4 1.1 % 1.3 % 
5 0.6 % 0.1 % 
 
Notably, Asp1033.32, which typically forms a salt bridge with basic amine functions of MR 
agonists as a key interaction for receptor activation45 and can be involved in the binding of 
MR antagonists as well,21 did not show an interaction with the monomeric ligand 19 (Figure 
20B). By contrast, an interaction of Asp1033.32 was evident with the dimeric compound 33 
(Figure 20B). In both simulations, Asp1033.32 formed an H-bonding network with Ser762.57 
and Trp993.28, in case of the simulation with 19 additionally with Tyr4307.43 (cf. Figure 20A), 
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which is characteristic of the inactive receptor conformation.23 As anticipated, the 
homodimeric ligand 33 showed more ‘allosteric contacts’ in the simulation compared to the 
monomeric ligand 19. Summarized, the results obtained from the MD simulations were 
consistent with the results of the aforementioned experiments, which suggested a dualsteric 
binding mode of the investigated tricyclic MR ligands 19 and 33. 
 
 
Figure 20. H-bond analysis of the MD simulation trajectories performed for the D103 cluster 
(comprising D103, W99, S76, Y430) (A) and ligand receptor interactions (B). In case of the 
homodimeric ligand 33 ‘allosteric contacts’ were considerably more pronounced compared 
to the monomeric ligand 19 (B). The % strength of interaction values represent cumulated 
values taking into account all possible atom to atom combinations of the given amino acid 
pairs (excluding the backbone) (A) or atom to atom combinations of the respective ligand 
and the given amino acid (including the backbone). 
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2.2.9 M2R binding studies with 50  
Compound 50, representing the allosterically interacting part of the dualsterically binding 
MR ligand 19, was investigated with respect to M2R binding by studying its potential 
inhibitory effect on M2R equilibrium binding of [3H]NMS and [3H]19 at intact CHO-hM2 cells. 
50 could not ‘inhibit’ M2R binding of [3H]NMS and [3H]19 at concentrations below 100 µM 
(Figure 21) suggesting that the allosteric interactions of 19 are not or only marginally 
responsible for the high M2R affinity of the dualsteric ligand 19. 
 
 
Figure 21. Effect of 50 on M2R equilibrium binding of [3H]NMS (c = 0.2 nM, Kd = 0.09 nM) 
and [3H]19 (c = 2 nM, Kd = 0.87 nM) determined at intact CHO-hM2 cells. 50 did not ‘inhibit’ 
M2R binding of [3H]NMS and [3H]19 at concentrations below 100 µM. Shown are data of 
representative experiments performed in triplicate (at least two independent experiments 
were performed and gave comparable results). 
  
Chapter 2 
58 
2.3.  Conclusion 
The presented study comprises the first report on tritium-labeled dibenzodiazepinone-type, 
M2R subtype-preferring MR antagonists including the comparison of a homodimeric 
derivative ([3H]33) with its monomeric counterpart ([3H]19). With Kd values below 1 nM both 
radioligands exhibited considerably higher M2R affinities than the structurally related 
pyridobenzodiazepinone-type MR antagonist [3H]10 (Kd = 11 nM, M2R), that was previously 
suggested to bind to the allosteric vestibule of the M2R.29 The synthesis of the radiolabeled 
compounds [3H]19 and [3H]33 contributed significantly to the elucidation of the M2R binding 
mode of the high affinity dibenzodiazepinone derivatives 19 and 33. The results from 
various binding experiments with [3H]19 and [3H]33, in particular, saturation binding studies 
in the absence and in the presence of well characterized allosteric M2R ligands (compounds 
8 and 9), strongly indicated that the presented type of M2R antagonists (19, 33, and 
presumably the reported congeners 20 and 21, too) interact simultaneously with both the 
orthosteric and the ‘common’ allosteric binding site. Therefore, this study demonstrates that 
the use of radiolabeled analogs can significantly contribute to a better understanding of the 
binding mode of complex receptor ligands. The dualsteric radioligands [3H]19 and [3H]33, 
which are synthetically conveniently available and exhibit high M2R affinity and high 
chemical stability, represent valuable pharmacological tools complementary to known 
orthosteric MR radioligands. Moreover, this work suggests dibenzodiazepinone-type MR 
ligands as privileged structures to develop M2R selective antagonists according to the 
dualsteric ligand approach8, 14, 16-20 by the synthesis of heterodimeric ligands comprising a 
linkage of the dibenzodiazepinone scaffold to reported allosteric M2R pharmacophores as 
well as to newly designed allosterically interacting moieties based on the information from 
MR crystal structures. 
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2.4.  Experimental Section 
2.4.1 General experimental conditions  
Chemicals and solvents were purchased from commercial suppliers and were used without 
further purifications unless otherwise specified. Acetonitrile for HPLC (gradient grade) was 
obtained from Merck (Darmstadt, Germany). N-methyl scopolamine (1), atropine (2), 
carbachol (3), gallamine (7), 8, 22, 34, 39 and 40 were purchased from Sigma-Aldrich 
(Deisenhofen, Germany). Oxotremorine sesquifumarate (4) was from MP Biomedicals 
(Eschwege, Germany), compound 9 was from Absource Diagnostic (Munich, Germany) and 
10 was purchased from Abcam (Cambridge, UK). [3H]NMS (specific activity = 80 Ci/mmol) 
was purchased from American Radiolabeled Chemicals Inc. (St. Louis, MO) via Hartman 
Analytics GmbH (Braunschweig, Germany). The syntheses of dibenzodiazepinone 
derivative 30 and urocanic acid derivative 48 were described previously.31 Xanomeline (5) 
and compound 36 were synthesized according to described procedures.46, 47 Technical 
grade solvents (CH2Cl2, ethyl acetate, light petroleum) were distilled before use. For solvent 
dehydration THF and diethyl ether were distilled over sodium, and CH2Cl2 was distilled over 
P2O5 after predrying over CaCl2. Millipore water was used throughout for the preparation of 
buffers and HPLC eluents. Polypropylene reaction vessels (1.5 or 2 mL) with screw cap 
(Süd-Laborbedarf, Gauting, Germany) were used for the synthesis of radioligands ([3H]19, 
[3H]33, [3H]47), for small scale reactions, for the investigation of chemical stabilities (19, 47) 
and for the preparation and storage of stock solutions. The chemical stability of 33 was 
investigated in a flat-bottom glass tube (40 × 8.2 mm) (Altmann Analytik GmbH, Munich, 
Germany), which was siliconized before use using Sigmacote (Sigma-Aldrich). Thin layer 
chromatography (TLC) was performed on Merck silica gel 60 F254 TLC aluminum plates. 
Visualization was accomplished by UV irradiation (λ = 254 or 366 nm) and by staining with 
ninhydrin or potassium permanganate. Silica Gel 60 (40-60 µm, Merck) was used for 
column chromatography. A Biotage Initiator microwave synthesizer (Biotage, Uppsala, 
Sweden) was used for microwave driven reactions. NMR spectra were recorded on a Bruker 
Avance 300 (7.05 T, 1H: 300.1 MHz, 13C: 75.5 MHz), Bruker Avance III HD 400 (9.40 T, 1H: 
400 MHz, 13C: 100 MHz) or a Bruker Avance III HD 600 equipped with a cryogenic probe 
(14.1 T 1H: 600.1 MHz, 13C: 150.9 MHz) (Bruker, Karlsruhe, Germany) with TMS as external 
standard. IR spectra were measured with a NICOLET 380 FT-IR spectrophotometer 
(Thermo Electron Corporation). Low-resolution mass spectrometry (MS) was performed on 
a Finnigan SSQ 710A instrument (CI-MS) (Thermo Finnigan, San Jose, CA). High-
resolution mass spectrometry (HRMS) analysis was performed on an Agilent 6540 UHD 
Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, Santa Clara, CA) using an 
ESI source. Preparative HPLC was performed with a system from Knauer (Berlin, Germany) 
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consisting of two K-1800 pumps and a K-2001 detector. A Kinetex-XB C18 (5 μm, 250 mm 
× 21 mm; Phenomenex, Aschaffenburg, Germany) or an Actus Triart C18 (5 μm, 150 mm 
× 21 mm; YMC Europe GmbH, Dinslaken, Germany) were used as stationary phases at a 
flow rate of 18 mL/min. Mixtures of acetonitrile and 0.1% aq TFA and mixtures of acetonitrile 
and 0.1% aq ammonia, respectively, were used as mobile phase. The detection wavelength 
was set to 220 nm throughout. The solvent of the collected fractions was removed by 
lyophilization using an Alpha 2-4 LD apparatus (Martin Christ, Osterode am Harz, Germany) 
equipped with a RZ 6 rotary vane vacuum pump (Vacuubrand, Wertheim, Germany). 
Analytical HPLC analysis of compounds 19, 33 and 47 (concentrations between 25 and 50 
μM) was performed with a system from Agilent Technologies composed of a 1290 Infinity 
binary pump equipped with a degasser, a 1290 Infinity autosampler, a 1290 Infinity 
thermostated column compartment, a 1260 Infinity diode array detector, and a 1260 Infinity 
fluorescence detector. A Kinetex-XB C18 (2.6 μm, 100 × 3 mm; Phenomenex) served as 
stationary phase at a flow rate of 0.5 mL/min except for the analysis of 50. Mixtures of 0.04% 
aq TFA (A) and acetonitrile (B) were used as mobile phase. The following linear gradient 
was applied: 0-20 min: A/B 90:10-68:32, 20-22 min: 68:32-5:95, 22-28 min: 5:95. Analytical 
HPLC analysis of compound 50 was performed using an Actus Triart C18 (3 μm, 150 × 2 
mm; YMC Europe) as stationary, and mixtures of 0.1% aq ammonia (C) and acetonitrile (B) 
as mobile phase (flow rate: 0.5 mL/min). The following linear gradient was applied: 0−10 
min: C/B 95:5-90:10, 10-20 min: 90:10-10:90, 20-28 min: 10:90. For all analytical HPLC 
runs the oven temperature was set to 25 °C, the injection volume was 20 μL and detection 
was performed at 220 nm. Melting points were determined with a Büchi 510 apparatus 
(Büchi, Essen, Germany) and are uncorrected.  
Annotation concerning the NMR spectra (1H, 13C) of the dibenzodiazepinone derivatives 
(31, 33, 37, 38, 46, 47): due to a slow rotation about the exocyclic amide group on the NMR 
time scale, two isomers (ratios provided in the experimental protocols) were evident in the 
1H- and 13C-NMR spectra. 
 
2.4.2 Compound characterization  
New organic compounds were characterized by 1H- and 13C-NMR spectroscopy, HRMS 
and melting point (if applicable). In addition, the target compounds 31, 33, 46, 47, 50 and 
52 were characterized by 2D-NMR spectroscopy (1H-COSY, HSQC, HMBC) and RP-HPLC 
analysis. Furthermore, IR spectra were acquired for the homodimeric ligands 33 and 47. 
The purity of final compounds, determined by RP-HPLC (220 nm), was ≥97% throughout 
(chromatograms shown in Appendix). 
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2.4.3 Chemistry: experimental protocols and analytical data 
Trimethyl 1,3,5-benzenetricarboxylate (23)48 Trimesic acid (22) (16 g, 76.1 mmol) was 
dissolved in MeOH (280 mL) and concentrated H2SO4 (4 mL, ca 75 mmol) was added 
dropwise under stirring. The mixture was refluxed for 24 h. Cooling to rt resulted in a partial 
precipitation of 23 as a white solid that was collected by vacuum filtration. The filtrate was 
evaporated to dryness to yield a white solid, which was dissolved in CH2Cl2 (40 mL) followed 
by washing with saturated aq NaHCO3 (2 × 15 mL) and drying over Na2SO4. Removal of 
the solvent under reduced pressure yielded 23 as a white solid that was combined with the 
above mentioned precipitated product (19.1 g, 75.8 mmol, 99%), mp 145 °C (lit.49 144-145 
°C). 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 3.92 (s, 9H), 8.56 (s, 3H). 13C-NMR (75 MHz, 
DMSO-d6): δ (ppm) 48.64, 130.97, 133.43, 164.56. MS (CI, NH3): m/z (%) 252 (25) [M]•+, 
221 (100) [M-OCH3]•+. C12H12O6 (252.22). 
 
3,5-Di(methoxycarbonyl)benzoic acid (24)33 1 N aq NaOH (19.8 mL, 19.8 mmol) was 
added dropwise to a suspension of 23 (5.55 g, 22.0 mmol) in MeOH (500 mL) over a period 
of 5 min and the mixture was stirred vigorously at rt for 18 h (after 8 h solid material had 
completely disappeared). The volatiles were removed under reduced pressure. The residue 
was dissolved in CH2Cl2 (75 mL) and the product was extracted with saturated aq NaHCO3 
(2 × 75 mL). The organic phase was dried over Na2SO4 and the solvent was evaporated to 
give non-converted starting material 23. The aqueous phase was acidified (pH 2) by the 
addition of concentrated aq hydrochloric acid to yield a white precipitate. Solid material was 
collected by vacuum filtration, washed with EtOAc (2 × 75 mL) and dried in vacuo to give 
24 as a white solid (3.95 g, 16.6 mmol, 75%), mp 145-147°C (lit.50 145-147 °C). 1H-NMR 
(300 MHz, CDCl3): δ (ppm) 4.00 (s, 6H), 8.90-8.94 (m, 3H). 13C-NMR (75 MHz, CDCl3): δ 
(ppm) 53.89, 130.44, 131.53, 135.28, 135.59, 165.41, 170.28. HRMS (ESI): m/z [M+H]+ 
calcd. for [C11H12O6]+ 239.0550, found 239.0549. C11H11O6 (238.20). 
 
Dimethyl 5-(hydroxymethyl)isophthalate (25)33 Carboxylic acid 24 (3.40 g, 14.3 mmol) 
was dissolved in anhydrous THF (24 mL). Borane dimethyl sulfide complex (2 M in THF, 
14.3 mL, 28.6 mmol) was added dropwise over a period of 20 min (effervescence occurred). 
The solution was stirred at room temperature for 24 h. MeOH (50 mL) was added and 
stirring was continued at rt for 30 min. The volatiles were removed in vacuo to yield a white 
solid, which was dissolved in EtOAc (75 mL) followed by washing with H2O (75 mL), 
saturated aq NaHCO3 (75 mL) and brine (50 mL). The organic phase was dried over 
Na2SO4 and the solvent was evaporated under reduced pressure to afford 25 as a white 
solid (2.79 g, 12.4 mmol, 87%), mp 102-104 °C (lit.33 104 °C). 1H-NMR (300 MHz, CDCl3): 
δ (ppm) 3.94 (s, 6H), 4.79 (d, 2H, J 0.7 Hz), 8.20-8.22 (m, 2H), 8.56 (t, 1H, J 1.7 Hz). 13C-
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NMR (75 MHz, CDCl3): δ (ppm) 52.58, 64.29, 129.91, 130.89, 132.12, 142.03, 166.33. MS 
(CI, NH3): m/z (%) 224 (40) [M]•+, 193 (100) [M-OCH3]•+. C11H12O5 (224.21). 
 
Dimethyl 5-(chloromethyl)isophthalate (26)33 Alcohol 25 (2.0 g, 8.9 mmol) was dissolved 
in thionyl chloride (1.3 mL, 17.9 mmol) and the mixture was refluxed under an atmosphere 
of argon for 1.5 h. CHCl3 (40 mL) was added and the solution was washed with 1 N aq 
NaOH (2 × 50 mL) and brine (2 × 50 mL). The organic phase was dried over Na2SO4 and 
the volatiles were removed under reduced pressure to yield 26 as a white solid (2.13 g, 8.8 
mmol, 98%), mp 119-121 °C (lit.33 118-120 °C). 1H-NMR (300 MHz, CDCl3): δ (ppm) 3.95 
(s, 6H), 4.65 (s, 2H), 8.25 (d, 2H, J 1.6 Hz), 8.63 (t, 1H, J 1.6 Hz). 13C-NMR (75 MHz, CDCl3): 
δ (ppm) 45.00, 52.67, 130.71, 131.34, 133.90, 138.58, 165.87. MS (CI, NH3): m/z (%) 
244/242 (10/25) [M]•+, 213/211 (30/70) [M-OCH3]•+. C11H11ClO4 (242.66). 
 
Dimethyl 5-(azidomethyl)isophthalate (27)33 Compound 26 (2.0 g, 8.2 mmol) was 
dissolved in acetone/water (3:1 v/v) (40 mL). Sodium azide (3.21 g, 49.5 mmol) was added 
and the mixture was refluxed for 18 h. The volatiles were removed in vacuo, the residue 
was dissolved in CHCl3 (75 mL) and the solution was washed with brine (2 × 50 mL). The 
organic phase was dried over Na2SO4 and the solvent removed under reduced pressure to 
yield 27 as a pale yellow solid (1.98 g, 7.9 mmol, 96%), mp 74-76 °C (lit.33 74-75 °C). 1H-
NMR (300 MHz, CDCl3): δ (ppm) 3.96 (s, 6H), 4.48 (s, 2H), 8.19 (d, 2H, J 1.6 Hz), 8.65 (t, 
1H, J 1.7 Hz). 13C-NMR (75 MHz, CDCl3): δ (ppm) 52.68, 54.03, 130.61, 131.38, 133.33, 
136.72, 165.94. HRMS (ESI): m/z [M+H]+ calcd. for [C11H12N3O4]+ 250.0823, found 
250.0822. C11H11N3O4 (249.23). 
 
5-(Aminomethyl)isophthalic acid hydrochloride (28)34 H2O (10 mL) and 
triphenylphosphine (1.89 g, 7.2 g) were added to a solution of 27 (1.6 g, 6.42 mmol) in THF 
(30 mL) and the mixture was stirred at room temperature for 10 h. 1 M aq NaOH (24.6 mL, 
24.6 mmol) was added and stirring was continued for 8 h. H2O (30 mL) was added followed 
by treatment with CH2Cl2 (1 × 100 mL) and EtOAc (1 × 100 mL). The aqueous phase, 
containing the product, was acidified (pH 5) by the addition of 1 N HCl. THF (100 mL) was 
added and the mixture was kept at −20 °C overnight yielding a white precipitate that was 
collected by filtration, washed with ethanol (2 × 30 mL) and dried to afford 28 as a white 
solid (0.89 g, 4.6 mmol, 71%). 1H-NMR (300 MHz, D2O): δ (ppm) 4.14 (s, 2H), 8.08 (d, 2H, 
J 1.7 Hz), 8.28 (t, 1H, J 1.6 Hz). 13C-NMR (75 MH, D2O): δ (ppm) 57.35, 131.07, 131.16, 
133.65, 134.44, 168.44. HRMS (ESI): m/z [M+H]+ calcd. for [C9H10NO4]+ 196.0605, found 
196.0613. C9H9NO4 · HCl (195.17 + 36.46). 
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N-tert-Butoxycarbonyl-5-(aminomethyl)isophthalic acid (29)51 Triethylamine (323 µL, 
2.31 mmol) and di-tert-butyl-dicarbonate (202 mg, 0.92 mmol) were added to a suspension 
of 28 (150 mg, 0.77 mmol) in H2O/dioxane (1:1 v/v) (16 mL) and the mixture was vigorously 
stirred at rt for 24 h. 1 N HCl was added (pH 2) and the mixture was kept at −78 °C overnight. 
Removal of the solvent by lyophilization yielded a white residue which was suspended in 
EtOAc (30 mL) followed by treatment with 0.1 M aq NaHSO4 (30 mL) and brine (30 mL). 
The organic phase was dried over Na2SO4 and the volatiles were removed under reduced 
pressure to give 29 as a white powder (140 mg, 0.47 mmol, 61%), mp >300 °C (decomp.). 
1H-NMR (300 MHz, MeOH-d4): δ (ppm) 1.47 (s, 9H), 4.34 (s, 2H), 8.16 (br s, 2H), 8.53 (br 
s, 1H). 13C-NMR (75 MHz, MeOH-d4): δ (ppm) 28.74, 44.38, 80.47, 130.52, 132.64, 133.39, 
158.61, 168.73. HRMS (ESI): m/z [M−H]− calcd. for [C14H16NO6]−, 294.0983, found 
294.1008. C14H17NO6 (295.29).  
 
5-(Aminomethyl)-N1,N3-bis(2-(3-(1-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)-1H-imidazol-4-
yl)propanamido)ethyl) isophthalamide pentakis(hydrotrifluoroacetate) (31) HOBt (39 
mg, 0.29 mmol), TBTU (188 mg, 0.584 mmol) and DIPEA (132 µL, 0.75 mmol) were added 
to a solution of 29 (43 mg, 0.15 mmol) in DMF and the mixture was stirred at rt for 15 min. 
Amine 30 (tris(hydrotrifluoroacetate))31 was added and stirring was continued at 60 °C for 3 
h. The volatiles were removed under reduced pressure, the residue was dissolved in 
CH2Cl2/TFA/H2O 1:1:0.1 (v/v/v, 8 mL) and the mixture was stirred at rt for 2 h followed by 
evaporation of the volatiles. Purification by preparative HPLC (column: Kinetex-XB C18, 
gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-60:40, tR = 16 min) yielded 31 as a white 
fluffy solid (89 mg, 0.048 mmol, 32%). Ratio of configurational isomers evident in the NMR 
spectra: ca 1.6:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.30-1.36 (m, 8H), 1.40-1.58 (m, 
6H), 1.80-1.98 (m, 8H), 2.60 (t, 4H, J 7.2 Hz), 2.85-2.94 (m, 2H), 2.97 (t, 4H, J 7.2 Hz), 3.00-
3.11 (m, 2H), 3.41 (t, 4H, J 6.2 Hz), 3.43-3.49 (m, 2H), 3.50 (t, 4H, J 6.1 Hz), 3.73 (d, 3H, J 
16.4 Hz), 3.80 (d, 1H, J 16.6 Hz), 4.15 (t, 4H, J 7.3 Hz), 4.24 (s, 2H), 4.41 (d, 1H, J 16.6 
Hz), 4.45 (d, 1H, J 16.6 Hz), 7.22-7.42 (m, 7H), 7.44-7.56 (m, 4H), 7.59-7.72 (m, 4H), 7.75 
(t, 1H, J 1.6 Hz), 7.90 (d, 1H, J 8.1 Hz), 7.96 (d, 1H, J 7.9 Hz), 8.06 (d, 2H, J 1.5 Hz), 8.28 
(t, 1H, J 1.7 Hz), 8.80 (d, 2H, J 1.5 Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ (ppm) 21.51, 
24.17, 30.39, 31.08, 34.26, 34.88, 36.00, 40.08, 40.93, 43.79, 50.34, 54.87, 55.23, 58.08, 
119.78, 123.08, 123.65, 126.85, 127.52, 127.89, 128.48, 128.87, 129.44, 130.11, 130.55, 
130.88, 131.21, 131.71, 131.87, 131.95, 132.34, 133.00, 133.40, 134.57, 134.92, 135.26, 
135.47, 135.52, 135.72, 137.02, 141.00, 142.67, 164.98, 165.48, 168.81, 168.84, 174.02. 
HRMS (ESI): m/z [M+4H]4+ calcd. for [C73H91N15O8]4+ 326.4289, found 326.4305. RP-HPLC 
(220 nm): 98% (tR = 11.7 min, k = 11.6). C73H87N15O8 · C10H5F15O10 (1302.60 + 570.12). 
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N1,N3-Bis(2-(3-(1-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-
5-yl)ethyl)piperidin-4-yl)butyl)-1H-imidazol-4-yl)propanamido)ethyl)-5-
(propionamidomethyl)isophthalamide tetrakis(hydrotrifluoroacetate) (33) 
Succinimidyl proprionate (32) (3.28 mg, 19 µM) was added to a solution of 31 (30 mg, 0.016 
mM) and DIPEA (22 µL, 0.128 mmol) in anhydrous DMF (0.45 mL) and the mixture was 
stirred at rt for 45 min. 10% aq TFA (1 mL) was added and the product was purified by 
preparative HPLC (column: Kinetex-XB C18, gradient: 0-25 min: 0.1% aq TFA/acetonitrile 
90:10-60:40, tR = 18 min). 33 was obtained as a white fluffy solid (28 mg, 0.015 mmol, 95%). 
IR (KBr): 3310, 3130, 3065, 2940, 2865, 1665, 1550, 1505, 1460, 1365, 1200, 1135, 800, 
720 cm-1. Ratio of configurational isomers evident in the NMR spectra: ca 1.7:1. 1H-NMR 
(600 MHz, MeOH-d4): δ (ppm) 1.15 (t, 3H, J 7.6 Hz), 1.30-1.33 (m, 8H), 1.38-1.57 (m, 6H), 
1.77-1.98 (m, 8H), 2.30 (q, 2H, J 7.6 Hz), 2.59 (t, 4H, J 7.1 Hz), 2.88-2.95 (m, 2H), 2.97 (t, 
4H, J 7.1 Hz), 3.01-3.08 (m, 2H), 3.40 (t, 4H, J 6.0 Hz), 3.42-3.47 (m, 2H), 3.48 (t, 4H, J 6.0 
Hz), 3.73 (d, 3H, J 16.3 Hz), 3.80 (d, 1H, J 16.6 Hz), 4.13 (t, 4H, J 7.3 Hz), 4.41 (d, 1H, J 
16.7 Hz), 4.44 (s, 2H), 4.45 (d, 1H, J 16.6 Hz), 7.24-7.40 (m, 7H), 7.45-7.55 (m, 4H), 7.60-
7.71 (m, 4H), 7.74 (t, 1H, J 1.6 Hz), 7.86 (d, 2H, J 1.6 Hz), 7.90 (d, 1H, J 8.1 Hz), 7.96 (d, 
1H, J 7.8 Hz), 8.12 (t, 1H, J 1.7 Hz), 8.77 (d, 2H, J 1.5 Hz). 13C-NMR (150.9 MHz, MeOH-
d4): δ (ppm) 10.39, 21.50, 24.15, 30.13, 30.38, 31.06, 34.25, 34.81, 36.00, 40.14, 40.93, 
43.67, 50.33, 54.90, 55.31, 58.02, 119.77, 123.08, 123.65, 126.22, 126.84, 127.52, 127.88, 
128.48, 128.88, 129.44, 130.11, 130.15, 130.55, 130.89, 131.21, 131.71, 131.95, 132.35, 
133.00, 133.40, 134.57, 134.91, 135.24, 135.42, 135.72, 136.38, 137.02, 141.61, 142.67, 
165.48,169.36, 174.03, 177.21. HRMS (ESI): m/z [M+4H]4+ calcd. for [C73H95N15O9]4+ 
340.4354, found 340.4367. RP-HPLC (220 nm): 98% (tR = 13.4 min, k = 13.6). C73H91N15O9 
· C8H4F12O8 (1358.66 + 456.09). 
 
4-(Piperidin-4-yl)butan-1-ol (35)52 Under an atmosphere of argon piperidine derivative 34 
(800 mg, 3.9 mmol) was suspended in anhydrous THF (15 mL) and the mixture was cooled 
in an ice-bath. LiAlH4 (365 mg, 9.6 mmol) was added portionwise over a period of 10 min. 
The resulting suspension was stirred at 0 °C for 1 h and under reflux for 12 h. The mixture 
was cooled to rt and 20% aq NaOH (w/w, 10 mL) was added and the suspension was 
vigorously stirred for 1 h. Solid material was removed by filtration through a pad of celite 
and the volatiles of the filtrate were removed under reduced pressure to yield 35 as a pale 
yellow oil (539 mg, 3.4 mmol, 89%), which was used without purification. HRMS (ESI): m/z 
[M+H]+ calcd. for [C9H20NO]+ 158.1540, found 158.1541. C9H19NO (157.26). 
 
5-(2-(4-(4-Hydroxybutyl)piperidin-1-yl)acetyl)-5,10-dihydro-11H-dibenzo[b,e][1,4] 
diazepin-11-one (37) Freshly grained K2CO3 (3.19 g, 6.9 mmol) was added to a solution of 
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35 (0.91 g, 5.8 mmol) and dibenzodiazepinone derivative 3653 in acetonitrile (30 mL) and 
the mixture was vigorously stirred under reflux for 5 h. Solid material was removed by 
filtration, the filtrate collected and the volatiles evaporated under reduced pressure. The 
residue was dissolved in EtOAc (30 mL) and the solution was washed with H2O (3 × 30 
mL). The organic phase was dried over Na2SO4 and the solvent was removed under 
reduced pressure. Purification by column chromatography (eluent: CH2Cl2/MeOH/NH3 (7 M 
in MeOH) 100:5:1 (Rf = 0.3)) afforded 37 as a colorless glass (1.0 g, 2.5 mmol, 43%). Ratio 
of configurational isomers evident in the NMR spectra: ca 2.1:1. 1H-NMR (300 MHz, MeOH-
d4): δ (ppm) 0.99-1.41 (m, 7H), 1.42-1.70 (m, 4H), 1.81-2.12 (m, 2H), 2.46-2.70 (m, 1H), 
2.83 (t, 1H, J 11.4 Hz), 2.97-3.29 (m, 2H), 3.52 (t, 2H, J 6.5 Hz), 7.16-7.73 (m, 7H), 7.88 (t, 
1H, J 9.3 Hz). 13C-NMR (150 MHz, MeOH-d4): δ (ppm) 24.05, 30.16, 32.90, 33.84, 36.42, 
37.37, 54.82, 54.99, 60.96, 62.91, 122.95, 126.56, 126.94, 127.76, 128.92, 129.46, 129.87, 
130.55, 132.01, 132.17, 134.27, 134.68, 135.92, 143.83. HRMS (ESI): m/z [M+H]+ calcd. 
for [C24H30N3O3]+ 408.2282, found 408.2290. C24H29N3O3 (407.51). 
 
5-(2-(4-(4-Bromobutyl)piperidin-1-yl)acetyl)-5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one (38) In a three-necked round-bottom flask compound 
37 (200 mg, 0.49 mmol) and triphenylphosphine (386 mg, 1.47 mmol) were dissolved in 
CH2Cl2 (5 mL) under an atmosphere of argon and the mixture was cooled to −5°C. 
Tetrabromomethane (1.058 g, 3.19 mmol) in CH2Cl2 (10 mL) was added dropwise to over 
a period of 10 min and the mixture was stirred at 0 °C for 5 h followed by washing with H2O 
(2 x 10 mL) and brine (1 x 10 mL). The organic phase was dried over Na2SO4 and the 
solvent was removed under reduced pressure. The residue was subjected to column 
chromatography (eluent: light petroleum/acetone/25% aq NH3 (83:16:1 (Rf = 0.5)) to give 
38 as a white solid (180 mg, 79%). Ratio of configurational isomers evident in the NMR 
spectra: ca 2:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 0.83-1.33 (m, 7H), 1.33-1.67 (m, 
4H), 1.86-2.05 (m, 2H), 2.45-2.71 (m, 1H), 2.85 (t, 1H, J 12.0 Hz), 2.98-3.30 (m, 2H), 3.42 
(t, 2H, J 6.7 Hz), 7.18-7.72 (m, 7H), 7.88 (t, 1H, J 9.5 Hz). 13C-NMR (150 MHz, MeOH-d4): 
δ (ppm) 26.31, 32.83, 34.13, 34.40, 36.27, 36.55, 54.89, 54.94, 60.93, 61.29, 123.00, 
126.95, 127.76, 128.89, 129.46, 130.56, 131.93, 132.16, 133.33, 133.75, 133.79, 134.25, 
135.89, 143.80. HRMS (ESI): m/z [M+H]+ calcd. for [C24H29BrN3O2]+ 470.1438, found: 
470.1437. C24H28BrN3O2 (470.41). 
 
(1,4-Dibenzyl-6-nitro-1,4-diazepan-6-yl)methanol (41)54 Amine 39 (0.98 mL, 4.16 mmol) 
and nitroethanol 40 (0.3 mL, 4.16 mmol) were dissolved in toluene/EtOH (1:1 v/v) (40 mL). 
Paraformaldehyde (450 mg, 14.8 mmol) was added portionwise and the suspension was 
vigorously stirred under reflux for 6 h. The volatiles were removed under reduced pressure, 
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the residue was dissolved in CH2Cl2 (15 mL) and the solution was washed with H2O (3 × 10 
mL). The organic phase was dried over Na2SO4 and the solvent evaporated. Purification by 
column chromatography (eluent: light petroleum/EtOAc 6:1-4:1 (Rf = 0.3, light 
petroleum/EtOAc 6:1)) yielded 41 as a pale yellow oil (1.3 g, 3.66 mmol, 87%). 1H-NMR 
(300 MHz, CDCl3): δ (ppm) 2.57-2.76 (m, 4H), 3.05 (d, 2H, J 14.5 Hz), 3.51 (d, 2H, J 14.3 
Hz), 3.65 (d, 2H, J 12.9), 3.68 (s, 2H), 3.74 (d, 2H, J 13.1 Hz), 7.29 (m, 10H). 13C-NMR (75 
MHz, CDCl3): δ (ppm) 59.06, 60.56, 63.86, 65.82, 94.64, 127.65, 128.56, 129.23, 138.66. 
HRMS (ESI): m/z [M+H]+ calcd. for [C20H26N3O3]+ 356.1969, found: 356.1978. C20H25N3O3 
(455.44). 
 
1,4-Dibenzyl-6-nitro-1,4-diazepane (42)55 Homopiperazine 41 (472 mg, 1.33 mmol) was 
dissolved in anhydrous THF (3.5 mL), potassium tert-butanolate (228 mg, 2.03 mmol) was 
added and the suspension was vigorously stirred at rt for 30 min. Insoluble material was 
removed by filtration and the volatiles were evaporated. The residue was dissolved in 
aqueous H2NOH × HCl (0.2 mmol, 10 mL) immediately followed by extraction with CH2Cl2 
(3 × 50 mL). The organic phase was dried over Na2SO4 and the volatiles were evaporated 
to afford compound 42 as a yellow oil (410 mg, 1.26 mmol, 95%), which was used without 
further purification. 1H-NMR (300 MHz, CDCl3): δ (ppm) 2.68 (s, 4H), 3.21-3.34 (m, 2H), 
3.40-3.52 (m, 2H), 3.75 (d, 4H, J 5.9 Hz), 4.59 (t, 1H, J 5.3 Hz), 7.22-7.36 (m, 10H). 13C-
NMR (75 MHz, CDCl3 MHz): δ (ppm) 56.72, 56.93, 62.82, 77.37, 127.48, 128.51, 128.86, 
138.69. HRMS (ESI): m/z [M+H]+ calcd. for [C19H24N3O2]+ 326.1863, found: 326.1884. 
C19H23N3O2 (325.41). 
 
1,4-Dibenzyl-1,4-diazepan-6-amine (43)56 Homopiperazine 42 (700 mg, 2.15 mmol) was 
dissolved in EtOH (25 mL). Raney 2800 (slurry in H2O, ca 5 mL) was carefully added and 
the suspension was stirred under an atmosphere of hydrogen at rt for 12 h. The catalyst 
was removed by filtration through a pad of celite and the volatiles were evaporated. The 
residue was subjected to column chromatography (eluent: CH2Cl2/MeOH/NH3 (7 M in 
MeOH) 100:10:1 (Rf = 0.2)) to give 43 as a pale yellow oil (278 mg, 0.94 mmol, 44%). 1H-
NMR (300 MHz, CDCl3): δ (ppm) 2.46-2.59 (m, 2H), 2.60-2.72 (m, 2H), 2.72-2.82 (m, 2H), 
2.81-2.92 (m, 2H), 3.16 (br s, 1H), 3.68 (d, 4H, J 5.0 Hz), 7.19-7.40 (m, 10H). 13C-NMR (75 
MHz, CDCl3 MHz): δ (ppm) 50.23, 56.43, 61.04, 63.48, 127.19, 128.40, 129.01, 139.26. 
HRMS (ESI): m/z [M+H]+ calcd. for [C19H26N3]+ 296.2121, found: 296.2128. C19H25N3 
(295.43). 
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tert-Butyl (1,4-dibenzyl-1,4-diazepan-6-yl)carbamate (44)57 Amine 43 (333 mg, 1.13 
mmol) was dissolved in CHCl3 (10 mL), the solution was cooled in an ice-bath and a solution 
of di-tert-butyldicarbonate (296 mg, 1.35 mmol) in CHCl3 (5 mL) was added dropwise over 
a period of 10 min. The bath was removed and the mixture was stirred at rt for 5 h followed 
by washing with H2O (3 × 15 mL). The organic phase was dried over Na2SO4 and the 
volatiles were removed under reduced pressure. Purification by column chromatography 
(eluent: CH2Cl2/MeOH 100:2.5 (Rf = 0.25)) yielded 44 as a pale yellow oil (361 mg, 0.91 
mmol, 81%). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.39 (s, 9H), 2.35-3.03 (m, 9H), 3.46-3.86 
(m, 5H), 7.14-7.48 (m, 10H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 28.56, 48.99, 56.98, 59.47, 
63.46, 77.36, 127.22, 128.46, 129.06, 139.41, 155.41. HRMS (ESI): m/z [M+H]+ calcd. for 
[C24H34N3O2]+ 396.2646, found: 396.2666. C24H33N3O2 (395.55). 
 
tert-Butyl (1,4-diazepan-6-yl)carbamate (45)58 Under an atmosphere of argon Pd/C (10%) 
(35 mg) was carefully added to a solution of 44 (70 mg, 0.18 mmol) in 2,2,2-trifluoroethanol 
(2 mL). The mixture was vigorously stirred under an atmosphere of hydrogen at rt for 12 h. 
Solid material was removed by filtration thought a pad of celite and the volatiles were 
evaporated to obtain 45 as a colorless oil (34 mg, 0.16 mmol, 88%), which was used without 
further purification. 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 1.37 (s, 9H), 2.52-2.59 (m, 2H), 
2.62-2.71 (m, 4H), 2.84-2.90 (m, 2H), 3.43-3.53 (m, 1H). 13C-NMR (75 MHz, DMSO-d6): δ 
(ppm) 28.2, 51.9, 53.1, 56.4, 77.3, 154.7. HRMS (ESI): m/z [M+H]+ calcd. for [C10H22N3O2]+ 
216.1707, found: 216.1707. C10H21N3O2 (215.30). 
 
5,5'-(2,2'-(((6-Amino-1,4-diazepane-1,4-diyl)bis(butane-4,1-diyl))bis(piperidine-4,1-
diyl))bis(acetyl))bis(5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one) 
pentakis(hydrotrifluoroacetate) (46) Dibenzodiazepinone 38 (60 mg, 0.13 mmol) and 
homopiperazine 45 (13 mg, 0.061 mmol) were dissolved in acetonitrile (1.5 mL). Freshly 
grained K2CO3 (38 mg, 0.24 mmol) was added and the mixture was stirred and heated in a 
microwave reactor at 120 °C for 1.5 h. The solvent was removed under reduced pressure 
and the residue was taken up in EtOAc (5 mL) followed by washing with H2O (3 × 5 mL). 
The organic phase was dried over Na2SO4 and the volatiles were removed in vacuo. The 
residue was dissolved in a mixture formed by CH2Cl2/TFA/H2O 1:1:0.1 (v/v/v, 3 mL) and the 
solution was stirred at rt for 3 h. The volatiles were evaporated and the residue was taken 
up in DMF/0.1% aq TFA 1:1 (v/v, 3 mL) and subjected to preparative HPLC (column: 
Kinetex-XB C18, gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-50:50, tR = 16 min) to 
yield 46 as a white fluffy solid (33 mg, 0.023 mmol, 37%). Ratio of configurational isomers 
evident in the NMR spectra: ca 1.5:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.26-1.57 (m, 
14H), 1.57-1.68 (m, 4H), 1.85-2.02 (m, 4H), 2.88-2.98 (m, 6H), 3.00-3.08 (m, 2H), 3.11-3.20 
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(m, 2H), 3.23-3.30 (m, 4H), 3.36-3.50 (m, 4H), 3.68-3.89 (m, 5H), 4.40 (d, 1.2H, J 16.8 Hz), 
4.44 (d, 0.8H, J 16.8 Hz), 7.24-7.41 (m, 5H), 7.45-7.56 (m, 4H), 7.60-7.71 (m, 4H), 7.75 (t, 
1H, J 7.7 Hz), 7.90 (d, 1H, J 8.4 Hz), 7.97 (d, 1H, J 7.8 Hz). 13C-NMR (150.9 MHz, MeOH-
d4): δ (ppm) 24.90, 26.54, 30.58, 34.47, 36.50, 53.81, 55.11, 55.47, 55.96, 58.08, 58.19, 
59.83, 123.23, 123.80, 127.00, 127.67, 128.02, 128.63, 129.03, 129.60, 130.26, 130.70, 
131.04, 131.36, 131.86, 132.12, 132.50, 133.16, 134.72, 135.09, 135.61, 136.87, 137.19, 
141.16, 142.83, 155.56 165.11, 165.59, 168.72, 168.98. HRMS (ESI): m/z [M+3H]3+ calcd. 
for [C53H70N9O4]3+ 298.8511, found: 298.8520. RP-HPLC (220 nm): 96% (tR = 12.5 min, k = 
12.5). C53H67N9O4 · C10H5F15O10 (894.18 + 570.12). 
 
N-(1,4-Bis(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-
yl)ethyl)piperidin-4-yl)butyl)-1,4-diazepan-6-yl)propionamide 
tetrakis(hydrotrifluoroacetate) (47) Succinimidyl proprionate 32 (2.7 mg, 0.015 mmol) 
was added to a solution of amine 46 (16 mg, 0.011 mmol) and DIPEA (15 µL, 0.087 mmol) 
in anhydrous DMF (400 µL) and the mixture was stirred at rt for 1.5 h. 10% aq TFA (20 µL) 
was added and the mixture was subjected to preparative HPLC (column: Kinetex-XB C18, 
gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-50:50, tR = 16 min) to yield 47 as a white 
fluffy solid (11.5 mg, 0.008 mmol, 72%). IR (KBr): 3435, 3060, 2945, 2865, 1680, 1505, 
1460, 1365, 1200, 1130, 800, 720 cm-1. Ratio of configurational isomers evident in the NMR 
spectra: ca 1.5:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.11 (t, 3H, J 7.7 Hz), 1.28-1.58 
(m, 14H), 1.66 (m, 4H), 1.86-2.01 (m, 4H), 2.24 (q, 2H, J 7.6 Hz), 2.93 (m, 2H), 3.00-3.08 
(m, 6H), 3.32-3.39 (m, 4H), 3.40-3.50 (m, 6H), 3.69-3.77 (m, 3H), 3.80 (d, 1H, J 16,7 Hz), 
4.31-4.37 (m, 1H), 4.40 (d, 1.2H, J 16.7 Hz), 4.44 (d, 0.8H, J 16.7 Hz), 7.23-7.42 (m, 5H), 
7.45-7.57 (m, 4H), 7.60-7.72 (m, 4H), 7.75 (t, 1H, J 7.7 Hz), 7.90 (d, 1H, J 8.2 Hz), 7.97 (d, 
1H, J 7.8 Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ (ppm) 10.03, 24.60, 26.08, 29.86, 30.43, 
34.32, 36.25, 52.93, 54.90, 54.96, 55.32, 57.59, 57.95, 58.04, 59.28, 123.08, 123.64, 
126.85, 127.50, 127.86, 128.47, 128.87, 129.43, 130.11, 130.55, 130.88, 131.22, 131.71, 
131.97, 132.35, 133.01, 133.40, 134.57, 134.93, 135.45, 135.72, 137.04, 141.00, 142.66, 
165.43, 168.56, 168.81, 176.89. HRMS (ESI): m/z [M+3H]3+ calcd. for [C56H74N9O5]3+ 
317.5266, found: 317.5273. RP-HPLC (220 nm): 98% (tR = 12.8 min, k = 12.9). C56H71N9O5 
· C8H4F12O8 (950.24 + 456.09). 
 
N-(2-Aminoethyl)-3-(1H-imidazol-4-yl)propanamide bis(hydrotrifluoroacetate) (49) 
Urocanic acid derivative 4831 (300 mg, 1.07 mmol) was dissolved in MeOH/TFA (1:1 v/v) (8 
mL) and a 10% Pd/C catalyst (30 mg) was carefully added under an atmosphere of argon. 
The mixture was stirred in an autoclave under an atmosphere of hydrogen at 7.9 atm at rt 
for 12 h. The catalyst was removed by filtration through a pad of celite and the volatiles 
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were evaporated to yield 49 as colorless oil (299 mg, 1.01 mmol, 95%), which was used 
without further purification. 1H-NMR (300 MHz, MeOH-d4): δ (ppm) 2.65 (t, 2H, J 7.3 Hz), 
2.98-3.09 (m, 4H), 3.46 (t, 2H, J 6.0 Hz), 7.31 (br s, 1H), 8.78 (d, 1H, J 1.4 Hz). 13C-NMR 
(75 MHz, MeOH-d4): δ (ppm) 21.15, 34.97, 38.32, 40.85, 117.10, 134.68, 134.78, 175.05. 
HRMS (ESI): m/z [M+H]+ calcd. for [C8H16N4O5]+ 183.1241, found: 183.1245. C8H15N4O5 · 
C4H2F6O2 (182.23 + 228.04). 
 
3-(1H-Imidazol-4-yl)-N-(2-propionamidoethyl)propanamide (50) A solution of 
succinimidyl proprionate 32 (23 mg, 0.134 mmol) in DMF (0.1 mL) was added to a solution 
of 49 (110 mg, 0.27 mmol) and DIPEA (0.234 mL, 1.34 mmol) in DMF (0.5 mL) and the 
mixture was stirred at rt for 30 min. 32% aq NH3 (0.15 mL) and H2O (3 mL) were added and 
the mixture was subjected to preparative HPLC (column: Actus Triart C18, gradient: 0-10 
min: 0.1% aq NH3/acetonitrile 95:5, 10-20 min: 95:5-88:12, tR = 10 min) to afford 50 as a 
white solid (27.5 mg, 0.115 mmol, 43%). 1H-NMR (400 MHz, MeOH-d4): δ (ppm) 1.11 (t, 
3H, J 7.6 Hz), 2.19 (q, 2H, J 7.6 Hz), 2.49 (t, 2H, J 7.6 Hz), 2.87 (t, 2H, J 7.6 Hz), 3.25 (m, 
4H), 6.79 (br s, 1H), 7.56 (d, 1H, J 1.2 Hz). 13C-NMR (100 MHz, MeOH-d4): δ (ppm) 10.37, 
23.93, 30.18, 36.86, 39.99, 40.05, 117.2, 135.93, 137.8, 175.46, 177.32. HRMS (ESI): m/z 
[M+H]+ calcd. for [C11H19N4O2]+ 239.1503, found: 239.1507. RP-HPLC (220 nm): 99% (tR = 
8.0 min, k = 3.0). C11H18N4O2 (238.29). 
 
5,5'-(2,2'-(Piperazine-1,4-diyl)bis(acetyl))bis(5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one) bis(hydrotrifluoroacetate) (52) Dibenzodiazepinone 
36 (100 mg, 0.35 mmol) and piperazine (51) (14 mg, 0.16 mmol) were dissolved in 
acetonitrile (2 mL). Freshly grained K2CO3 (88 mg, 0.64 mmol) was added and the 
suspension was stirred in a microwave reactor at 130 °C (approx. 4 bar) for 30 min. 
Insoluble material was removed by filtration, the volatiles were evaporated and the residue 
subjected to preparative HPLC (column: Kinetex-XB C18, gradient: 0-25 min: 0.1% aq 
TFA/acetonitrile 15:85-55:45, tR = 16 min) to yield 52 as a white fluffy solid (28 mg, 0.034 
mmol, 20%). Four isomers were evident in the 1H- and 13C-NMR spectrum and two isomers 
were evident by RP-HPLC analysis (ratio 1:1). HRMS analysis revealed a uniform sample 
with respect to the molecular formula. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 2.55-3.18 (m, 
8H), 3.43-3.56 (m, 1H), 3.56-3.65 (m, 1H), 3.65-3.72 (m, 0.5H), 3.72-3.84 (m, 0.5H), 3.86-
3.98 (m, 0.5H), 4.05-4.16 (m, 0.5H) 7.22-7.39 (m, 5H), 7.40-7.53 (m, 4H), 7.53-7.75 (m, 
5H), 7.84-7.98 (m, 2H). 13C-NMR (150.9 MHz, MeOH-d4): δ (ppm). 51.52, 52.08, 52.27, 
52.80, 58.19, 58.48, 58.91, 59.46, 123.17, 123.52, 123.63, 123.68, 126.94, 127.49, 127.58, 
127.75, 127.87, 128.72, 128.79, 129.04, 129.80, 129.88, 130.02, 130.11, 130.35, 130.44, 
130.56, 130.81, 131.06, 131.44, 131.61, 132.35, 132.40, 132.48, 132.65, 134.18, 134.63, 
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135.19, 135.29, 135.53, 135.76, 135.92, 137.13, 142.44, 143.04, 143.24, 166.99, 168.14, 
168.96, 169.14, 169.47. HRMS (ESI): m/z [M+H]+ calcd. for [C34H31N6O4]+ 587.2402, found: 
587.2423. RP-HPLC (220 nm): 98% (tR = 15.4, 15.6 min, k = 15.7, 15.9) C34H30N6O4. 
C4H2F6O2 (586.65 + 228.04). 
 
2.4.4 Investigation of the chemical stability 
The chemical stability of 19, 33 and 47 was investigated in PBS (pH 7.4) at 22 ± 1 °C. The 
incubation was started by the addition of 2 μL of a 10 mM solution of 19, 33 or 47 to PBS 
(198 μL) to yield a final concentration of 100 μM. After 0, 24 and 48 h, aliquots (20 μL) were 
taken and added to 1% aq TFA (20 μL). The resulting solutions were analyzed by RP-HPLC 
(analytical HPLC system and conditions see general experimental conditions; tR 8.8 min 
(19), 13.5 min (33), 12.8 min (47)). 
 
2.4.5 Synthesis of the radioligands [3H]19, [3H]33 and [3H]47.  
The tritiated dibenzodiazepinone derivatives [3H]19, [3H]33 and [3H]47 were prepared by 
[3H]propiolynation of the amino-functionalyzed precursors 30, 31 and 46, respectively, using 
a reported protocol with modifications.59 A solution of succinimidyl [2,3-3H]-proprionate 
([3H]32) (specific activity: 80 mCi/mmol; from American Radiolabeled Chemicals, St. Louis, 
MO, via Hartman Analytics, Braunschweig, Germany) (for [3H]19 and [3H]47: 2.5 mCi, 5.5 
µg, 31.25 nmol (each), for [3H]33: 2 mCi, 4.4 µg, 25 nmol) in hexane/EtOAc 9:1 was 
transferred into a 1.5-mL reaction vessel with a screw cap and the volatiles were evaporated 
in a vacuum concentrator (ca 30 min at about 30 °C). A solution of the precursor molecule 
(30: 411 µg, 0.76 µmol; 31: 870 µg, 0.46 µmol; 46: 400 µg, 0.27 µmol) in DMF/DIPEA (50:1 
v/v) (55 µL) was added and the mixture was shaken at rt for 45 min. In case of [3H]47 the 
excess of precursor 46 was ‘quenched’ by 4-fluorobenzoylation. For that purpose 
succinimidyl ester 53 (250 µg, 1.05 µmol) was added to the mixture and shaken at rt for one 
additional hour. After completed incubation and ‘precursor quenching’, 2% aq TFA (90 µL) 
and H2O/acetonitrile (3:1 v/v) (85 µL) were added. [3H]19, [3H]33 and [3H]47 were purified 
using an analytical HPLC system (Waters, Eschborn, Germany) consisting of two 510 
pumps, a pump control module, a 486 UV/vis detector, and a Flow-one Beta series A-500 
radiodetector (Packard, Meriden, CT). A Luna C18 (3 μm, 150 mm × 4.6 mm, Phenomenex, 
Aschaffenburg, Germany) was used as stationary phase at a flow rate of 0.8 mL/min. 
Mixtures of 0.05% aq TFA (A) and acetonitrile containing 0.04% TFA (B) were used as 
mobile phase. The following linear gradients were applied: [3H]19 and [3H]33, 0-20 min: A/B 
90:10-68:32, 20-30 min: 68:32-5:95, 30-38 min: 5:95, tR = 16.4 and 20.0 min, respectively); 
[3H]47, 0-20 min: A/B 90:10-75:25, 20-25 min: 75:25, 25-27 min: 75:25-5:95, 27-35 min: 
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5:95, tR = 24.7 min). For each radioligand, two HPLC runs (UV detection: 220 nm; no 
radiometric detection) were performed. Each radioligand was collected in a 2-mL reaction 
vessel with screw cap. The volumes of the combined eluates were reduced in a vacuum 
concentrator to 600 µL and EtOH (600 µL) was added. The solutions were transferred into 
3-mL borosilicate glass vials with conical bottom (Wheaton NextGen 3 mL V-vials). The 2-
mL reaction vessels were rinsed twice with EtOH/water (50:50 v/v) (various volumes), and 
the washings were transferred to the 3-mL glass vials to obtain tentative stocks with 
volumes of 1000 μL ([3H]19), 1000 μL ([3H]33) or 1200 μL ([3H]47). For the quantification, a 
five-point or four-point calibration was performed with the corresponding ‘cold’ forms 19 
(0.1, 0.2, 0.35, 0.5, 0.75 µM), 33 (0.2, 0.4, 0.7, 1, 1.5 µM) and 47 (0.1, 0.2, 0.5, 1 µM) 
(injection volume throughout 100 µL, UV detection at 220 nm) using the aforementioned 
HPLC system and conditions (in case of [3H]47 the linear gradient was modified: 0-20 min: 
A/B 90:10-69:31, 20-30 min: 69-31:5:95, 30-38 min: 5:95, tR = 19.9 min). Aliquots of the 
tentative stock solutions ([3H]19: 2.2 µL, [3H]33: 2.2 µL, [3H]47: 2 µL) were added to 0.05% 
aq TFA/acetonitrile (9:1 v/v) (127.8 and 128 µL, respectively), 100 µL of the resulting 
solutions were analyzed by HPLC, and five times 2 μL were counted in 3 mL of Rotiszint 
eco plus (Carl Roth, Karlsruhe, Germany) with a LS 6500 liquid scintillation counter 
(Beckman-Coulter, Munich, Germany). These analyses were repeated. The molarities of 
the tentative stock solutions were calculated from the mean of the peak areas and the linear 
calibration curves. In order to determine the radiochemical purities and to confirm the 
chemical identities, solutions (100 µL) of [3H]19 (0.23 µM), [3H]33 (0.20 µM) and [3H]47(0.20 
µM) spiked with 19 (5 µM), 33 (5 µM) and 47 (3 µM), respectively, were analyzed by HPLC 
using the conditions as for the quantification and additionally radiometric detection (flow rate 
of the liquid scintillator (Rotiscint eco plus/acetonitrile (85:15 v/v): 4.0 mL/min). For all 
radioligands the radiochemical purity was 99%. For [3H]19 and [3H]33 this analysis was 
repeated after 1 year of storage at −20 °C, whereas in case of [3H]47 it was repeated after 
9 months of storage at −20°C (radiochemical purities: [3H]19, 96%; [3H]33, 97%; [3H]47, 
96%). Calculated specific activities: [3H]19, 2.96 TBq/mmol (72.7 Ci/mmol); [3H]33, 1.81 
TBq/mmol (49.0 Ci/mmol); [3H]47, 2.19 TBq/mmol (59.3 Ci/mmol). The final activity 
concentration was adjusted to 27.75 MBq/mL ([3H]19) or 18.5 MBq/mL ([3H]33, [3H]47) by 
the addition of H2O/EtOH (1:1 v/v) resulting in molarities of 10.3 µM ([3H]19), 10.2 µM 
([3H]33) and 8.44 µM ([3H]47). Radiochemical yields: [3H]19, 36.0 MBq, 39%; [3H]33, 24.0 
MBq, 32%; [3H]47, 34.7 MBq, 38%. 
 
2.4.6 Cell Culture and preparation of cell homogenates 
CHO-K9 cell lines stably transfected with the human M1-M5 muscarinic receptors were 
obtained from the Missouri S&T cDNA Resource Center (Rolla, MO). Cells were cultured in 
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HAM’s F12 medium supplemented with fecal calf serum (Biochrom, Berlin, Germany) (10%) 
and G418 (Biochrom) (750 µg/mL). CHO-hM2 cell homogenates were prepared according 
to a reported procedure with minor modifications.60 The harvest buffer (50 mM TRIS, 1 mM 
EDTA) was supplemented with protease inhibitor (SIGMAFAST, Sigma-Aldrich)). Aliquots 
of 200 µL were transferred to 2-mL cups and stored at −80°C. 
2.4.7 Radioligand binding experiments  
All radioligand binding experiments were performed at 23 ± 1 °C. Leibovitz L-15 medium 
(Gibco, Life Technologies GmbH, Darmstadt, Germany) supplemented with 1% BSA 
(Serva, Heidelberg, Germany) (in the following referred to as L15 medium) was used as 
binding buffer throughout. The effects of various MR ligands on the equilibrium binding of 
[3H]NMS (equilibrium competition binding assay) and the effect of 19 on saturation binding 
of [3H]NMS were determined at intact adherent CHO-hMxR (x = 1-5) in white 96-well plates 
with clear bottom (Corning Life Sciences, Tewksbury, MA; Corning cat. no. 3610) using the 
protocol of previously described MR binding studies with [3H]NMS.31 The concentration of 
[3H]NMS was 0.2 nM (M1, M2, M3), 0.1 nM (M4) or 0.3 nM (M5) and the incubation time was 
3 h throughout. For studying the effect of 8 on the M2R equilibrium binding of [3H]NMS, the 
radioligand was additionally applied at concentrations of 0.1 and 2 nM. Unspecific binding 
was determined in the presence of 2 (500-fold excess to [3H]NMS).  
Saturation and competition binding experiments as well as association and dissociation 
experiments with [3H]19 were performed at intact adherent CHO-hM2 cells in white 96-well 
plates with clear bottom (Corning Life Sciences) using the recently described experimental 
procedure for saturation and equilibrium competition binding studies with [3H]NMS at CHO-
hMxR (x = 1-5) cells.31 In case of competition binding studies the concentration of [3H]19 was 
2 nM. For competition binding experiments with 8 additional concentrations of [3H]19 were 
applied (4, 8, 15 and 30 nM). For both, saturation and competition binding studies, the 
incubation time was 2 h. Unspecific binding was determined in the presence of 2 (500-fold 
excess to [3H]19). For M2R association experiments with [3H]19 CHO-hM2 cells were 
incubated with [3H]19 (2 nM) and the incubation was stopped after different periods of time 
(between 1 and 140 min) by suction of the radioligand solution, washing of the cells twice 
with ice-old PBS and further processing as described previously.31 Unspecific binding was 
determined in the presence of 2 (400 nM). In case of dissociation experiments cells were 
preincubated with [3H]19 (2 nM) for 105 min. The radioligand solution was removed by 
suction, the cells were covered with L15 medium (200 μL) containing 2 (400 nM) and the 
plates were gently shaken. After different periods of time (between 0 and 300 min) the cells 
were washed twice with ice-cold PBS followed by cell lysis and further processing as 
reported previously.31 To determine unspecific binding the same experiment was 
performed, but 2 (400 nM) was added during the preincubation step. 
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Saturation binding experiments with [3H]33 and [3H]47 at live adherent CHO-hM2 cells 
(incubation time: 2 h) were performed using white 96-well plates with clear bottom (Corning 
Life Sciences) and the experimental protocol as for binding studies with [3H]19 (see above). 
M2R association and dissociation experiments with [3H]33 were performed at intact 
adherent CHO-hM2 cells in Primaria 24-well plates (Corning Life Sciences) using the 
procedure as for association and dissociation experiments with [3H]19 with the following 
modifications: The total volume of L15 medium per well was 250 instead of 200 µL, and the 
volume of PBS for washing steps was 500 instead of 200 µL. Cell lysis was performed with 
200 µL of lysis solution (instead of 25 µL). For activity measurements the lysis solution was 
transferred into 6-mL scintillation vials filled with 3 mL of Rotiscint eco plus (Carl Roth), 
which were kept at least 1 h in the dark prior to the measurement using a LS 6500 liquid 
scintillation counter (Beckman-Coulter). For association experiments the concentration of 
[3H]33 was 1 nM. The incubation was stopped after different periods of time (between 1 and 
140 min). Unspecific binding was determined in the presence of 2 (200 nM). For dissociation 
experiments cells were preincubated with [3H]33 (1 nM) for 90 min. The dissociation was 
started by covering of the cells with L15 medium (250 μL) containing 2 (200 nM) and was 
followed over a period of 300 min. Unspecific binding was determined by the addition of 2 
(200 nM) during the preincubation period. 
For saturation binding experiments with [3H]33 at intact suspended CHO-hM2 cells the cell 
suspension was prepared as follows: Cells (80-100% confluency) were scraped off a 175-
cm2 culture flask and centrifuged at 400 g for 5 min. The supernatant was discarded and 
the cells were re-suspended in L15 medium at a density of 200,000 cells/mL. Saturation 
binding experiments were performed in Primaria 96-well plates (Corning Life Science) using 
a final volume of 200 µL per well. For the determination of total binding wells were prefilled 
with L-15 medium (160 µL) and L15 medium (20 µL) containing [3H]33 10-fold concentrated. 
For the determination of unspecific binding (in the presence of 2, 500-fold excess to [3H]33) 
wells were prefilled with L-15 medium (140 µL), L15 medium (20 µL) containing 2 10-fold 
concentrated and L15 medium (20 µL) containing [3H]33 10-fold concentrated. To all wells 
20 µL of the CHO-hM2 cell suspension (200,000 cells/mL) were added and the plates were 
shaken at 23°C for 2 h. The cell mass was collected on GF/C filter mats (0.26 mm; 
Whatman, Maidstone, UK) (pretreated with 0.3% polyethylenimine) and washed with cold 
PBS using a Brandel Harvester (Brandel, Gaithersburg, MD). Filter pieces for each well 
were punched out and transferred into 1450-401 96-well plates (PerkinElmer). Rotiscint eco 
plus (Carl Roth) (200 μL) was added and the plates were vigorously shaken for at least 3 h 
and afterwards kept in the dark for at least 1 h prior to the measurement of radioactivity 
(dpm) with a MicroBeta2 plate counter (PerkinElmer, Rodgau, Germany). 
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Saturation and competition binding experiments with [3H]33 and saturation binding 
experiments with [3H]47 at CHO-hM2 cell homogenates were performed in Primaria 96-well 
plates (Corning Life Sciences) according to the procedure for saturation binding 
experiments with [3H]33 at intact suspended CHO-hM2 cells (see above) using 10 µL of cell 
homogenate instead of 20 µL of cell suspension. The total volume per well was 100 µL 
instead of 200 µL, i.e. in case of total binding wells were prefilled with L-15 medium (80 µL) 
followed by the addition of L15 medium (10 µL) containing the radioligand 10-fold 
concentrated and cell homogenate (10 µL). On the day of the experiment CHO-hM2 cell 
homogenates were thawed and re-suspended using a 1-mL syringe (Henke-Sass Wolf 
GmBh, Tuttlingen, Germany) equipped with a needle (0.90 × 40 mm, B. Braun, Melsungen, 
Germany) followed by centrifugation at 500 g at 4°C for 5 min. The supernatant was 
discarded and the pellets were re-suspended in L15 medium using a 1-mL syringe equipped 
with a needle (0.45 × 25 mm, B. Braun). The homogenates were stored on ice until use. 
The total amount of protein per well was between 25 and 30 µg. Unspecific binding was 
determined in the presence of 2 (500-fold excess to [3H]33 or [3H]47). In case of competition 
binding studies with various ligands the concentration of [3H]33 was 0.5 nM. For competition 
binding experiments with 8 additional concentrations of [3H]33 were applied (0.4, 1, 2 and 
4 nM). For both, saturation ([3H]33, [3H]47) and competition ([3H]33) binding studies, the 
incubation period was 2 h. 
Note: To keep the total volume per well at 200 µL in case of saturation binding experiments 
performed with [3H]19 and [3H]NMS in the presence of 8, 9 or 19, and at 100 µL in case of 
saturation binding studies performed with [3H]33 in the presence of 8, the addition of L15 
medium (20 and 10 µL, respectively) containing 8, 9 or 19 (10-fold concentrated) was 
compensated by an equivalent reduction of the volume of L15 medium added to the wells. 
 
2.4.8 IP1 accumulation assay  
The measurement of M2R stimulated activation of the G-protein mediated pathway was 
performed by applying the IP-One HTRF® assay (Cisbio, Codolet, France) according to the 
manufacturer’s protocol. In brief, HEK-293 cells were grown to a confluency of approx. 70% 
and transiently co-transfected with the cDNAs of the human M2 receptor (Missouri S&T 
cDNA Rescourse Center) and the hybrid G-protein Gαqi5-HA (Gαq protein with the last five 
amino acids at the C-terminus replaced by the corresponding sequence of Gαi; gift from the 
J. David Gladstone Institutes, San Francisco, CA),22, 61 applying TransIT-293 Mirus 
transfection reagent (MoBiTec, Goettingen, Germany). After one day, cells were detached 
from the culture dish with Versene (Life Technologies GmbH, Darmstadt, Germany), 
seeded into black 384-well plates (10,000 cells/well) (Greiner Bio-One, Frickenhausen, 
Germany) and maintained for 24 h at 37 °C. After incubation with the test compounds, 
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dissolved in stimulation buffer (final concentration range from 1 pM up to 100 µM), at 37 °C 
for 1 h, the detection reagents were added (IP1-d2 conjugate and Anti-IP1cryptate TB 
conjugate, each dissolved in lysis buffer), and incubation was continued at rt for 60 min. 
Time resolved fluorescence resonance energy transfer (HTRF) was determined using a 
Clariostar plate reader (BMG, Ortenberg, Germany) measuring fluorescence at 620 (± 10) 
nm and 670 (± 10) nm (excitation at 330 nm). In the agonist mode, each compound (19, 33) 
was tested in duplicate in three individual experiments in comparison to the reference 
compound carbachol (3, eight experiments). Antagonist properties of 2, 19 and 33 were 
determined after preincubation of the cells with 2, 19 or 33 for 30 min, subsequent addition 
of the MR agonist 3 (at a final concentration of 300 nM) and continued incubation at 37°C 
for 1 h (five independent experiments each). 
 
2.4.9 Molecular dynamics simulation  
The crystal structure of the inactive hM2R bound to the antagonist QNB (PDB ID: 3UON)21 
was used as template. Minor modifications were performed using the modelling suite 
SYBYL-X 2.0 (Tripos Inc., St. Louis, MO USA): The ICL3 was reconstituted by insertion of 
eight alanine residues using the loop search module within SYBYL-X 2.0. Coordinates of 
non-ligand and non-receptor molecules were removed. The protein preparation wizard 
(Schrödinger LLC, Portland, OR USA) was used to refine the receptor model: The N- and 
C-terminus were capped by the introduction of an acetyl and a methylamide group, 
respectively, and amino acid side chains containing hydrogen bond donors and acceptors 
were optimized for hydrogen bonding. Histidine residues were simulated in the uncharged 
form as the Nε-H tautomer. Residues other than histidine were simulated in their dominant 
protonation state at pH 7. Disulphide bonds were maintained between C963.25 and C176ECL2 
as well as between C413ECL3 and C416ECL3, and a sodium ion was placed next to D692.50.62 
Ligand (19, 33) geometries were energetically optimized using the LigPrep module 
(Schrödinger LLC). Tertiary amine groups in 19 and 33 were protonated resulting in a net 
charge of +1 and +2, respectively. 
‘Flexible’ docking of 19 and 33 to the hM2R model was performed using the induced fit 
docking module (Schrödinger LLC). For initial docking, Y1043.33, Y4036.51 and Y4267.39 were 
temporarily mutated to alanine, and the ligands 19 and 33 were docked within a box of 30 
× 30 × 30 Å and a box of 46 × 46 × 46 Å, respectively, around the crystallographic binding 
pose of QNB. Prior to redocking, performed in the extended precision mode, a second side 
chain trimming (mutation of Y1043.33, Y4036.51 and Y4267.39 to alanine) was executed in case 
of 33, and, after redocking, a second prime refinement was applied (including a reversion 
of the alanine mutations). Among the reasonable ligand binding poses, the pose, 
corresponding to the lowest XP GScore, was selected as template for the MD simulation. 
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The respective ligand-receptor complexes were aligned to the hM2R entry (PDB ID: 3UON) 
in the orientations of proteins in membranes (OPM) database63 using the protein structure 
alignment tool (Schrödinger LLC). The CHARMM GUI64-68 interface was used to insert the 
prepared ligand-receptor complexes into a hydrated, equilibrated 
palmitoyloleoylphosphatidylcholine (POPC) bilayer, comprising 180 POPC molecules as 
well as sodium chloride at a concentration of 150 mM (net charge of the entire system was 
zero). The system contained about 72,000 (19) and 81,000 (33) atoms and the box size 
was approximately 86 × 86 × 106 Å and 86 × 86 × 118 Å, respectively. The CHARMM36 
parameter set was used for the protein structure,69-71 lipid,72 and inorganic ions,73 and the 
CHARMM TIP3P model for water74 to define the geometry and partial charges. The protein 
parameters included CMAP terms. Ligand geometry and partial charge parameters were 
derived from the CHARMM ParamChem web server, version 1.0.075-78. Each simulation was 
executed on one Nvidia GTX 1080 GPU (approx. 9 TFlops) using the CUDA version of 
PMEMD,79, 80 implemented in AMBER16 (AMBER 2016, University of California, San 
Francisco, CA). After minimization, the system was heated from 0 to 100 K in the NVT 
ensemble during 50 ps and from 100 to 310 K in the NPT ensemble during 450 ps, applying 
harmonic restraints of 10 kcal · mol-1 · Å-1 to protein and ligand atoms as well as 2.5 kcal · 
mol-1 · Å-1 to POPC atoms. At the first heating step (0 to 100 K), initial velocities were 
randomly assigned using Langevin dynamics. The simulation systems were successively 
equilibrated at 310 K in the NPT ensemble using a Langevin thermostat,81, 82 a collision 
frequency of 1.0 ps-1 and a Berendsen barostat83 with semi-isotropic pressure scaling 
maintaining a target pressure of 1 bar with a pressure relaxation time of 0.5 ps. During the 
subsequent 10-ns equilibration period harmonic restraints were reduced step-wise (every 2 
ns) to 0 kcal · mol-1 · Å-1. The interaction cut-off was set to 8.0 Å and long-range 
electrostatics were computed using the particle mesh Ewald (PME) method.84 Bonds 
involving hydrogen atoms were constrained using SHAKE85 to enable a frame step size of 
2 fs. The final frame of the equilibration period was used as input for the simulations over 2 
µs (19) and 3 µs (33). The ‘production runs’ were essentially performed as the equilibration 
runs, but the Berendsen barostat was replaced by the Monte Carlo Barostat. Data were 
collected every 100 ps and analyzed by means of cpptraj every ns. For cluster analysis, the 
average linkage algorithm86 was applied, setting a cluster size of 5 (cf. Table 5). H-bond 
plots were prepared with the programming language R (R Development Core Team (2008), 
R: A language and environment for statistical computing, R Foundation for Statistical 
Computing, Vienna, Austria, http://www.R-project.org; Karline Soetaert (2016), plot3D: 
Plotting Multi-Dimensional Data, R package version 1.1, https://CRAN.R-
project.org/package=plot3D; Philip Johnson (2015), devEMF: EMF Graphics Output 
Device, R package version 2.0, https://CRAN.R-project.org/package=devEMF). Figures 
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showing molecular structures of the M2R in complex with 19 or 33 were generated with 
PyMOL Molecular Graphics system, version 1.8.2.1 (Schrödinger LLC). 
 
2.4.10 Data processing  
Data of the IP1 accumulation assay (agonist mode) were processed by plotting the ratios 
(emission 670 nm/emission 620 nm) of the HTRF measurements against log(concentration 
3) and analysis by a four-parameter logistic equation (GraphPad Prism Software 6.0, 
GraphPad Software, San Diego, CA), followed by normalization (0% = ‘top’ (maximum of 
IP1 accumulation), 100% = ‘bottom’ (basal activity)) of the four-parameter logistic fit and 
analysis of the normalized data by a four-parameter logistic equation (log(agonist) vs. 
response - variable slope). Data of the IP1 accumulation assay (antagonist mode) were 
processed by plotting the fluorescence ratio against log(concentration antagonist) and 
analysis by a four-parameter logistic equation (GraphPad Prism), followed by normalization 
(0% = ‘top’ (IP1 accumulation elicited by 3 (0.3 µM)) of the four-parameter logistic fit, 100% 
= ‘bottom’ (basal activity)) and analysis of the normalized data by a four-parameter logistic 
equation (log(inhibitor) vs. response - variable slope). pIC50 values were converted into pKb 
values according to the Cheng-Prusoff equation87 (logarithmic form). Specific binding data 
(DPM) from saturation binding experiments were plotted against the free radioligand 
concentration and analyzed by a two-parameter equation describing hyperbolic binding 
(one site-specific binding, GraphPad Prism) to obtain Kd and Bmax values. The free 
radioligand concentration (nM) was calculated by subtracting the amount of specifically 
bound radioligand (nM) (calculated from the specifically bound radioligand in dpm, the 
specific activity and the volume per well) from the total radioligand concentration. Unspecific 
binding data from saturation binding experiments were fitted by linear regression. In case 
of saturation binding experiments with [3H]19 or [3H]33 in the presence of compounds 8, 9 
as well as saturation binding experiments with [3H]NMS in the presence of 19, specific 
binding data (in DPM) were analyzed by a two-parameter equation describing hyperbolic 
binding (one site-specific binding, GraphPad Prism) to obtain Kd and Bmax values. 
Additionally, specific binding data were normalized to the Bmax value, specific binding (%) 
was plotted against log(radioligand concentration) followed by analysis using a four-
parameters logistic fit (log(agonist) vs. response-variable slope, GraphPad Prism). Data for 
the ‘Schild’ analysis were obtained from the rightward shift (ΔpKd) of the saturation isotherm 
and transformation into log(r-1) (where r = 10ΔpKd). Log(r-1) was plotted against 
log(concentration 8, 9 or 19) and the data were analyzed by linear regression to obtain the 
slope and the ‘pA2’ values (intercept with the X axis). Specific binding data from association 
experiments with [3H]19 and [3H]33 were analyzed by a two-parameters equation describing 
an exponential rise to a maximum (one-phase association, GraphPad Prism) to obtain the 
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observed association rate constant kobs and the maximum of specifically bound radioligand 
(B(eq)) which was used to calculate specifically bound radioligand (B(t)) in %. Data from 
dissociation experiments (% specifically bound radioligand (B(t)) plotted over time) were 
analyzed by a three-parameter equation (one phase decay, GraphPad Prism) (in case of 
[3H]19 ‘plateau’ was defined as 0) or by a three-parameter equation to obtain the 
dissociation rate constant koff. The association rate constants (kon) of the radiolabeled 
dibenzodiazepinone derivatives were calculated from kobs, koff and the radioligand 
concentration ([RL]) according to the correlation: kon = (kobs-koff)/[RL]. Total binding data 
(DPM) from radioligand competition binding experiments (determination of the effect of 
various MR ligands on the equilibrium binding of [3H]NMS, [3H]19 or [3H]33) were plotted 
against log(concentration competitor) and analyzed by a four-parameter logistic equation 
(log(inhibitor) vs. response-variable slope, GraphPad Prism) followed by normalization 
(100% = ‘top’ of the four-parameter logistic fit, 0% = unspecifically bound radioligand (DPM) 
determined in the presence of 2 at 200 or 500-fold excess) and analysis of the normalized 
data by a four-parameter logistic equation (effect of 8 on the equilibrium binding of [3H]NMS, 
[3H]19 or [3H]33; cf. Fig. 8) or by a four-parameter logistic equation fused to the Cheng-
Prusoff equation (logarithmic form) (equation 1) to obtain pIC50 and pKi values, respectively. 
Statistical significance was assessed by a one-sample t-test.  
(equation 1) 
𝑌 =
𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚
1 + 10(𝑙𝑜𝑔𝐼𝐶50−𝑋) ∗ 𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒
+  𝐵𝑜𝑡𝑡𝑜𝑚 
𝑙𝑜𝑔𝐼𝐶50 = log (10𝑙𝑜𝑔𝐾𝑖 ∗ (1 +
𝐻𝑜𝑡𝑁𝑀
𝐻𝑜𝑡𝐾𝑑𝑁𝑀
)) 
 
HotNM = radioligand concentration in nM, HotKdNM = Dissociation constant (Kd) of the 
radioligand in nM 
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3.1. Introduction 
In the last decades, fluorescence-based techniques have been increasingly used for 
studying ligand-receptor interactions; hence there is a growing demand for suitable 
fluorescent probes. In contrast to radiolabeled probes, fluorescent ligands harbor less 
problems concerning safety precautions and waste disposal. Moreover, they are applicable 
to fluorescent microscopy and flow cytometry, techniques which have become routine in 
many laboratories. A general issue regarding the design of small-molecule fluorescent 
ligands is the impairment of the bioactivity caused by the conjugation to the bulky 
fluorophore. Usually, the pharmacophore (ligand) and the fluorophore are hold apart by 
some form of linker or spacer moiety.1 Numerous fluorescent probes have been reported 
for GPCRs, for instance for neuropeptide Y2-6, histamine7-11, opioid12-14, dopamine15, 
neurotensin16 and adenosine17 receptors. Concerning muscarinic receptors, several reports 
on fluorescently labeled M1R derivatives based on the structure of the antagonist 
pirenzepine (Figure 1) were published; for instance, compound 55 (BODIPY FL-labeled 
ligand) (Figure 1), studied by Ilien and coworkers in FRET-based assays, the lissamine-
rhodamine B-labeled ligand 56 and the Cy3-labeled compound 57 (Figure 1), which were 
shown to bind bitopically/dualsterically at the EGFP-fused hM1R.18 Notably, the length of 
the linker and the nature of the fluorophore had a significant impact on the M1R affinity of 
pirenzepine derived analogs of 55-57.18, 19 Furthermore, a fluorescent derivative of the M1R 
allosteric modulator AC-42 (Figure 1), bearing a lissamine-rhodamine B fluorophore (58) 
(Figure 1) was prepared and investigated by FRET-based techniques.19 In contrast to the 
M1R, reports on M2R-M5R fluorescent probes are rare.  
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Figure 1. Structures and M1R binding affinity of the fluorescently labeled M1R ligands 55-
58, which were suggested to exhibit a bitopic/dualsteric binding mode.18, 19 (a) Tahtauoi et 
al.18 (b) Daval et al.19 
 
The tricyclic dibenzodiazepinone-type MR ligand 1920, derived from the M2R-preferring 
antagonist DIBA (cf. Chapter 1, Figure 4), was recently prepared as a tritium-labeled ligand, 
and, by various binding studies with [3H]19, this molecular tool was proven to interact 
dualsterically with the hM2R (cf. Chapter 2). Aiming at fluorescent molecular tools for the 
M2R, fluorescently labeled analogs of the monomeric ligand 19 as well as fluorescently 
labeled homo- and heterodimeric dibenzodiazepinone-type MR ligands were prepared 
using red-emitting cyanine dyes, and investigated with respect to their M1R-M5R affinity. 
Selected compounds were characterized by flow cytometry and high-content imaging based 
binding studies as well as by confocal microscopy. 
 
3.2. Results and discussion 
3.2.1  Chemistry 
The fluorescent monomeric and dimeric dibenzodiazepinone-type MR ligands were 
prepared using red emitting cyanine dyes in order to have low background fluorescence 
when applying the fluorescent ligands at cells. Two commercially available cyanine dyes 
(purchased as N-succinimidyl ester), i.e. S 0536 (59) and S 0586 (60) (emission maximum 
> 650 nm) (Figure 2A) were used. Treatment of the DIBA-derived amine precursors 3020, 
31 (cf. Chapter 2) and 6521 with 59 or 60 (Figure 2A) resulted in the fluorescently labeled 
DIBA derivatives 61-64 and 66 (Figure 2B). 
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Figure 2. (A) Structures of the fluorescent dyes (succinimidyl esters 59 and 60), which were 
used for the labeling of dibenzodiazepinone-type MR ligands. (B) Synthesis of the 
fluorescently labeled MR ligands 61-64 and 66. Reagents and conditions: (a) DIPEA, DMF, 
rt, 1 h, 34% (61), 41% (62), 36% (63), 26% (64), 34% (66). 
 
Fluorescent ligands 62 and 64 were investigated with respect to their stability under assay-
like conditions (PBS pH 7.4) (Figure 3). 
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Figure 3. HPLC analysis of 62 (A) and 64 (B) after incubation in PBS (pH 7.4) at 23 °C for 
up to 48 h. HPLC conditions see experimental section. 
 
No decomposition was observed for both 62 and 64 within the incubation period of 48 h 
(Figure 3A and Figure 3B). Interestingly, compound 64 adsorbed strongly to the vessel 
material (siliconized (Sigmacote) glass tubes) resulting in a reduction of the peak area by 
approx. 90% after 24 h (Figure 3B). The use of other materials (polypropylene and 
“siliconized” polypropylene tubes) did not result in a lower adsorption of 64 (data not shown). 
Notably, after removal of the aqueous solution after 48 h, most of the intact fluorescently-
labeled ligand could be desorbed and recovered by rinsing of the tube with acetonitrile/0.1% 
aq TFA (1:1 v/v) (Figure 3B, recovery). 
 
3.2.2 Radioligand binding studies with [3H]NMS 
The MR affinities of the fluorescently labeled dibenzodiazepinone derivatives 61-64 and 66 
were determined at live CHO-hMxR cells (x = 1-5) using the orthosteric antagonist [3H]NMS 
as radioligand. All the fluorescent ligands exhibited high M2R binding with pKi values > 8.8 
(Table 1), i.e. their M2R affinities were comparable to those of the structurally closely related, 
but not fluorescently labeled compounds 1920, 33 (cf. Chapter 2 Table 1) and 65.21 The 
complete MR selectivity profile was determined for compounds 62 and 64 (Table 1, Figure 
4). While both fluorescent ligands exhibited an excellent M2/M3 and M2/M5 selectivity, no 
preference for the M2R over the M1 and M4 receptor subtype became evident. Thus, a 
putative dualsteric binding mode of this type of fluorescent ligands does not result in an 
improved selectivity profile as also reported for other dualsteric MR ligands.22, 23 
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Table 1. M1-M5 receptor affinities (pKi values) of the dibenzodiazepinone-type fluorescent 
ligands 62-64 and 66, obtained from equilibrium competition binding studies with [3H]NMS 
at live CHO-hMxR cells (x = 1-5). 
compd. dyea 
pKib 
M1R M2R M3R M4R M5R 
61 S 0536 n.d. 9.03 ± 0.08 n.d. n.d. n.d. 
62 S 0586 8.28 ± 0.17 9.10 ± 0.04 6.30 ± 0.05 8.35 ± 0.19 6.91 ± 0.24 
63 S 0536 n.d. 8.85 ± 0.07 n.d. n.d. n.d. 
64 S 0586 8.64 ± 0.03 9.20 ± 0.03 6.61 ± 0.02 8.54 ± 0.16 6.52 ± 0.07 
66 S 0586 n.d. 9.59 ± 0.03 n.d. n.d. n.d. 
aProvided are the code numbers of the succinimidyl esters of the fluorescent dyes used for the 
preparation of the fluorescent ligands (cf. Figure 2A). bMean values ± SEM from 3-4 independent 
experiments (each performed in triplicate). Kd values / applied concentrations of [3H]NMS: M1: 0.12 / 
0.2 nM, M2: 0.090 / 0.2 nM, M3: 0.089 / 0.2 nM, M4: 0.040 / 0.1 nM, M5: 0.24 / 0.3 nM.  
 
 
Figure 4. Effect of the dibenzodiazepinone-type MR ligands 62 (A) and 64 (B) on MxR 
equilibrium binding of [3H]NMS determined at CHO-hMxR cells (x = 1-5). Data represent 
mean values ± SEM from at least three independent experiments (each performed in 
triplicate). 
 
3.2.3 Fluorescence properties of compounds 61, 62 and 64  
The fluorescence quantum yields were determined (reference: cresyl violet perchlorate) for 
monomeric fluorescent ligands 61 and 62, and for the homodimeric ligand 64 in PBS (pH 
7.4) and in PBS supplemented with 1% bovine serum albumin (BSA) to study the influence 
of proteins on the quantum yield (Table 2). By selecting compounds 61, 62 and 64 both 
types of fluorophores, used in this work, were covered. 
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Table 2. Fluorescence properties of the fluorescent ligands 61, 62 and 64 in PBS and PBS 
containing 1% BSA: excitation/emission maxima and fluorescent quantum yields Φ 
(reference: cresyl violet perchlorate). 
Compound Dyea 
PBS PBS+1% BSA 
λex/λem Φ (%) λex/λem Φ (%) 
61 S 0536 645/666 24.4 663/676 51.1 
62 S 0586 651/669 21.6 658/673 36.8 
64 S 0586 650/668 4.1 658/673 43.4 
aProvided are the code numbers of the succinimidyl esters of the fluorescent dyes used for the 
preparation of the fluorescent ligand (cf. Figure 2A). 
 
The investigated fluorescent ligands (61, 62, 64) showed a higher quantum yield in PBS 
supplemented with 1% BSA compared to PBS alone (Table 2). This phenomenon was 
previously observed for fluorescently labeled NPY Y1 antagonists,4 too, and can be 
explained by interactions (hydrophobic, electrostatic) of the fluorophores with the protein, 
resulting in a changed chemical environment and reduced molecular motion (increased 
rigidity) of the fluorophore. Therefore, when BSA free buffers are used for binding assays 
with such kind of fluorescent ligands, the fluorescence quantum yield can potentially 
increase in the receptor bound state. However, this effect may also occur in case of 
unspecific interactions of the ligand with other membrane proteins or the lipid bilayer. The 
increase in fluorescence quantum yield by adding BSA was most pronounced for the 
homodimeric ligand 64 (> 10-fold), as in this case the quantum yield in neat PBS was 
considerably lower compared to the monomeric ligands 61 and 62 (Table 2). It can be 
speculated that in case of the dimeric ligand 64 there is a “cross-talk” between the 
fluorophore and the two dibenzodiazepinone moieties, which is absent in the presence of 
proteins. 
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Figure 5. Excitation and corrected emission spectra (recorded at 22 °C) of the fluorescent 
ligands 61 (A), 62 (B) and 64 (C) at a concentration of 2.5 µM in PBS supplemented with 
1% BSA and of fluorescent ligand 64 (D) in neat PBS. (E) Absorption spectra (400-800 nm) 
of the dimeric compound 64 (2.5 µM) in PBS and PBS supplemented with 1% BSA 
(recorded at 22 °C). 
 
Excitation and corrected emission spectra of 61, 62 and 64 in PBS containing 1% BSA 
appeared to be very similar (Figure 5A-C). All fluorescent ligands are suited for an excitation 
with the red diode laser (635 nm), which usually belongs to the standard equipment of flow 
cytometers and confocal microscopes. Notably, whereas in case of the monomeric ligands 
61 and 62 the shape of the excitation and absorption spectra was similar (data not shown), 
the shape of the absorption spectrum of the dimeric ligand 64 was different (bathochromic 
shift, decreased absorption coefficient) (excitation spectrum in PBS shown in Figure 5D, 
absorption spectrum shown in Figure 5E). It is a matter of speculation if the dimeric nature 
of compound 64 has an influence on the spectroscopic properties of the attached 
fluorophore and/or on the physicochemical properties of the fluorescent probe. 
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3.2.4 Flow cytometric M2R saturation binding studies with 62 and 64 
The fluorescent ligands 62 and 64, which showed excellent M2R affinities (pKi values > 9.0 
nM, cf. Table 1) were applied to flow cytometric saturation binding studies using intact CHO-
hM2R cells. The obtained Kd values of 4.6 nM and 3.2 nM, respectively (Figure 6A and 
Figure 6B, Table 3), were about five times higher than the corresponding Ki values of 0.79 
and 0.63 nM (cf. Table 1) obtained from competition binding experiments with [3H]NMS at 
live CHO-hM2R cells. At concentrations corresponding to the Kd value, unspecific binding 
was around 10% of the total binding for both fluorescent ligands (Figure 6A and Figure 6B). 
The orthosteric antagonist atropine (2), used to determine unspecific binding, was capable 
of completely preventing one-site (monophasic) specific binding of the fluorescent ligands, 
indicating that 62 and 64 bind to the orthosteric binding pocket of the M2R.  
 
Figure 6. Representative saturation isotherms (specific binding, dashed line) obtained from 
flow cytometric saturation binding experiments performed with 62 (A) and 64 (B) at intact 
CHO-hM2R cells. Unspecific binding was determined in the presence of atropine (2) (500-
fold excess). Cells were incubated with the fluorescent ligands at 22 °C in the dark for 2 h. 
Experiments were performed in duplicate. Measurements were performed with a 
FACSCalibur flow cytometer (Becton Dickinson). Specific binding data were analyzed by 
an equation describing one-site (monophasic) binding. Error bars of specific binding 
represent propagated errors calculated according to the Gaussian law of errors. Error bars 
of total and unspecific binding represent the mean ± SEM from at least two independent 
experiments (each performed in duplicate). 
 
3.2.5 Application of the fluorescent ligands 62 and 64 to high content imaging 
3.2.5.1 Saturation binding 
The fluorescent ligands 62 and 64 were also applied to plate reader-based high-content 
analysis (combination of a microscope and a plate reader for fluorescence detection) using 
live CHO-hM1R and CHO-hM2R cells. In order to find optimal assay conditions, saturation 
isotherms of 62 at intact CHO-hM2 cells were recorded using a protocol with and without a 
washing step (cf. general experimental conditions) prior to the measurement of the plate 
6 4 / n M
g
e
o
m
e
tr
ic
 m
e
a
n
 i
n
 F
L
-4
0 2 0 4 0 6 0 8 0
0
2 5 0
5 0 0
7 5 0
1 0 0 0
1 2 5 0
to ta l b in d in g
u n s p e c if ic  b in d in g
s p e c if ic  b in d in g
B
K d  =  2 .0  n M
6 2 / n M
g
e
o
m
e
tr
ic
 m
e
a
n
 i
n
 F
L
-4
0 1 0 2 0 3 0 4 0 5 0
0
2 5 0
5 0 0
7 5 0
1 0 0 0
1 2 5 0
A
K d  =  4 .1  n M
Chapter 3 
96 
with an Image Express (IX) Ultra plate reader. A considerable difference in unspecific 
binding became evident between the non-washed (Figure 7A) and the washed (Figure 7B) 
plate, suggesting that a washing step after the incubation period (prior to the measurement) 
is advantageous for the analysis of the data. In fact, without the application of a washing 
step, it was impossible to calculate a dissociation constant, because a discrimination 
between total and unspecific binding of the florescent probe 62 at CHO-M2 cells failed 
(Figure 7A). 
 
Figure 7. Representative thumbnail fluorescence images acquired with an IX Ultra plate 
reader of a high-content imaging saturation binding assay performed with the fluorescent 
ligand 62 at intact CHO-hM2R cells in a 96-well plate. Omitting a washing step prior to the 
measurement with the plate reader resulted in considerably higher unspecific binding (A) 
compared to the assay including a washing step (B). 
 
By contrast, in case of saturation binding experiments with compound 64 at CHO-hM2R 
cells almost no differences in unspecific binding and in the resulting Kd values (Figure 8B) 
were found, regardless whether a washing step was carried out or omitted (thumbnail 
fluorescence images not shown). In order to use identical protocols for binding studies with 
62 and 64, a washing procedure was always applied before the measurements. The bound 
fluorescence detected by high-content imaging was quantified by granularity analysis as 
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reported elsewhere.24 The Kd values, obtained from M2R saturation binding experiments 
including the washing step prior to the measurement, amounted to 14 nM for 62 and 10 nM 
for 64, being slightly higher compared to the Kd values obtained from flow cytometric 
saturation binding studies (Table 3). At concentrations around the Kd value, unspecific 
binding amounted to around 2% of the total binding (Figure 8A and Figure 8B). In addition, 
saturation binding experiments with 62 and 64 were performed at CHO-hM1R cells (Figure 
8C and Figure 8D). The Kd values amounted to 19 nM (62) and 11 nM (64) (Table 3), 
confirming that the fluorescent ligands 62 and 64 do not exhibit M2R selectivity. In case of 
M2R binding data, the Kd values obtained from high content imaging saturation binding 
studies at the M1R were higher compared to the respective Ki values derived from 
competition binding experiments with [3H]NMS (Table 3). These deviations might be caused 
by the different assay readouts (radiochemical vs. fluorescence-based), and, in case of 62, 
by the high adsorption to the plate material (high content imaging) resulting in a 
considerable decrease in free fluorescent ligand.  
 
Figure 8. Representative saturation isotherms obtained from high-content imaging 
saturation binding experiments performed with 62 (A) and 64 (B) at intact CHO-hM2R cells 
as well as with 62 (C) and 64 (D) at intact CHO-hM1R cells. Dashed lines represent total 
and unspecific binding of 62 (B) and 64 (C) obtained from experiments performed without 
a washing step prior the measurement of the plate. Unspecific binding was determined in 
the presence of atropine (2) (500-fold excess). Cells were incubated with the fluorescent 
ligand at 22 oC in the dark for 1 h. Experiments were performed in triplicate. Measurements 
were performed with an IX Ultra Confocal Plate Reader (Molecular Devices). Specific 
binding data were analyzed by an equation describing one-site (monophasic) binding. Error 
bars of specific binding represent propagated errors calculated according to the Gaussian 
law of errors. Error bars of total and unspecific binding represent the SEM (n = 3).  
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Table 3. Comparison of M1R and M2R binding data of 62 and 64 obtained from various 
binding assays. 
Ligand 
CHO-hM1R cells CHO-hM2R cells 
Ki  [nM]a Kd  [nM]c Ki  [nM]a Kd  [nM]b Kd  [nM]c 
62 5.1 ± 2.4 27 ± 2.6 0.79 ± 0.070 4.6 ± 0.69 14 ± 1.6 
64 2.3 ± 0.24 11 ± 1.2 0.64 ± 0.039 3.2 ± 0.58 10 ± 2.0 
aDissociation constant determined by equilibrium competition binding with [3H]NMS at intact CHO-
hM2 cells; mean ± SEM from at least three independent experiments (performed in triplicate). 
bDissociation constant from flow cytometric saturation binding studies at live CHO-hM2R cells; mean 
± SEM from three independent experiments (performed in duplicate). cDissociation constant from 
high-content imaging saturation binding studies at live CHO-hM2R cells; mean ± SEM from three 
independent experiments (performed in triplicate). 
In order to investigate if the fluorophore unspecifically stains the cells, saturation binding 
experiments with UR-MK331, which represents the N-propyl amide analog of the 
fluorescent dye implemented in the structure of 62, 64 and 66 (cf. Figure 2), were performed 
at the M2R. As becomes obvious from Figure 9, no binding of this cyanine dye to CHO-
hM2R cells was detected at concentrations of up to 400 nM.  
 
Figure 9. Representative thumbnail fluorescence images acquired with an IX Ultra plate 
reader of a high-content imaging saturation binding assay performed with the reference 
compound UR-MK331 at intact CHO-hM2R cells. A washing step was included prior the 
measurement of the plate. 
 
3.2.5.2 Competition binding 
The effects of various described orthosteric (antagonists 1 and 2; agonists 4 and 5), 
allosteric (8 and 9) and dualsteric (19 and 33) MR ligands on the equilibrium binding of the 
monomeric fluorescent ligand 62 and the homodimeric ligand 64 were determined at live 
CHO-hM2R cells by means of high content imaging (Figure 10A and Figure 10B). A washing 
step was applied before measuring the plates with the IX Ultra plate reader. All four-
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parameter logistic curves reached 0% specific binding of 62 or 64, indicating a competitive 
mechanism between the fluorescent ligand and the investigated MR ligands (Figure 10A 
and Figure 10B). It should be noted that in case of the allosteric modulators 8 and 9, a 
strongly negative cooperativity could also result in sigmoidal “displacement” curves with 
lower curve plateaus not different from 0% specific fluorescent ligand binding (cf. General 
Introduction, section 1.2.1.1). The obtained pIC50 values were converted into the 
corresponding pKi values (presented in Table 4) using the logarithmic form of the Cheng-
Prusoff equation, and the Kd values (14 nM for 62 and 10 nM for 64) determined in high-
content imaging saturation binding studies (cf. Table 3). Generally, the pKi values were in 
good agreement with reported data (Table 4), although MR ligand affinities determined with 
the dimeric fluorescent ligand 64 were lower compared to M2R affinities obtained from 
equilibrium competition binding experiments with 62 (Table 4). Interestingly, the same 
phenomenon was observed in case of equilibrium competition binding studies with the 
dimeric radioligand [3H]33 and its monomeric counterpart [3H]19 (cf Chapter 2, Table 3). 
 
Figure 10. Concentration-dependent effects of various reported orthosteric (1, 2, 4, 5), 
allosteric (8, 9) and dualsteric (19, 33) MR ligands on M2R equilibrium binding of 62 (c = 10 
nM) (A) and 64 (c = 10 nM) (B) determined at intact CHO-hM2R cells using high-content 
imaging. Data were analyzed by four parameter logistic fits. Mean values ± SEM from at 
least three independent experiments (performed in duplicate). 
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Table 4. M2R binding data (pKi or pIC50) of various orthosteric (1-5), allosteric (8-9) and 
dualsteric (19, 33) MR ligands determined by the use of 62, 64 or [3H]NMS. 
Ligand 62 
pKi a 
64 
pKi a 
[3H]NMS 
pKi*or pIC50** (± SEM) 
1 10.1 ± 0.03 9.11 ± 0.08 9.7*b 
2 8.74 ± 0.12 8.02 ± 0.07 7.8-9.2*c 
4 6.10 ± 0.03 5.62 ± 0.06 5.0-6.6*c 
5 6.77 ± 0.15 6.44 ± 0.14 6.5-7.4*d 
8 6.30 ± 0.16 5.95 ± 0.09 6.32 ± 0.18**e 
9 5.15 ± 0.06 5.01 ± 0.15 <4.5**f 
19 9.12 ± 0.28 8.26 ± 0.17 9.12 ± 0.05*g 
33 9.68 ± 0.23 9.30 ± 0.21 9.39 ± 0.05*g 
aDetermined by high-content imaging equilibrium competition binding studies with 62 (c = 10 nM) or 
with 64 (c = 10 nM) at intact CHO-hM2R cells; mean values ± SEM from at least three independent 
experiments (performed in duplicate). bDei et al.25 cpKi values from equilibrium (competition) binding 
experiments reported in the literature (data taken from the IUPHAR/BPS database 
(guidetopharmacology.org, (Nov. 2016)). dJakubik et al.26 epIC50 value obtained from nonlinear four-
parameter logistic curve analyses of data characterizing the inhibition of [3H]NMS (c = 0.2 nM) 
equilibrium binding at live CHO-hM2R cells; mean ± SEM from at least three independent 
experiments (performed in triplicate). fInhibitory effect on M2R equilibrium binding of [3H]NMS (c = 0.2 
nM) at intact CHO-hM2R cells (cf. Chapter 2, Figure 7B). gpKi values taken from Chapter 2, Table 1. 
 
3.2.5.3 M2R Saturation binding with 62 and 64 in the presence of the allosteric 
modulator 8 (Schild-like analysis) 
In order to unveil a putative involvement of the allosteric vestibule in M2R binding of the 
fluorescent ligands 62 and 64, saturation binding experiments were performed in the 
presence the allosteric modulators 8 applied at increasing concentrations (Schild-like 
analysis Figure 11).27-29 This kind of experiment is equivalent to the Schild analysis used to 
investigate the inhibiting effect of a receptor antagonist on the response elicited by an 
agonist, and was applied, for instance, to prove the dualsteric binding mode of [3H]19 and 
[3H]33 at the M2R (cf. Chapter 2, Figure 15) as well as of a fluorescent pirenzepine derivative 
at the M1R.30 In the presence of 8, the saturation isotherms of both, the monomeric ligand 
62 and the homodimeric ligand 64, were rightward shifted resulting in linear ‘Schild’ 
regressions with a slope not different from unity (Figure 11A and Figure 11B, Table 5). 
These results were indicative of a competitive mechanism between the allosteric M2R ligand 
8 and the fluorescent dibenzodiazepinone-type ligands 62 and 64. The ‘pA2’ values of 8 
derived from the ‘Schild’ regressions were in good agreement with the pKi values of 8 from 
equilibrium competition binding studies with 62 and 64 as well as with reported M2R affinities 
(pKA) of 8 (Table 5). With regard to the fact that 62 and 64 address the orthosteric binding 
site of the M2R (concluded from experimental data presented in Figure 6, Figure 8 and 
Figure 10) the results of the Schild-like analyses strongly suggested, as already reported 
Fluorescently-labeled monomeric and dimeric dibenzodiazepinone-type MR ligands 
101 
for the dibenzodiazepinone-type MR ligands 19 and 33 (cf. Chapter 2), a dualsteric binding 
mode of 62 and 64 at the M2R, that is, a simultaneous binding to the orthosteric site and the 
allosteric vestibule. 
 
Figure 11. Saturation binding of 62 (A) and 64 (B) in the presence of 8 at increasing 
concentrations. Presented are saturation isotherms of specific fluorescent ligand binding to 
the M2R in linear scale (left) and semi-logarithmic scale (middle), and ‘Schild’ regressions 
(right) resulting from the rightward shifts (ΔpKd) of the saturation isotherms (log(r−1) plotted 
vs. log(concentration allosteric modulator), where r = 10ΔpKd). The presence of the allosteric 
modulator 8 led to a parallel rightward shift of the saturation isotherms of both, the 
monomeric (62) and the homodimeric (64) fluorescently labeled dibenzodiazepinone 
derivative. In both cases the slope of the linear ‘Schild’ regression was nearly equal to unity, 
indicating a competitive interaction between the fluorescent ligands and the allosteric ligand 
8. Experiments were performed at intact CHO-hM2R cells. Data represent mean values ± 
SEM from at least three independent experiments (each performed in triplicate). 
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Table 5. Summary of M2R binding data of the allosteric M2R modulator 8 determined by the 
use of the fluorescently labeled dibenzodiazepinone derivatives 62 and 64. 
Florescent 
ligand 
Slopea ‘pA2’b pKic pKAd 
62 1.00 ± 0.05 6.38 ± 0.04 6.22 ± 0.16  
6.00*/6.53** 
64 0.93 ± 0.09 6.67 ± 0.12 5.95 ± 0.09 
aSlope of the ‘Schild’ regression constructed based on fluorescent ligand binding data from saturation 
binding experiments with 62 or 64 in the presence of increasing fixed concentrations of the allosteric 
ligands 8; mean values ± SEM from at least three sets of independent saturation binding experiments 
(performed in triplicate). The slope of the linear ‘Schild’ regression was not different from unity (P 
>0.2). bThe ‘pA2’ value corresponds to the X-axis intercept of the linear ‘Schild’ regression (cf. Figure 
11) and reflects the affinity of the investigated allosteric ligand 8. cpKi values taken from Chapter 2 
Table 3. dMohr et al.31 (pKA determined by [3H]NMS* or [3H]AF-DX 384** displacement. 
 
3.2.6 Application of the fluorescent ligand 62 and 64 to confocal microscopy 
The fluorescent probes 62 and 64 were also applied to confocal microscopy using live CHO-
hM2R cells. A significant difference between total and unspecific binding was evident for 
both ligands (Figure 12 and Figure 13) after different incubation times (5-45 min). Unspecific 
binding was determined in the presence of the MR antagonist atropine (2). The major 
fraction of detected fluorescence appeared to be associated to the cell membrane. An 
increase in intracellular fluorescence over time was not observed. 
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Figure 12. Binding of the fluorescent ligand 62 to CHO-hM2R cells at 30 °C, visualized by 
confocal microscopy after 5, 15, 25, 35 and 45 min. (A) Total binding of 62 (30 nM). (B) 
Unspecific binding of 62 (30 nM) determined in the presence of atropine (10 μM). Images 
were acquired with a Zeiss LSM 710 confocal microscope. T PMT = transmitted light 
detector/photomultiplier tube.   
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Figure 13. Binding of the fluorescent ligand 64 to CHO-hM2R cells at 30 °C, visualized by 
confocal microscopy after 5, 15, 25, 35 and 45 min. (A) Total binding of 64 (30 nM). (B) 
Unspecific binding of 64 (30 nM) determined in the presence of atropine (10 μM). Images 
were acquired with a Zeiss LSM 710 confocal microscope. T PMT = transmitted light 
detector/photomultiplier tube.  
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3.3. Summary and conclusion 
The high-affinity cyanine dye-labeled dibenzodiazepinone-type MR ligands comprising two 
monomeric (61 and 62), two homodimeric (63 and 64) and one heterodimeric (66) 
fluorescent ligand are presented. Equilibrium binding studies with [3H]NMS at CHO-hM2R 
cells yielded low Ki values (< 1 nM) for 61-64 and 65 (Table 1). Complete MR selectivity 
profiles, determined for 62 and 64, revealed a lack of M2R selectivity towards the M1 and 
the M4 subtype (Table 1). Saturation isotherms of the homodimeric ligand 64 and its 
monomeric counterpart 62 derived from flow cytometric and high-content imaging M2R 
binding experiments gave comparable Kd values (flow cytometry: 4.6 nM (62) and 3.2 nM 
(64); high-content imaging analysis: 14 nM (62) and 10 nM (64)), proving that this type of 
fluorescent probes represents useful molecular tools suited for such techniques. 
Competition binding studies with 62 or 64 and reported orthosteric, allosteric and dualsteric 
MR ligands afforded Ki values, which were in good agreement with literature data (Table 4). 
In order to unmask a putative dualsteric binding mode of 62 and 64 at the M2R, Schild-like 
analyses were performed with the allosteric modulator 8. The resulting linear “Schild” 
regressions, showing slopes not different from unity, strongly suggested that both ligands, 
the monomeric compound 62 and the homodimeric ligand 64, interact in a competitive 
manner with 8, indicating an allosteric interaction of 62 and 64 additional to the occupation 
of the orthosteric binding site of the M2R (dualsteric binding mode). Application of 62 and 
64 to confocal microscopy showed that both probes were able to label the cell membrane 
specifically via binding to M2Rs. In conclusion, this study demonstrated that 
dibenzodiazepinone-type MR ligands are suited to prepare dualsterically binding, high-
affinity fluorescent MR ligands. However, the development of fluorescent MR ligands, which 
bind selectively to one MR subtype such as the M2R, requires structural optimizations of the 
presented type of compounds to be addressed in future studies. 
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3.4. Experimental section 
3.4.1 General experimental conditions  
Chemicals and solvents were purchased from commercial suppliers and were used without 
further purifications unless otherwise specified. Acetonitrile for HPLC (gradient grade) was 
obtained from Merck (Darmstadt, Germany). N-methyl scopolamine (1), atropine (2), W84 
(8) and H33342 were purchased from Sigma-Aldrich (Deisenhofen, Germany). 
Oxotremorine sesquifumarate (4) was from MP Biomedicals (Eschwege, Germany) and 
compound 9 was purchased from Absource Diagnostic (Munich, Germany). The fluorescent 
dye succinimidyl esters 59 (S 0536) and 60 (S 0586) were obtained from FEW Chemicals 
(Bitterfeld-Wolfen, Germany). [3H]NMS (specific activity = 80 Ci/mmol) was purchased from 
American Radiolabeled Chemicals Inc. (St. Louis, MO) via Hartman Analytics GmbH 
(Braunschweig, Germany). UR-MK331 was kindly provided by Dr. M. Keller (Institute of 
Pharmacy, University of Regensburg). Xanomeline (5) was synthesized according to 
described procedures.32 The synthesis of compounds 19 and 30 was reported previously.20 
The synthesis of the homodimeric ligand 31 is described in Chapter 2 and the preparation 
of 65 is described elsewhere21. Millipore water was used throughout for the preparation of 
buffers and HPLC eluents. Polypropylene reaction vessels (1.5 or 2 mL) with screw cap 
(Süd-Laborbedarf, Gauting, Germany) were used for the synthesis of the fluorescent 
ligands (61-64 and 66) and for the preparation and storage of stock solutions. The chemical 
stability of 62 and 64 was investigated in a flat-bottom glass tube (40 × 8.2 mm) (Altmann 
Analytik GmbH, Munich, Germany), which was siliconized before use using Sigmacote 
(Sigma-Aldrich). High-resolution mass spectrometry (HRMS) analysis was performed on an 
Agilent 6540 UHD Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, Santa 
Clara, CA) using an ESI source. Preparative HPLC was performed with a system from 
Knauer (Berlin, Germany) consisting of two K-1800 pumps and a K-2001 detector. A 
Kinetex-XB C18 (5 μm, 250 mm × 21 mm; Phenomenex, Aschaffenburg, Germany) was 
used as stationary phase at a flow rate of 18 mL/min. Mixtures of acetonitrile and 0.1% aq 
TFA were used as mobile phase. The detection wavelength was set to 220 nm throughout. 
The solvent of the collected fractions was removed by lyophilization using an Alpha 2-4 LD 
apparatus (Martin Christ, Osterode am Harz, Germany) equipped with a RZ 6 rotary vane 
vacuum pump (Vacuubrand, Wertheim, Germany). Analytical HPLC analysis of compounds 
61-64 and 66 (concentrations between 25 and 50 μM) was performed with a system from 
Agilent Technologies composed of a 1290 Infinity binary pump equipped with a degasser, 
a 1290 Infinity autosampler, a 1290 Infinity thermostated column compartment, a 1260 
Infinity diode array detector, and a 1260 Infinity fluorescence detector. A Kinetex-XB C18 
(2.6 μm, 100 × 3 mm; Phenomenex) served as stationary phase at a flow rate of 0.5 mL/min. 
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Mixtures of 0.04% aq TFA (A) and acetonitrile (B) were used as mobile phase. The following 
linear gradient was applied: 0-20 min: A/B 90:10-68:32, 20-22 min: 68:32-5:95, 22-28 min: 
5:95. For all analytical HPLC runs the oven temperature was set to 25 °C, the injection 
volume was 20 μL and detection was performed at 220 nm. The stock solutions (final 
concentration 1 mM) of fluorescent ligands were prepared in DMSO and were stored at -78 
oC. 
3.4.2 Chemistry: experimental protocols and analytical data 
 
4-(2-((1E,3E)-5-((E)-3,3-dimethyl-1-(6-oxo-6-((2-(3-(1-(4-(1-(2-oxo-2-(11-oxo-10,11-
dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)-1H-imidazol-4-
yl)propanamido)ethyl)amino)hexyl)indolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-
dimethyl-3H-indol-1-ium-1-yl)butane-1-sulfonate bis(hydrotrifluoroacetate) (61) The 
reaction was carried out in a 1.5-mL polypropylene reaction vessel equipped with a micro 
stir bar. Compound 30 (7.0 mg, 7.6 μmol) and DIPEA (6.6 mg, 9.0 μL, 51 μmol) were 
dissolved in anhydrous DMF (50 μL) followed by the addition of 59 (3.6 mg, 5.1 μmol) in 
anhydrous DMF (50 μL) and stirring was continued at room temperature in the dark for 1 h. 
10% aq TFA (100 μL) was added and purification by preparative HPLC (gradient: 0-25 min: 
0.1% aq TFA/acetonitrile 85:15-55:45, tR = 18 min) afforded 61 as a blue fluffy solid (2.4 
mg, 1.7 μmol, 34%). HRMS (ESI): m/z [M+2H]2+ calcd. for [C67H85N9O7S]2+ 579.8146, found: 
579.8153. RP-HPLC (220 nm): 99% (tR = 14.5, k = 14.8). C67H83N9O7S . C4H2F6O4 (1158.52 
+ 228.05). 
 
4-(2-((1E,3E)-5-((E)-3,3-dimethyl-1-(6-oxo-6-((2-(3-(1-(4-(1-(2-oxo-2-(11-oxo-10,11-
dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)-1H-imidazol-4-
yl)propanamido)ethyl)amino)hexyl)-5-sulfoindolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-
dimethyl-3H-indol-1-ium-1-yl)butane-1-sulfonate bis(hydrotrifluoroacetate) (62) 
Compound 62 was prepared from amine 30 (3.2 mg, 3.5 μmol) and compound 60 (1.9 mg, 
2.3 μmol) according to the procedure for the synthesis of 61. DIPEA: 3.0 mg, 4.0 μL, 23 
μmol. Purification by preparative HPLC (gradient: 0-25 min: 0.1% aq TFA/acetonitrile 85:15-
55:45, tR = 14 min) afforded 62 as a blue fluffy solid (1.4 mg, 0.95 μmol, 41%). HRMS (ESI): 
m/z [M+2H]2+ calcd. for [C67H85N9O10S2]2+ 619.7930, found: 619.7925. RP-HPLC (220 nm): 
98% (tR = 10.0, k = 9.9) C67H83N9O10S2 . C4H2F6O4 (1238.57 + 228.05). 
 
 
 
Chapter 3 
108 
4-(2-((1E,3E)-5-((E)-1-(6-((3,5-bis((2-(3-(1-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)-1H-imidazol-4-
yl)propanamido)ethyl)carbamoyl)benzyl)amino)-6-oxohexyl)-3,3-dimethylindolin-2-
ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-3H-indol-1-ium-1-yl)butane-1-sulfonate 
tetrakis(hydrotrifluoroacetate) (63) Compound 63 was prepared from amine 31 (6.0 mg, 
4.6 μmol) and compound 59 (2.2 mg, 3.1 μmol) according to the procedure for the synthesis 
of 61. DIPEA: 4.0 mg, 5.4 μL, 31 μmol. Purification by preparative HPLC (gradient: 0-25 
min: 0.1% aq TFA/acetonitrile 85:15-40:60, tR = 16 min) afforded 63 as a blue fluffy solid 
(2.6 mg, 1.1 μmol, 36%). HRMS (ESI): m/z [M+4H]4+ calcd. for [C108H133N17O12S]4+ 
473.0010, found: 473.0005. RP-HPLC (220 nm): 99% (tR = 13.3, k = 13.5) C108H129N17O12S 
. C8H4F12O8 (1889.39 + 456.09). 
 
4-(2-((1E,3E)-5-((E)-1-(6-((3,5-Bis((2-(3-(1-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)-1H-imidazol-4-
yl)propanamido)ethyl)carbamoyl)benzyl)amino)-6-oxohexyl)-3,3-dimethyl-5-
sulfoindolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-3H-indol-1-ium-1-yl)butane-
1-sulfonate tetrakis(hydrotrifluoroacetate) (64) Compound 64 was prepared from amine 
31 (6.0 mg, 4.6 μmol) and 60 (7.6 mg, 3.1 μmol) according to the procedure for the synthesis 
of 61. DIPEA: 4.0 mg, 5.4 μL, 31 μmol. Purification by preparative HPLC (gradient: 0-25 
min: 0.1% aq TFA/acetonitrile 85:15-55:45, tR = 15 min) afforded 64 as a blue fluffy solid 
(2.9 mg, 1.2 μmol, 26%). HRMS (ESI): m/z [M+3H]3+ calcd. for [C108H132N17O15S2]3+ 
656.9843, found: 656.9838. RP-HPLC (220 nm): 99% (tR = 10.4, k = 10.3) C108H129N17O15S2 
. C8H4F12O8 (1969.44 + 456.09). 
 
4-(2-((1E,3E)-5-((E)-3,3-dimethyl-1-(5-((3-((2-(4-(2-oxo-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)-[1,4'-bipiperidin]-1'-yl)ethyl)carbamoyl)-5-((2-(3-(1-(4-(1-(2-
oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-
yl)butyl)-1H-imidazol-4-yl)propanamido)ethyl)carbamoyl)benzyl)amino)pentyl)-5-
sulfoindolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-3H-indol-1-ium-1-yl)butane-
1-sulfonate pentakis(hydrotrifluoroacetate) (66) Compound 66 was prepared from 
amine 65 (5.0 mg, 4.9 μmol) and 60 (2.6 mg, 3.3 μmol) according to the procedure used for 
the synthesis of 61. DIPEA: 4.3 mg, 6.0 μL, 33 μmol. Purification by preparative HPLC 
(gradient: 0-25 min: 0.1% aq TFA/acetonitrile 85:15-55:45, tR = 14 min) afforded 66 as a 
blue fluffy solid (2.3 mg, 1.0 μmol, 34%). HRMS (ESI): m/z [M+3H]3+ calcd. for 
[C93H121N14O12S2]3+ 563.2910, found: 563.2916. RP-HPLC (220 nm): 97% (tR = 9.4, k = 9.2) 
C93H118N14O12S2 . C8H4F12O8 (1688.17 + 470.11). 
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3.4.3 Compound characterization 
The identity of the fluorescent ligands 61-64 and 66 was determined by HRMS. Their purity 
was determined by RP-HPLC (220 nm) and was ≥97% throughout (chromatograms shown 
in the appendix). 
 
3.4.4 Determination of fluorescence quantum yields  
The determination of the fluorescence quantum yields of 61, 62 and 64 in PBS and PBS 
containing 1% BSA was performed with a Cary Eclipse spectrofluorimeter and a Cary 100 
UV/VIS photometer (Varian Inc., Mulgrave, Victoria, Australia) as described previously with 
minor modifications.5 All spectra were recorded using acryl cuvettes (10 × 10 mm, Ref. 
67.755, Sarstedt, Nümbrecht, Germany). Fluorescence spectra were recorded at the slit 
adjustments (excitation/emission) 10/5 nm and 10/10 nm. Table 6 provides an overview of 
the used concentrations of the fluorescent ligands and the applied excitation wavelengths. 
The concentration of cresyl violet perchlorate in EtOH was 2 µM. Fluorescence spectra of 
cresyl violet perchlorate were recorded using an excitation wavelength of 575 nm. 
Table 6. Concentrations and excitation wavelengths used for the determination of 
fluorescence quantum yields. 
Compound 
concentration [µM] excitation wavelength [nm] 
PBS PBS + 1% BSA PBS PBS + 1% BSA 
61 2.5 2.5 605 610 
62 2.5 2.5 604 609 
64 2.5 2.5 617 613 
 
3.4.5 Investigation of the chemical stability 
The chemical stability of 62 and 64 was investigated in PBS (pH 7.4) at 22 ± 1 °C. The 
incubation was started by the addition of 10 μL of a 1 mM solution of 62 or 64 to PBS (100 
μL) to yield a final concentration of 100 μM. After 0, 24 and 48 h, aliquots (20 μL) were taken 
and added to 1% aq TFA/acetonitrile (8:2 v/v) (20 μL). The resulting solutions were analyzed 
by RP-HPLC (analytical HPLC system and conditions see general experimental conditions; 
tR: 10.0 min (62), 10.4 min (64)). To investigate the adsorption of 62 to the siliconized glass 
tube, the PBS solution containing (residual) 62 was removed from the tube and 0.1% aq 
TFA/acetonitrile (1:1 v/v) (100 μL) was added. The solution was gently shaken, an aliquote 
(20 μL) was taken and added to 1% aq TFA (20 μL), and the resulting solution were 
analyzed by RP-HPLC (referred to as “recovery” in Figure 3). 
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3.4.6 Cell Culture 
CHO-K9 cell lines stably transfected with the DNA of the human M1-M5 muscarinic receptors 
were obtained from the Missouri S&T cDNA Resource Center (Rolla, MO). Cells were 
cultured in HAM’s F12 medium supplemented with fetal calf serum (Biochrom, Berlin, 
Germany) (10%) and G418 (Biochrom) (750 µg/mL). 
 
3.4.7 [3H]NMS competition binding experiments 
Radioligand binding studies with [3H]NMS were performed at 22 ± 1 °C. Leibovitz L-15 
medium (Gibco, Life Technologies GmbH, Darmstadt, Germany) supplemented with 1% 
BSA (Serva, Heidelberg, Germany) (in the following referred to as L15 medium) was used 
as binding buffer. The effects of the fluorescent ligands 61-64 and 66 on the equilibrium 
binding of [3H]NMS (equilibrium competition binding assay) were determined at intact 
adherent CHO-hMxR cells (x = 1-5) in white 96-well plates with clear bottom (Corning Life 
Sciences, Tewksbury, MA; Corning cat. no. 3610) using the protocol of previously described 
MR binding studies with [3H]NMS20 with the following modification: the total volume of L15 
medium per well was 200 µL instead of 188 µL, i.e. the cells were covered with L15 medium 
(160 µL) followed by the addition of L15 medium (20 µL), neat (to determine total binding) 
or containing atropine or the studied compound 10-fold concentrated, and L15 medium (20 
µL) containing the radioligand 10-fold concentrated. The concentration of [3H]NMS was 0.2 
nM (M1, M2, M3), 0.1 nM (M4) or 0.3 nM (M5) and the incubation time was 3 h throughout. 
Unspecific binding was determined in the presence of atropine (2) (500-fold excess to 
[3H]NMS).  
 
3.4.8 Flow cytometric saturation binding experiments 
Flow cytometric saturation binding studies with 62 and 64 at live CHO-hM2R cells were 
performed with a FACSCaliburTM flow cytometer (Becton Dickinson, Heidelberg, Germany), 
equipped with an argon laser (488 nm) and a red diode laser (635 nm). Cells were seeded 
in a 175-cm2 culture flask 5-6 days prior to the experiment. On the day of the experiment, 
cells were treated with trypsin, suspended in culture medium and centrifuged. The cell pellet 
was re-suspended in Leibovitz’s L15 culture medium (Gibco, Life Technologies, Darmstadt, 
Germany) supplemented with 1% BSA (in the following referred to as L15 medium). The 
cell density was adjusted to 1 × 106 cells/mL. 490 μL of the cell suspension were added to 
1.5 mL reaction vessels (Sarstedt, Nümbrecht, Germany) containing 5 µL of a solution of 
the fluorescent ligand (100-fold concentrated) in DMSO/H2O (1:1 v/v) and 5 μL of 
DMSO/H2O (1:1 v/v), to determine total binding. For the determination of unspecific binding 
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(in the presence of atropine (2) at 500-fold access to the fluorescent ligand), 490 μL of the 
cell suspension were added to reaction vessels containing 5 µL of a solution of the 
fluorescent ligand (100-fold concentrated) in DMSO/H2O (1:1 v/v) and 5 μL of a solution of 
atropine (100-fold concentrated) in DMSO/H2O (1:1 v/v). Compounds 62 and 64 were used 
at final concentrations of 0.005-50 nM and 0.15-80 nM, respectively. The samples (prepared 
in duplicate) were incubated at 22 °C under gentle shaking in the dark. Fluorescence signals 
were recorded in channel FL-4 (excitation: 635 nm, emission: 661 ± 18 nm, gain: 700-800 
V). Measurements were stopped after counting of 20,000 gated events.  
 
3.4.9 High-content imaging based saturation and competition binding assay with 62 
and 64 
One day prior to the experiment, CHO-hM2R or CHO-hM1R cells were seeded at 35,000-
40,000 cells per well into the central 60 wells of a black/transparent 96-well plate (Grenier 
655090). On the day of the experiment the medium was removed by suction, the cells were 
washed with HBSS containing 0.1 % BSA33 (in the following referred to as HBSS-BSA) (50 
μL), and covered with HBSS-BSA (80 µL) containing the permeable nuclear dye H33342 (2 
μg/mL). To determine total binding, HBSS-BSA (10 μL) and HBSS-BSA (10 μL) containing 
the fluorescent ligand (10-fold concentrated) were added. For the determination of 
unspecific binding and to study the effect of a compound of interest on M2R binding of the 
fluorescent ligand (competition binding assay) HBSS-BSA (10 μL) containing atropine or 
the ‘competitor’ (10-fold concentrated) and HBSS-BSA (10 μL) containing the fluorescent 
ligand (10-fold concentrated) were added. During incubation at room temperature in the 
dark for 60 min the plates were gently shaken. After incubation, the cells were washed with 
HBSS-BSA (50 μL) and covered with HBSS-BSA (50 μL) followed by immediate acquisition 
of the images using the IX Ultra confocal plate reader (Molecular Devices, Sunnyvale CA). 
The washing procedure was performed within < 3 min. The excitation laser lines of the Ultra 
plate reader were 405 nm (Hoechst 33342) and 635 nm (Cy5). Two sites/well were 
measured throughout. The following final concentrations of 62 and 64 were used for 
saturation binding studies: 0.4-400 nM (62, M1R), 0.4-400 nM (62, M2R), 0.2-100 nM (64, 
M1R) and 0.2-100 nM (64, M2R). For competition binding experiments at CHO-hM2R cells, 
62 and 64 were applied at final concentrations of 10 nM. Unspecific binding was determined 
in the presence of atropine (2) (in case of saturation binding experiments 500-fold excess 
to the fluorescent ligand, in case of competition binding experiments at final concentration 
of 1 µM) in case of competition binding experiments). Saturation binding experiments were 
performed in triplicate and competition binding assays were performed in duplicate. M2R 
saturation binding experiments with 62 and 64 in the presence of various fixed 
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concentrations of 8 were performed as described above with the following modification: the 
cells were covered with 70 µL of HBSS-BSA instead of 80 µL to compensate the extra 
addition of HBSS-BSA (10 µL) containing 8 (10-fold concentrated). The washing step prior 
to the measurement was performed. 
 
3.4.10 Confocal microscopy  
One day prior to the experiment CHO-hM2R cells seeded in Nunc LabTekTM II chambered 
coverglasses with 8 chambers (Thermo fisher scientific) (ca. 80000 cells/well). The culture 
medium was removed, the cells were washed with HBSS-BSA (cf. section 3.4.9) (200 μL) 
and covered with HBSS-BSA (320 μL). HBSS-BSA (40 μL) and HBSS-BSA (40 μL) 
containing the fluorescent probe (10 fold concentrated) were added for total binding. For 
unspecific binding HBSS-BSA (40 μL) containing the competing agent atropine (final 
concentration: 10 μM) and HBSS-BSA (40 μL) containing the fluorescent probe (10 fold 
concentrated) were added. Images were acquired after an incubation period of 5-45 min 
with a Zeiss LSM710 confocal laser scanning microscope (Zeiss, Jena, Germany). The 
objective was 63x magnification with oil (1.4 NA). The excitation laser lines were 405 nm 
(2.0%) and 633 nm (10%), filter settings were 410-514 nm (Hoechst 33342 channel) and 
638-759 nm (Cy5 channel), and the pinhole setting was 44 μm throughout. 
 
3.4.11 Data processing 
Retention (capacity) factors k were calculated from retention times (tR) according to k = 
(tR−t0)/t0 (t0 = dead time). Raw data from flow cytometric experiments were processed with 
the aid of the FlowJo software (FlowJo LLC, Ashland, OR) to obtain geometrical mean 
values of FL-4. Fluorescence images from high content imaging were analyzed using the 
granularity analysis (2-3-μm-diameter granules; MetaXpress 5.3, Molecular Devices) to 
obtain fluorescent arbitrary values. For the granularity algorithm, fluorescent intensity 
thresholds were adapted to maximize the identification of specifically bound fluorescent 
ligand (without distinguishing membrane from intracellular localization) by referring to total 
and unspecific binding. Specific binding data from saturation binding experiments (flow 
cytometry, high content imaging), obtained by subtracting unspecific binding data from total 
binding data, were plotted against the fluorescent ligand concentration and analyzed by a 
two-parameter equation describing hyperbolic binding (one site-specific binding, GraphPad 
Prism) to obtain Kd values. Unspecific binding data from saturation binding experiments 
were fitted by linear regression. In case of saturation binding experiments in the presence 
of compound 8, specific binding data were analyzed by a two-parameter equation 
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describing hyperbolic binding (one site-specific binding, GraphPad Prism) to obtain Kd and 
Bmax values. Additionally, specific binding data were normalized to the Bmax value, specific 
binding (%) was plotted against log(concentration 62 or 64) followed by analysis using a 
four-parameter logistic fit (log(agonist) vs. response, applied constraints: bottom = 0%, top 
= 100%; GraphPad Prism). Data for the ‘Schild’ plot were obtained from the rightward shift 
(ΔpKd) of the saturation isotherm and transformation into log(r-1) (where r = 10ΔpKd). Log(r-
1) was plotted against log(concentration of 8) and the data were analyzed by linear 
regression to obtain the slope and the ‘pA2’ value (intercept with the X axis). Total binding 
data from competition binding experiments (determination of the effect of 61-64 and 66 on 
the equilibrium binding of [3H]NMS and the effect of various MR ligands on M2R binding of 
62 and 64) were plotted against log(concentration competitor) and analyzed by a four-
parameter logistic equation (log(inhibitor) vs. response-variable slope, GraphPad Prism) 
followed by normalization (100% = ‘top’ of the four-parameter logistic fit, 0% = unspecifically 
bound radioligand or fluorescent ligand determined in the presence of 2) and analysis of 
the normalized data by a four-parameter logistic equation. pIC50 values were converted to 
pKi values according to the Cheng-Prusoff equation34 used in its logarithmic form. Statistical 
significance was assessed by a one-sample t-test. 
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Chapter 4 
 Conjugation of dibenzodiazepinone-type muscarinic 
receptor antagonists to short peptides: a new avenue to 
highly selective M2R ligands
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4.1. Introduction 
Over the last decades, extensive efforts have been made to design molecules, which 
selectively bind to one of the five muscarinic receptor (MR) subtypes.1 In fact, due to the 
high sequence homology of the MRs orthosteric binding site2, potent and selective 
therapeutics without side effects, attributed to “MR promiscuity”, are still an unfulfilled need. 
For instance, antagonism at presynaptic M2R in the CNS has been suggested as an 
approach to increase cholinergic function in Alzheimer’s patients.3-6 However, for that 
purpose, highly selective M2R antagonists are required because concomitant blocking of 
postsynaptic M1R must be strictly prevented. 
As the M2R exhibits various accessory (allosteric) sites several compounds addressing 
these less conserved allosteric binding sites have been developed (cf Chapter 2);7-9 
however, high-affinity M2R modulators are still lacking.10 The dualsteric ligand approach, 
which means connecting an orthosteric ligand with an allosteric modulator through a linker 
in order to increase receptor selectivity, has emerged as a promising strategy to design 
novel MR ligands.10-16 However, no reports on highly selective (dualsteric) M2R ligands can 
be found in the literature to date. Due to their relatively high affinity for the hM2R, 
pyridobenzodiazepinone-type (10, 67 and 68) (Figure 1) and dibenzodiazepinone-type (17, 
19 and 69) (Figure 1) MR ligands were described17-19 as preferred scaffolds to develop 
highly potent and selective M2R antagonists. For instance, compounds 17, 19 and 68 exhibit 
high M2R affinity with Ki values in the low nanomolar range (≤ 0.8 nM), but a poor selectivity 
towards the other receptor subtypes (especially the M1R and M4R) (Figure 1). Worth 
mentioning, compounds 10, 19 and 68 were suggested to interact with both, the orthosteric 
and an allosteric binding site.20, 21 Over the past decades, only a few new chemical scaffolds 
were described as candidates for designing selective M2R antagonists. Piperidinyl-
piperazine derivative 70, for instance, exhibits high M2R affinity (Ki = 0.1 nM) and a 
remarkable M2R/M1R selectivity (330-fold) (Figure 1). Nevertheless, the M2R/M4R selectivity 
was still unsatisfactory (12-fold). Indene-derivative 71 (Figure 1), which was designed based 
on the structure of the H1R-antagonist dimethindene, exhibits moderate M2R affinity and no 
selectivity at all (Figure 1).  
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Figure 1. Structure and selectivity profile of a selection of (selective) M2R antagonist 
described in literature. n.a.: no data available. References: (a) Dörje et al.22 (b) Gitler et al.17 
(c) Keller et al.23 (d) Doods et al.24 (e) Maggio et al.25 (f) McCombie et al.26 (g) Boehme et 
al.27 
 
Recently, a series of high-affinity, M2 subtype-preferring (weakly selective) MR antagonists 
derived from the dibenzodiazepinone 17, including compound 19 and two homodimeric 
analogs, was reported.23 Aiming at a better understanding of the binding mode of such 
dibenzodiazepinone-type MR ligands, the tritiated form of 19 and of the homodimeric 
congener of 19 (33, cf. Chapter 2) were synthesized ([3H]19, [3H]33) and pharmacologically 
characterized (cf. Chapter 2). Compounds 19 and 33 were shown to interact dualsterically 
with the hM2R (cf. Chapter 2). Prompted by these studies, as well as by the fact that 
conjugation of dibenzodiazepinone-type MR ligands to fluorescent dyes was well tolerated 
with respect to M2R binding, the dibenzodiazepinone pharmacophore as in 17 was linked 
to di- or tripeptides in order to obtain dualsteric ligands (in the following referred to as DIBA-
peptide conjugates) with improved M2R selectivity. Two different linkers, which chemical 
structures were design based on docking simulation and literature reported M2R models, 
were used to connect the DIBA pharmacophore with short peptides (Figure 2).  
 
Figure 2. Schematic presentation of the aim of the present chapter. n.a: no data available. 
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4.2. Results and discussion 
4.2.1 Chemistry 
Two amino-functionalized dibenzodiazepinone scaffolds, bearing a linear aliphatic linker 
(83)19 or a linker additionally containing a basic piperazine moiety (84)28 were conjugated to 
short peptides which design was based on docking simulation experiments (data not shown) 
and on the M2R structures available in the literature. The peptide synthesis (compounds 72-
82) was carried out manually on a 2-ClTrt resin according to the Fmoc strategy following a 
reported protocol (“double” coupling procedure with HBTU/HOBt/DIPEA) (Scheme 1).29 
Prior to the cleavage from the resin the N-terminus of all the peptides was N-acetylated by 
treatment with acetic anhydride to facilitate the coupling of the peptides to the DIBA-derived 
amine precursors and to prevent a protonation of the N-terminus under assay conditions. 
After cleavage from the resin, the C-terminus of the peptides was amidated by amine 83 or 
84 in order to obtain the protected DIBA-peptide conjugates. Cleavage of the protecting 
groups using TFA yielded compounds 87-108 (Scheme 1). Moreover, propionylation of 
amine 83 using succinimidyl propionate (32) afforded the reference compound 85 (Scheme 
1). 
 
Scheme 1 Schematic presentation of the synthesis of the DIBA-peptide conjugates. 
Reagents and conditions: (a) (1) peptide elongation by SPPS (Fmoc strategy), Fmoc-
aa/HBTU/HOBt/DIPEA (5/5/5/10 equiv.), solvent DMF/NMP (8:2, v/v), “double” coupling at 
rt, 60 min. Fmoc deprotection was carried out with 20% piperidine in DMF/NMP (8:2, v/v), 
rt, 2 × 10 min; (2) acetic anhydride, DIPEA, rt, 30 min; (3) CH2Cl2/HFIP (3:1, v/v), rt, 2 × 20 
min, 47-98%; (b) (1) EDC × HCl (added to a stirred mixture of the respective peptide, 83 or 
84 and HOBt in DMF), HOBt, DMF, 5 °C, 2 h, in case of 84 (provided as 
tris(hydrotrifluoroacetate) DIPEA (2 equiv.) was added; (2) TFA/CH2Cl2/H2O (1:1:0.1, v/v/v) 
or with TFA/H2O (95:5, v/v), rt, 3 h, 27-75%; (c) DIPEA, DMF, rt, 1 h, 99%. 
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The conditions used for amide coupling between the amines 83 or 84 and the side-chain 
protected peptides (72-82) were crucial with regard to the retention of the stereochemistry 
at Cα of the C-terminal amino acid of the peptides. For example, when amine 83 was 
coupled with tripeptide 82 applying a preactivation step of 82 with HBTU/HOBt in the 
presence of DIPEA for 10 min, a diastereomeric mixture of the product was obtained (Figure 
3A). The epimerization at Cα occurs due to the intramolecular cyclization of the activated 
C-terminal α-amino acid affording a 5(4H)-oxazolone30 which, under basic conditions, 
undergoes a keto-enol tautomerism provoking the formation of the epimerized product 
(S,S,R)-86 (Figure 3A). The formation of two diastereomers was confirmed by RP-HPLC 
(Figure 3B). By contrast, when EDC × HCl/HOBt was used as coupling reagent (without the 
preactivation of 82) and no base was added, the reaction led to the formation of the 
enantiomerically pure product (S,S,S)-86 (Figure 3A and Figure 3C).  
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Figure 3. (A) Coupling of peptide 82 to amine 83 using different conditions. (a) HBTU, 
(added to a mixture of 82, DIPEA and HOBt in DMF. The resulting mixture was stirred at rt 
for 10 min before the addition of amine 83) DMF, rt, 3 h; (b) EDC × HCl, HOBt, DMF, 5 °C, 
3 h. Amine 83 was immediately added to the reaction mixture (no preactivation step was 
applied, see experimental section); (C/D) RP-HPLC analysis (conditions see experimental 
section) of the reaction mixtures of the coupling reactions presented under (A). 
 
An overview of the chemical structure of all DIBA-peptide conjugates is given in Table 1 
together with the RP-HPLC purities after purification by preparative HPLC.  
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Table 1. Structures and RP-HPLC purities of the DIBA-peptide conjugates 87-108. 
 
aPurities determined by analytical RP-HPLC (λ = 220 nm).
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4.2.2 Equilibrium competition binding at hM1-hM5R. 
The M1-M5 receptor affinities of the DIBA-peptide conjugates (87-108) and reference compound 85 
were determined by radioligand equilibrium competition binding using stably transfected CHO-cells 
and the orthosteric MR antagonist [3H]NMS as radioligand. As the dibenzodiazepinone-type MR 
ligands 19 (monomeric derivative) and 33 (homodimeric ligand) were shown to interact 
simultaneously with the orthosteric and with the allosteric binding site of the hM2R (cf. Chapter 2), 
the DIBA-peptide derivatives presented in this chapter were anticipated to bind to the orthosteric site 
of MRs via the dibenzodiazepinone pharmacophore, being competitive with [3H]NMS. The peptide 
moieties potentially interact with an allosteric site of the receptor. Therefore, data from equilibrium 
competition binding with [3H]NMS were analyzed by four-parameter logistic curve fitting and pIC50 
values were converted to pKi values. An overview of the MR binding data of 85 and 87-108 together 
with their MR selectivity profile is provided in Table 2. The subset of compounds bearing a short 
linker (85, 87-97) exhibited lower affinities at all MR subtypes (M1-M5) compared to the subset of 
derivatives containing the longer linker with a basic piperazine moiety (Figure 4 and Figure 5, Table 
2). Compounds 90 and 91, both containing a leucine and a glutamine in their structure (cf. Table 1), 
displayed the lowest affinity at the five MR subtypes (Figure 4, Table 2). Interestingly, compound 85, 
containing a propionyl residue instead of the peptide moiety (cf.Table 1), and compound 87 (“Ala-
Ala-DIBA”), which has only methyl groups as amino acid side chains, showed an increased affinity 
at M1-M4 receptors compared to the leucine/glutamine-containing derivatives 90 and 91. Within the 
“short-linker” subset of DIBA-peptide derivatives, the range of pKi values determined for M2R binding 
was 6.4-9.0 (Table 2). Compounds containing one or two basic amino acids (92, 93, 95-97) exhibited 
the highest M2R affinities, which was in agreement with previous reports about the importance of 
basic moieties for ligand binding at the M2R.7, 31, 32 By contrast, all “long-linker” DIBA-peptide 
conjugates exhibited high M2R affinities (pKi = 9.42-10.21, Table 2). In case of the subtypes M1 and 
M3-M5 the situation was similar: whereas the pKi values of the compounds of the “short-linker” series 
(87-97) varied by approx. two orders of magnitude, pKi values obtained for the derivatives of the 
“long-linker” series (98-108) varied only by approx. one order of magnitude (Figure 4, Figure 5 and 
Figure 6; Table 2). The DIBA-peptide derivative with the lowest pronounced M2R selectivity was 
evident in the “short-linker” compound subset (91, Ki M1R:M2R:M3R:M4R:M5R = 1.4:1:44:1.9:2.1, 
Table 2). The “short-linker” derivative 96 and the “long linker” derivative 108, containing the peptide 
sequences Lys-Arg and Lys-Ala-Arg, respectively, exhibited the most pronounced M2R selectivities 
(96, Ki M1R:M2R:M3R:M4R:M5R = 58:1:6900:99:300; 108, Ki M1R:M2R:M3R:M4R:M5R = 
49:1:1800:70:3500; Table 2, Figure 6 and Figure 7). As described previously for 
dibenzodiazepinone- and pyridobenzodiazepinone-type MR ligands17, 19, 22, 24-27 (for structures 
cf.Figure 1), the M2 selectivity towards the M1 subtype was the lowest compared to M2/M3-M5 
selectivities. Compounds 96 and 108 showed the highest M2R affinities within the respective 
compound subset with pKi values of 9.00 and 10.21, respectively (Table 1). As both DIBA-peptide 
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conjugates contain two basic amino acids (Lys and Arg), these results demonstrate that positively 
charged residues are advantageous for M2R binding, which is consistent with reports on orthosteric 
and allosteric M2R ligands.7, 31, 32 Notably, the DIBA-peptide conjugates of the “long-linker” subset 
showed a considerably more pronounced M2/M5 receptor selectivity compared to the “short-linker” 
derivatives (Table 2, Figure 6). The reference compound 85 showed no M2/M1 selectivity and only a 
very low M2/M4 selectivity, indicating that the considerable gain in M2R selectivity as found for 96 and 
108 is mediated by the peptide structure. Worth mentioning, compound 97, which is structurally 
closely related to 96 (Lys-Ala-Arg vs. Lys-Arg; cf. Table 1), showed, compared to 96, a decreased 
M2R affinity (pKi 8.11 vs. 9.00, Figure 4B and Table 2) and an impaired selectivity profile (Ki 
M1R:M2R:M3R:M4R:M5R = 11:1:350:15:39) (Table 2). To the best knowledge of the author, 
compounds 96 and 108 represent the most selective M2R ligands with Ki values in the low nanomolar 
and the picomolar range, respectively, which were described to date33 and represent excellent 
candidates for the development of highly selective M2R ligands. 
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Figure 4. Concentration-dependent effects of the dibenzodiazepinone-type MR ligands containing 
the “short” tetramethylene linker (85, 87-97) on MxR equilibrium binding of [3H]NMS (x = 1-5), 
determined at live CHO-hM1 (A), CHO-hM2 (B), CHO-hM3 (C), CHO-hM4 (D) and CHO-hM5 (E). Data 
were analyzed by four-parameter logistic fits. Mean values ± SEM from at least three independent 
experiments (performed in triplicate).  
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Figure 5. Concentration-dependent effects of the dibenzodiazepinone-type MR ligands containing 
the “long” piperazinyl linker (98-108) on MxR equilibrium binding of [3H]NMS (x = 1-5) determined at 
live CHO-hM1 (A), CHO-hM2 (B), CHO-hM3 (C), CHO-hM4 (D) and CHO-hM5 (E). Data were analyzed 
by four-parameter logistic fits. Mean values ± SEM from at least three independent experiments 
(performed in triplicate). 
lo g (c )
%
 s
p
e
c
if
ic
a
ll
y
 b
o
u
n
d
 [
3
H
]N
M
S
0
2 0
4 0
6 0
8 0
1 0 0
-1 0 -9 -8 -7 -6
98
99
100
101
102
103
104
105
106
107
108
-
M 1 R
A
lo g (c )
%
 s
p
e
c
if
ic
a
ll
y
 b
o
u
n
d
 [
3
H
]N
M
S
0
2 0
4 0
6 0
8 0
1 0 0
-1 1 -1 0 -9 -8 -7-
M 2 R
B
lo g (c )
%
 s
p
e
c
if
ic
a
ll
y
 b
o
u
n
d
 [
3
H
]N
M
S
0
2 0
4 0
6 0
8 0
1 0 0
-9 -8 -7 -6 -5 -4-
M 3 R
C
lo g (c )
%
 s
p
e
c
if
ic
a
ll
y
 b
o
u
n
d
 [
3
H
]N
M
S
0
2 0
4 0
6 0
8 0
1 0 0
-1 1 -1 0 -9 -8 -7 -6-
M 4 R
D
lo g (c )
%
 s
p
e
c
if
ic
a
ll
y
 b
o
u
n
d
 [
3
H
]N
M
S
0
2 0
4 0
6 0
8 0
1 0 0
-9 -8 -7 -6 -5 -4-
M 5 R
E
  
Table 2. M1-M5 receptor affinities of the DIBA-peptide conjugates (87-108) and compound 85 obtained from equilibrium competition binding studies with [3H]NMS. 
Presented are mean values ± SEM from 3-9 independent experiments (each performed in triplicate). Kd values19 / applied concentrations of [3H]NMS: M1: 0.12 / 0.2 nM; M2: 0.090 / 
0.2 nM; M3: 0.089 / 0.2 nM; M4: 0.040 / 0.1 nM; M5: 0.24 / 0.3 nM. 
compd. linker 
amino acids 
sequence 
M1R M2R M3R M4R M5R 
selectivity toward M2R (Ki (MxR)/Ki 
(M2R)) 
pKi pKi pKi pKi pKi M1R M3R M4R M5R 
85 short / 7.14 ± 0.05 7.10 ± 0.05 5.30 ± 0.08 6.64 ± 0.08 5.14 ± 0.14 0.8 70 3.2 69 
87 short Ala-Ala 6.45 ± 0.03 7.62 ± 0.01 5.90 ± 0.03 6.96 ± 0.09 5.86 ± 0.11 13 58 5.2 42 
88 short Trp-Tyr 6.72 ± 0.04 7.48 ± 0.11 5.84 ± 0.04 6.93 ± 0.05 7.23 ± 0.12 4.6 45 3.6 1.2 
89 short Trp-Ala-Tyr 7.10 ± 0.06 7.70 ± 0.05 5.98 ± 0.04 7.39 ± 0.11 6.91 ± 0.09 3.4 57 2.3 4.4 
90 short Gln-Leu 6.05 ± 0.07 6.51 ± 0.02 4.67 ± 0.03 5.93 ± 0.08 5.81 ± 0.04 2.5 74 4.3 3.4 
91 short Gln-Ala-Leu 6.17 ± 0.03 6.40 ± 0.05 4.80 ± 0.06 6.15 ± 0.02 5.91 ± 0.04 1.4 44 1.9 2.1 
92 short Lys-Tyr 7.70 ± 0.12 8.74 ± 0.08 5.82 ± 0.09 7.93 ± 0.08 7.12 ± 0.12 10 720 7.0 3 
93 short Lys-Ala-Tyr 7.30 ± 0.05 8.37 ± 0.02 6.21 ± 0.05 7.59 ± 0.10 6.64 ± 0.05 10 160 6.9 37 
94 short Tyr-Lys 7.13 ± 0.01 7.33 ± 0.04 5.03 ± 0.01 6.48 ± 0.08 6.14 ± 0.02 1.3 220 7.8 11 
95 short Tyr-Ala-Lys 6.82 ± 0.08 8.03 ± 0.10 5.34 ± 0.05 7.20 ± 0.05 6.67 ± 0.09 14 530 7.1 16 
96 short Lys-Arg 7.17 ± 0.07 9.00 ± 0.02 5.21 ± 0.06 7.04 ± 0.03 6.37 ± 0.07 58 6900 99 300 
97 short Lys-Ala-Arg 7.01 ± 0.03 8.11 ± 0.02 5.60 ± 0.06 7.01 ± 0.11 6.37 ± 0.08 11 350 15 39 
98 long Ala-Ala 8.52 ± 0.08 9.42 ± 0.04 6.84 ± 0.09 8.52 ± 0.17 6.33 ± 0.07 6.9 420 10 880 
99 long Trp-Tyr 8.86 ± 0.05 10.10 ± 0.03 7.90 ± 0.09 8.73 ± 0.06 7.40 ± 0.04 15 180 26 350 
100 long Trp-Ala-Tyr 8.71 ± 0.05 10.06 ± 0.03 7.49 ± 0.06 8.75 ± 0.04 7.50 ± 0.10 19 420 22 270 
101 long Gln-Leu 8.69 ± 0.04 9.62 ± 0.10 7.24 ± 0.13 8.88 ± 0.15 6.52 ± 0.13 7.0 270 6.5 920 
102 long Gln-Ala-Leu 8.60 ± 0.07 9.45 ± 0.05 6.85 ± 0.09 8.30 ± 0.11 6.61 ± 0.10 6.1 450 16 500 
103 long Lys-Tyr 8.92 ± 0.02 10.08 ± 0.20 7.59 ± 0.01 8.91 ± 0.16 7.14 ± 0.15 10 270 15 550 
104 long Lys-Ala-Tyr 8.73 ± 0.08 9.93 ± 0.01 7.38 ± 0.07 8.76 ± 0.18 7.01 ± 0.14 14 390 19 630 
105 long Tyr-Lys 8.74 ± 0.17 10.12 ± 0.03 7.82 ± 0.06 8.99 ± 0.12 6.84 ± 0.05 24 220 16 1300 
106 long Tyr-Ala-Lys 8.70 ± 0.10 9.94 ± 0.02 7.58 ± 0.13 8.45 ± 0.03 7.49 ± 0.07 16 290 34 200 
107 long Lys-Arg 8.98 ± 0.10 10.21 ± 0.06 7.34 ± 0.06 8.65 ± 0.17 6.94 ± 0.11 15 800 44 1300 
108 long Lys-Ala-Arg 8.45 ± 0.03 10.21 ± 0.06 6.99 ± 0.07 8.40 ± 0.05 6.52 ± 0.09 49 1800 70 3500 
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Figure 6. “Radar” charts presenting M1R-M5R affinities of reference compound 85 and 
dibenzodiazepinone derivatives 87-97 (DIBA-peptide conjugates containing the short linker) 
(A), as well as compounds 98-108 (DIBA-peptide conjugates containing the long linker) (B). 
Each vertex of the chart represents a MR subtype (M1-M5) plotted against pKi values 
(increasing from the center towards the outside). Solid lines indicate the most selective 
derivatives (96 in A and 108 in B). 
 
Figure 7. MR selectivity profile of 96 (A) and 108 (B) demonstrated by [3H]NMS 
displacement curves at MR subtypes M1-M5 (extracted from Figure 4A-E and Figure 5A-E, 
respectively). 
  
lo g (c ) 9 6
%
 s
p
e
c
if
ic
a
ll
y
 b
o
u
n
d
 [
3
H
]N
M
S
- 1 2 -1 0 -8 -6 -4
0
2 0
4 0
6 0
8 0
1 0 0
M 1 R  /  7 .1 9
M 2 R  /  9 .0 0
M 3 R  /  5 .2 9
M 4 R  /  7 .0 3
M 5 R  /  6 .3 6
M R  s u b ty p e  /  p K i
A
lo g (c ) 1 0 8
%
 s
p
e
c
if
ic
a
ll
y
 b
o
u
n
d
 [
3
H
]N
M
S
- 1 4 -1 2 -1 0 -8 -6 -4
0
2 0
4 0
6 0
8 0
1 0 0
M 1 R  /  8 .4 5
M 2 R  / 1 0 .2 1
M 3 R  /  7 .0 2
M 4 R  /  8 .4 0
M 5 R  /  6 .5 0
M R  s u b ty p e  /  p K i
B
Chapter 4 
132 
4.3. Conclusion 
Linkage of two amino-functionalized dibenzodiazepinone-type MR ligands (83 and 84, 
Scheme 1), derived from the M2R-preferring MR antagonist DIBA (17), to di- and tripeptides 
yielded a series of DIBA-peptide conjugates (22 compounds), comprising two compound 
subsets according to the type of linker (short/non-basic vs. long/basic). M1-M5 receptor 
binding data were determined by equilibrium competition binding with [3H]NMS using intact 
CHO-hMxR cells (x = 1-5). For both subsets of DIBA-peptide conjugates, the compound 
with the highest M2R affinity exhibited the highest M2R selectivity, too (“short-linker” subset: 
96, pKi = 9.00, Ki M1R:M2R:M3R:M4R:M5R = 58:1:6900:99:300; “long-linker” subset: 108, 
pKi = 10.21, Ki M1R:M2R:M3R:M4R:M5R = 49:1:1800:70:3500). Noteworthily, both hits, 96 
and 108, contained two basic amino acids (Lys, Arg), indicating the importance of polar and 
positively charged moieties for M2R binding and selectivity. Compounds 96 and 108, due to 
their high M2R affinity and good selectivity, are considered valuable leads to develop high-
affinity and highly selective M2R antagonists. Both compounds represent the most selective 
M2R antagonists described to date with a Ki in the low nanomolar range (96) or in the 
picomolar range (108). Investigations on the M2R binding mode of compounds such as 96 
and 108, supposed to be dualsteric, will be subject of future studies. For that purpose 
docking studies and MD simulations based on the reported crystal structures of MR 
receptors, as well as various binding studies involving different radioligands, allosteric 
modulators and receptor mutants are envisaged. 
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4.4. Experimental section 
4.4.1 General experimental conditions  
Chemicals and solvents were purchased from commercial suppliers and were used without 
further purifications unless otherwise specified. HOBt hydrate, DMF (for peptide synthesis) 
and NMP (for peptide synthesis) were obtained from Acros Organics/Fischer Scientific 
(Nidderau, Germany). Dichloromethane (CH2Cl2), DIPEA, N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC × HCl), 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) 
and trifluoroacetic acid (TFA), were from Sigma-Aldrich (Deisenhofen, Germany). HBTU 
and piperidine were from Iris Biotech (Marktredwitz, Germany). Acetonitrile for HPLC 
(gradient grade) was purchased from Merck (Darmstadt, Germany) and [3H]NMS (specific 
activity = 80 Ci/mmol) was purchased from American Radiolabeled Chemicals Inc. (St. 
Louis, MO) via Hartman Analytics GmbH (Braunschweig, Germany). Millipore water was 
used throughout for the preparation of buffers and HPLC eluents. Polypropylene reaction 
vessels (1.5 or 2 mL) with screw cap (Süd-Laborbedarf, Gauting, Germany) were used for 
small scale reactions and for the preparation and storage of stock solutions. Temperature-
controlled reaction with polypropylene reaction vessels were performed in a Thermocell 
mixing block from Bioer (Hangzhou, China). Thin layer chromatography (TLC) was 
performed on Merck silica gel 60 F254 TLC aluminum plates. Visualization was accomplished 
by UV irradiation (λ = 254 or 366 nm) and by staining with ninhydrin or potassium 
permanganate. NMR spectra were recorded on a Bruker Avance 300 (7.05 T, 1H: 300.1 
MHz, 13C: 75.5 MHz) or a Bruker Avance III HD 600 equipped with a cryogenic probe (14.1 
T 1H: 600.1 MHz, 13C: 150.9 MHz) (Bruker, Karlsruhe, Germany). High-resolution mass 
spectrometry (HRMS) analysis was performed on an Agilent 6540 UHD Accurate-Mass Q-
TOF LC/MS system (Agilent Technologies, Santa Clara, CA) using an ESI source. 
Preparative HPLC was performed with a system from Knauer (Berlin, Germany) consisting 
of two K-1800 pumps and a K-2001 detector. A Kinetex-XB C18 (5 μm, 250 mm × 21 mm; 
Phenomenex, Aschaffenburg, Germany) was used as stationary phases at a flow rate of 18 
mL/min. Mixtures of 0.1% aq TFA and acetonitrile were used as mobile phase. The 
detection wavelength was set to 220 nm throughout. The solvent of the collected fractions 
was removed by lyophilization using an Alpha 2-4 LD apparatus (Martin Christ, Osterode 
am Harz, Germany) equipped with a RZ 6 rotary vane vacuum pump (Vacuubrand, 
Wertheim, Germany). Analytical HPLC analysis of compounds 85-106 (concentrations 
between 25 and 50 μM) was performed with a system from Agilent Technologies composed 
of a 1290 Infinity binary pump equipped with a degasser, a 1290 Infinity autosampler, a 
1290 Infinity thermostated column compartment, a 1260 Infinity diode array detector, and a 
1260 Infinity fluorescence detector. A Kinetex-XB C18 (2.6 μm, 100 × 3 mm; Phenomenex) 
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served as stationary phase at a flow rate of 0.5 mL/min. Mixtures of 0.04% aq TFA (A) and 
acetonitrile (B) were used as mobile phase. For HPLC analysis of compounds 87-108 the 
following linear gradient was applied: 0-20 min: A/B 90:10-70:30, 20-22 min: 70:30-5:95, 
22-28 min: 5:95. HPLC analysis of 85 was performed using the following gradient: 0-12 min: 
A/B 90:10-70:30, 12-16 min: 70:30-5:95, 16-20 min: 5:95 whereas for HPLC analysis of 
compounds 86 the following gradient was used: 0-20 min: A/B 80:20-30:70, 20-22 min: 
30:70-5:95, 22-28 min: 5:95. For all analytical HPLC runs the oven temperature was set to 
25 °C, the injection volume was 20 μL and detection was performed at 220 nm. 
Annotation concerning the NMR spectra (1H, 13C) of the dibenzodiazepinone derivatives 
(85, 87-108): due to a slow rotation about the exocyclic amide group on the NMR time scale, 
two isomers (ratios provided in the experimental protocols) were evident in the 1H- and 13C-
NMR spectra. 
 
4.4.2 Compound characterization 
All target compounds (85, 87-108) were characterized by 1H-NMR, 13C-NMR and 2D-NMR 
(1H-COSY, HSQC, HMBC) spectroscopy, HRMS and RP-HPLC analysis. The purity of the 
final compounds, determined by RP-HPLC (220 nm), was ≥95% throughout 
(chromatograms shown in the appendix). 
 
4.4.3 Chemistry: experimental protocols and analytical data 
4.4.3.1 Solid-phase peptide synthesis (SPPS)  
Peptides were synthesized by manual SPPS applying the Fmoc strategy. 5 mL BD Discardit 
II syringes (Becton Dickinson, Heidelberg, Germany) equipped with a 35-μm polyethylene 
frit (Roland Vetter Laborbedarf OHG, Ammerbuch, Germany) served as reaction vessels. 
Protected standard L-amino acids (Fmoc-Ala-OH, Fmoc-Gln-(Trt)-OH, Fmoc-Lys(Boc)-OH, 
Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH) and the solid supports H-Ala-2-ClTrt PS resin, H-
Arg(Pbf)-2-ClTrt PS resin, H-Leu-2-ClTrt PS resin, H-Lys(Boc)-2-ClTrt PS resin, H-Tyr(tBu)-
2-ClTrt PS resin were purchased from Merck Chemicals (Schwalbach am Taunus, 
Germany). DMF/NMP (8:2 v/v) was used as solvent throughout (ca. 2.2 mL per 1 mmol 
Fmoc-aa). Standard amino acids (5-fold excess) were preactivated with 
HBTU/HOBt/DIPEA (5/5/10 equiv.) for 5 min and added to the resin. The vessel was shaken 
at rt for 60 min. The coupling procedure was repeated (“double coupling”). After coupling of 
the final Fmoc-aa, the resin was washed with solvent (4×) followed by Fmoc deprotection 
with 20% piperidine in DMF/NMP (8:2 v/v). For the acetylation of the N-terminus a mixture 
formed by acetic anhydride (5 equiv.) and DIPEA (10 equiv.) in DMF/NMP (8:2 v/v) was 
added and the vessel was shaken at rt for 30 min. After the acetylation step, the resin was 
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washed with solvent (4×) and CH2Cl2 (treated with K2CO3) (6×). The peptides were cleaved 
off from the 2-ClTrt resin by treatment with CH2Cl2/HFIP (3:1 v/v) (rt, 2 × 20 min). The resin 
was separated by filtration and washed once with CH2Cl2/HFIP (3:1) (1 mL). The filtrates 
were combined, the volatiles evaporated and the resulting residue was used in the next step 
without any purification. The chemical identity and purity of the protected peptides 72-82 
was assessed by high-resolution mass spectrometry and analytical HPLC (data not shown). 
 
4.4.3.2 Synthesis of the DIBA-peptide conjugates 87-108 from amines 83 or 84 and 
the side-chain protected peptides 72-82  
The coupling reaction was performed in polypropylene reaction vessels (1.5 or 2 mL) with 
screw cap. EDC × HCl (1.2 equiv.) and HOBt (1.2 equiv.) were added to a solution of the 
respective side-chain protected peptide in DMF (0.1-0.4 mL). In case of compounds derived 
from 83 1 equiv. of 83, dissolved in DMF (0.1 mL), was immediately added and stirring was 
continued at 5 °C for 3 h. For the synthesis of compounds derived from 84 a solution of 84 
× 3 TFA (1 equiv.) and DIPEA (3 equiv.) in DMF (0.1 mL) was immediately added and 
stirring was continued at 5 °C for 3 h. 1% aq TFA (0.1-0.4 mL, depending on the volume of 
DMF, final ratio 1:1) was added and the mixture was subjected to preparative HPLC to yield 
the protected intermediates, which were dissolved in TFA/CH2Cl2/H2O (1:1:0.1 v/v/v) (for 
the preparation of 88, 89, 92-95, 99, 100, 103-106) or TFA/H2O (95:5 v/v) (for the 
preparation of 90, 91, 96, 97, 101, 102, 107, 108). The mixtures were stirred at rt for 3 h, 
the solvent was removed under reduced pressure and the residue was subjected to 
preparative HPLC yielding the purified DIBA-peptide conjugates as hydrotrifluoroacetates. 
N-(4-(1-(2-Oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-
yl)ethyl)piperidin-4-yl)butyl)propionamide hydrotrifluoroacetate (85) Purification by 
preparative HPLC (gradient: 0-25 min: 0.1% aq TFA/acetonitrile 95:5-60:40, tR = 18 min) 
yielded 85 as a white fluffy solid (32 mg, 0.055 mmol, 96%). Ratio of configurational isomers 
evident in the NMR spectra: 1.8:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.11 (t, 3H, J 7.7 
Hz), 1.27-1.37 (m, 4H), 1.38-1.56 (m, 5H), 1.85-2.00 (m, 2H), 2.17 (q, 2H, J 7.6 Hz), 2.87-
2.96 (m, 1H), 2.99-3.08 (m, 1H), 3.15 (t, 2H, J 7.2 Hz), 3.39-3.49 (m, 1H), 3.67-3.83 (m, 
2H), 4.39 (d, 0.6H, J 17 Hz), 4.43 (d, 0.4H, J 17 Hz), 7.23-7.31 (m, 0.8H), 7.31-7.36 (m, 
1.2H), 7.36-7.41 (m, 0.4H), 7.44-7.55 (m, 2.2H), 7.59-7.71 (m, 2H), 7.73-7.78 (m, 0.4H), 
7.90 (dd, 0.6H, J 1.7 7.7 Hz), 7.97 (d, 0.4H, J 7.8 Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ 
(ppm) 10.59, 24.66, 30.22, 30.41, 30.47, 34.39, 36.31, 40.07, 54.95, 55.01, 55.37, 57.94, 
58.04, 123.08, 123.64, 126.84, 127.51, 127.87, 128.49, 128.89, 129.45, 130.10, 130.54, 
130.88, 131.20, 131.70, 131.97, 132.34, 133.01, 133.43, 134.57, 134.94, 135.45, 135.73, 
137.04, 141.02, 142.68, 164.96, 165.45, 168.56, 168.81, 177.02. HRMS (ESI): m/z [M+H]+ 
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calcd for [C27H35N4O3]+ 463.2709, found 463.2729. RP-HPLC (220 nm): 99% (tR = 8.3 min, 
k = 8.0). C27H34N4O3 · C2HF3O2 (462.59 + 114.02). 
(S)-2-Acetamido-N-((S)1-oxo-1-((4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)amino)propan-2-
yl)propanamide hydrotrifluoroacetate (87) Purification by preparative HPLC (gradient: 0-
25 min: 0.1% aq TFA/acetonitrile 90:10-70:30, tR = 11 min) yielded 87 as a white fluffy solid 
(25 mg, 0.035 mmol, 71%). Ratio of configurational isomers evident in the NMR spectra: ca 
1.6:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.26-1.38 (m, 10H), 1.41-1.55 (m, 5H), 1.86-
1.97 (m, 2H), 1.98 (s, 3H), 2.87-2.97 (m, 1H), 2.98-3.08 (m, 1H), 3.40-3.49 (m, 1H), 3.68-
3.83 (m, 2H), 4.19-4.31 (m, 2H), 4.39 (d, 0.6H, J 17 Hz), 4.44 (d, 0.4H, J 17 Hz), 7.23-7.31 
(m, 0.8H), 7.31-7.42 (m, 1.7H), 7.44-7.55 (m, 2H), 7.60-7.72 (m, 2H), 7.75 (t, 0.5H, J 7.8 
Hz), 7.90 (dd, 0.6H, J 7.9 1.6 Hz), 7.97 (dd, 0.4H, J 6.8 1.1 Hz). 13C-NMR (150.9 MHz, 
MeOH-d4): δ (ppm) 17.80, 18.11, 22.65, 24.58, 30.34, 30.60, 34.49, 36.34, 40.20, 50.67, 
51.25, 55.11, 55.19, 55.53, 58.09, 58.18, 126.99, 127.66, 128.03, 128.64, 129.04, 129.60, 
130.25, 130.69, 131.03, 131.34, 131.85, 132.11, 132.50, 133.16, 133.58, 134.72, 135.09, 
135.60, 135.87, 137.18, 141.17, 142.83, 162.26, 162.50, 165.13, 165.61, 168.70, 168.96, 
173.89, 174.97, 175.20. HRMS (ESI): m/z [M+H]+ calcd for [C32H43N6O5]+ 591.3295, found 
591.3307. RP-HPLC (220 nm): 96% (tR = 16.7 min, k = 17.2). C32H42N6O5 · C2HF3O2 (590.72 
+ 114.02). 
(S)-2-Acetamido-N-((S)-3-(4-hydroxyphenyl)-1-oxo-1-((4-(1-(2-oxo-2-(11-oxo-10,11-
dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)amino)propan-2-
yl)-3-(1H-indol-3-yl)propanamide hydrotrifluoroacetate (88) Purification by preparative 
HPLC (gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-43:57, tR = 14 min) yielded 88 as 
a white fluffy solid (31 mg, 0.034 mmol, 72%). Ratio of configurational isomers evident in 
the NMR spectra: 1.4:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.09-1.49 (m, 9H), 1.72-
1.86 (m, 2H), 1.87 (s, 3H), 2.61-2.65 (m, 4H), 2.99-3.09 (m, 3H), 3.14-3.22 (m, 1H), 3.32-
3.40 (m, 1H), 3.55-3.77 (m, 2H), 4.29-4.41 (m, 2H), 4.54-4.60 (m, 1H), 6.66 (d, 2H, J 8.8 
Hz), 6.90 (d, 2H, J 8.8 Hz), 6.96-7.00 (m, 1H), 7.04 -7.08 (m, 1H), 7.09 (br s, 1H), 7.23-7.40 
(m, 3.4H), 7.45-7.56 (m, 3.2H), 7.58-7.70 (m, 2H), 7.70-7.78 (m, 0.4H), 7.90 (d, 0.6H, J 7.8 
Hz), 7.98 (d, 0.4H, J 7.6 Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ (ppm) 22.54, 24.48, 28.50, 
30.06, 30.08, 30.41, 34.26, 36.20, 37.73, 40.01, 55.00, 55.35, 55.94, 56.14, 58.02, 110.83, 
112.41, 116.23, 119.33, 119.91, 122.54, 123.09, 123.66, 124.63, 126.86, 127.53, 127.86, 
128.47, 128.65, 128.77, 128.87, 129.43, 130.11, 130.55, 130.85, 131.24, 131.38, 131.73, 
131.96, 132.36, 133.04, 133.41, 134.58, 134.91, 135.48, 135.69, 137.01, 137.97, 141.00, 
142.64, 157.33, 164.89, 165.39, 168.58, 168.83, 173.02, 173.57, 173.66. 138.04, 140.99, 
142.64, 157.26, 164.89, 165.38, 168.60, 168.84, 173.28, 173.88, 174.72, 174.94. HRMS 
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(ESI): m/z [M+H]+ calcd for [C46H52N7O6]+ 798.3979, found 798.3992. RP-HPLC (220 nm): 
96% (tR = 20.2 min, k = 21.0). C46H51N7O6 · C2HF3O2 (797.96 + 114.02). 
(S)-2-Acetamido-N-((S)-1-(((S)-3-(4-hydroxyphenyl)-1-oxo-1-((4-(1-(2-oxo-2-(11-oxo-
10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-
yl)butyl)amino)propan-2-yl)amino)-1-oxopropan-2-yl)-3-(1H-indol-3-yl)propanamide 
hydrotrifluoroacetate (89) Purification by preparative HPLC (gradient: 0-25 min: 0.1% aq 
TFA/acetonitrile 90:10-43:57, tR = 14 min) yielded 89 as a white fluffy solid (24 mg, 0.024 
mmol, 50%). Ratio of configurational isomers evident in the NMR spectra: 1.4:1. 1H-NMR 
(600 MHz, MeOH-d4): δ (ppm) 1.11 (d, 3H, J 7.3 Hz), 1.18-1.45 (m, 9H), 1.71-1.89 (m, 2H), 
1.92-1.96 (m, 3H), 2.58-2.91 (m, 3H), 2.98-3.05 (m, 1H), 3.07-3.20 (m, 3H), 3.21-3.28 (m, 
1H), 3.32-3.38 (m, 1H), 3.57-3.70 (m, 2H), 4.11 (q, 1H, J 7.3 Hz), 4.30-4.41 (m, 2H), 4.53-
4.58 (m, 1H), 6.67 (d, 2H, J 8.67 Hz), 6.96-7.01 (m, 3H), 7.04-7.09 (m, 1H), 7.16 (br s, 1H), 
7.24-7.41 (m, 3.4H), 7.47-7.54 (m, 2.2H), 7.56 (d, 1H, J 7.9 Hz), 7.60-7.70 (m, 2H), 7.73-
7.78 (m, 0.4H), 7.90 (d, 0.6H, J 7.8 Hz), 7.99 (d, 0.4H, J 7.6 Hz). 13C-NMR (150.9 MHz, 
MeOH-d4): δ (ppm) 17.23, 22.65, 24.48, 28.44, 30.03, 30.43, 34.23, 36.21, 37.63, 40.16, 
51.43, 55.00, 55.35, 56.44, 56.55, 57.95, 58.03, 110.78, 112.44, 116.19, 119.30, 119.91, 
122.58, 123.10, 123.66, 124.71, 126.87, 127.54, 127.86, 128.47, 128.77, 128.88, 129.18, 
129.43, 130.12, 130.56, 130.86, 131.21, 131.74, 131.98, 132.36, 133.04, 133.41, 134.59, 
134.92, 135.48, 135.70, 137.03, 138.04, 140.99, 142.64, 157.26, 164.89, 165.38, 168.60, 
168.84, 173.28, 173.88, 174.72, 174.94. HRMS (ESI): m/z [M+H]+ calcd for [C49H57N8O7]+ 
869.4350, found 869.4364. RP-HPLC (220 nm): 98% (tR = 20.5 min, k = 21.3). C49H56N8O7 
· C2HF3O2 (869.04 + 114.02). 
(S)-2-Acetamido-N1-((S)-4-methyl-1-oxo-1-((4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)amino)pentan-2-
yl)pentanediamide hydrotrifluoroacetate (90) Purification by preparative HPLC 
(gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-70:30, tR = 15 min) yielded 90 as a 
white fluffy solid (29 mg, 0.036 mmol, 75%). Ratio of configurational isomers evident in the 
NMR spectra: 1.7:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 0.90 (d, 3H, J 6.6 Hz), 0.94 (d, 
3H, J 6.6 Hz), 1.25-1.37 (m, 4H), 1.39-1.72 (m, 8H), 1.82-2.00 (m, 6H) 2.00-2.10 (m, 1H), 
2.29 (t, 2H, J 7.4 Hz), 2.88-2.97 (m, 1H), 3.00-3.08 (m, 1H), 3.13-3.22 (m, 2H), 3.40-3.48 
(m, 1H), 3.68-3.83 (m, 2H), 4.25-4.30 (m, 1H), 4.30-4.35 (m, 1H), 4.36-4.46 (m, 1H), 7.24-
7.31 (m, 0.8H), 7.31-7.36 (m, 1.2H), 7.36-7.41 (m, 0.4H), 7.46-7.55 (m, 2.2H), 7.59-7.72 
(m, 2H), 7.73-7.78 (m, 0.4H), 7.90 (dd, 0.6H, J 8.3 1.5 Hz), 7.97 (dd, 0.4H, J 7.9 1.0 Hz). 
13C-NMR (150.9 MHz, MeOH-d4): δ (ppm) 21.85, 22.50, 23.43, 24.38, 25.91, 28.68, 30.22, 
30.42, 32.49, 34.36, 36.18, 39.98, 41.79, 53.40, 54.60, 54.97, 55.05, 55.41, 57.94, 58.02, 
123.09, 123.66, 126.86, 127.52, 127.88, 128.48, 128.89, 129.44, 130.12, 130.55, 130.88, 
131.21, 131.71, 131.95, 132.35, 133.01, 133.45, 134.59, 134.94, 135.45, 135.72, 137.02, 
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141.02, 142.68, 165.04, 165.52, 168.57, 168.83, 173.69, 173.87, 174.68, 177.65, 177.69. 
HRMS (ESI): m/z [M+H]+ calcd for [C37H52N7O6]+ 690.3979, found 690.3993. RP-HPLC (220 
nm): 95% (tR = 14.5 min, k = 14.8). C37H51N7O6 · C2HF3O2 (689.86 + 114.02). 
(S)-2-Acetamido-N1-((S)-1-(((S)-4-methyl-1-oxo-1-((4-(1-(2-oxo-2-(11-oxo-10,11-
dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)amino)pentan-2-
yl)amino)-1-oxopropan-2-yl)pentanediamide hydrotrifluoroacetate (91) Purification by 
preparative HPLC (gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-70:30, tR = 15 min) 
yielded 91 as a white fluffy solid (26 mg, 0.030 mmol, 32%). Ratio of configurational isomers 
evident in the NMR spectra: 1.7:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 0.90 (d, 3H, J 
6.4 Hz), 0.95 (d, 3H, J 6.4 Hz), 1.23-1.70 (m, 15H), 1.85-2.01 (m, 6H), 2.01-2.09 (m, 1H), 
2.33 (t, 2H, J 7.8 Hz), 2.87-2.97 (m, 1H), 2.99-3.01 (m, 1H), 3.17 (t, 2H, J 6.9 Hz), 3.40-3.49 
(m, 1H), 3.69-3.84 (m, 2H), 4.20-4.31 (m, 3H), 4.37-4.46 (m, 1H), 7.24-7.31 (m, 0.8H), 7.32-
7.36 (m, 1.2H), 7.37-7.40 (m, 0.4H), 7.46-7.55 (m, 2.2H), 7.60-7.71 (m, 2H), 7.73-7.78 (m, 
0.4H), 7.90 (d, 0.6H, J 8.32 Hz), 7.97 (d, 0.4H, J 8.1 Hz). 13C-NMR (150.9 MHz, MeOH-d4): 
δ (ppm) 17.50, 21.75, 22.52, 22.54, 23.47, 24.33, 25.98, 28.45, 30.10, 30.47, 32.41, 34.35, 
36.13, 39.94, 39.99, 41.68, 51.20, 53.45, 55.00, 55.13, 55.43, 57.96, 58.05, 123.10, 123.66, 
126.86, 127.51, 127.87, 128.48, 128.89, 129.44, 130.13, 130.56, 130.89, 131.22, 131.72, 
131.98, 132.37, 133.03, 133.44, 134.59, 134.94, 135.45, 135.74, 137.05, 141.02, 142.67, 
165.03, 165.52, 168.55, 168.82, 173.80, 174.38, 174.65, 175.01, 177.63. HRMS (ESI): m/z 
[M+H]+ calcd for [C40H57N8O7]+ 761.4350, found 761.4357. RP-HPLC (220 nm): 95% (tR = 
14.5 min, k = 14.8). C40H56N8O7 · C2HF3O2 (760.94 + 114.02). 
(S)-2-Acetamido-6-amino-N-((S)-3-(4-hydroxyphenyl)-1-oxo-1-((4-(1-(2-oxo-2-(11-oxo-
10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-
yl)butyl)amino)propan-2-yl)hexanamide bis(hydrotrifluoroacetate) (92) Purification by 
preparative HPLC (gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-67:33, tR = 11 min) 
yielded 92 as a white fluffy solid (28 mg, 0.029 mmol, 58%). Ratio of configurational isomers 
evident in the NMR spectra: 1.6:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.16-1.54 (m, 
11H), 1.55-1.71 (m, 4H), 1.85-1.96 (m, 2H), 1.97 (s, 3H), 2.81-2.96 (m, 4H), 2.97-3.09 (m, 
3H), 3.14-3.22 (m, 1H), 3.39-3.50 (m, 1H), 3.66-3.84 (m, 2H), 4.15-4.21 (m, 1H), 4.36-4.50 
(m, 2H), 6.69 (d, 2H, J 8.6 Hz), 7.03 (d, 2H, J 8.5 Hz), 7.25-7.31 (m, 0.8H), 7.32-7.36 (m, 
1.2H), 7.36-7.40 (m, 0.4H), 7.45-7.55 (m, 2.2H), 7.61-7.71 (m, 2H), 7.73-7.77 (m, 0.4H), 
7.90 (d, 0.6H, J 8.3 Hz), 7.97 (d, 0.4H, J 7.9 Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ (ppm) 
22.51, 23.58, 24.56, 28.08, 30.07, 30.46, 32.05, 34.33, 36.27, 37.99, 40.16, 40.42, 55.05, 
55.10, 55.41, 56.23, 57.94, 58.03, 116.24, 123.01, 123.66, 126.85, 127.54, 127.89, 128.49, 
128.88, 128.92, 129.45, 130.11, 130.54, 130.87, 131.20, 131.38, 131.71, 131.94, 132.34, 
132.99, 133.44, 134.58, 134.93, 135.47, 135.71, 137.00, 141.01, 142.69, 157.28, 164.98, 
165.48, 168.57, 168.83, 173.22, 173.84. HRMS (ESI): m/z [M+H]+ calcd for [C41H54N7O6]+ 
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740.4136, found 740.4134. RP-HPLC (220 nm): 99% (tR = 13.1 min, k = 13.2). C41H53N7O6 
· C4H2F6O4 (739.92 + 228.04). 
(S)-2-Acetamido-6-amino-N-((S)-1-(((S)-3-(4-hydroxyphenyl)-1-oxo-1-((4-(1-(2-oxo-2-
(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-
yl)butyl)amino)propan-2-yl)amino)-1-oxopropan-2-yl)hexanamide 
bis(hydrotrifluoroacetate) (93) Purification by preparative HPLC (gradient: 0-25 min: 0.1% 
aq TFA/acetonitrile 90:10-67:33, tR = 11 min) yielded 93 as a white fluffy solid (31 mg, 0.030 
mmol, 63%). Ratio of configurational isomers evident in the NMR spectra: 1.6:1. 1H-NMR 
(600 MHz, MeOH-d4): δ (ppm) 1.51-1.26 (m, 4H), 1.27 (d, 3H, J 7.2 Hz), 1.35-1.52 (m, 7H), 
1.63-1.71 (m, 3H), 1.74-1.81 (m, 1H), 1.83-1.97 (m, 2H), 1.97-2.02 (m, 3H), 2.84-3.00 (m, 
5H), 3.00-3.08 (m, 2H), 3.13-3.21 (m, 1H), 3-40-3.49 (m, 1H), 3.67-3.84 (m, 2H), 4.20-4.27 
(m, 2H), 4.37-4.47 (m, 2H), 6.69 (d, 2H, J 8.4 Hz), 7.03 (d, 2H, J 8.5 Hz), 7.24-7.31 (m, 
0.8H), 7.32-7.36 (m, 1.2H), 7.36-7.40 (m, 0.4H), 7.45-7.55 (m, 2.2H), 7.60-7.71 (m, 2H), 
7.73-7.77 (m, 0.4H), 7.90 (dd, 0.6H, J 1.6 7.7 Hz), 7.97 (d, 0.4H, J 7.7 Hz). 13C-NMR (150.9 
MHz, MeOH-d4): δ (ppm) 17.64, 22.51, 22.53, 23.70, 24.48, 28.11, 30.05, 30.49, 32.22, 
34.35, 36.23, 38.14, 40.04, 40.46, 50.90, 55.02, 55.40, 56.48, 57.96, 58.03, 116.22, 123.09, 
123.66, 126.86, 127.54, 127.88, 128.49, 128.89, 128.95, 129.45, 130.11, 130.55, 130.88, 
131.21, 131.34, 131.71, 131.94, 132.35, 133.00, 133.43, 134.59, 134.93, 135.47, 135.71, 
137.01, 141.00, 142.68, 157.29, 165.00, 165.49, 168.57, 168.83, 173.15, 173.73, 174.43, 
174.62. HRMS (ESI): m/z [M+2H]2+ calcd for [C44H60N8O7]2+ 406.2292, found 406.2302. RP-
HPLC (220 nm): 97% (tR = 11.1 min, k = 11.1). C44H58N8O7 · C4H2F6O4 (811.00 + 228.04). 
(S)-2-((S)-2-Acetamido-3-(4-hydroxyphenyl)propanamido)-6-amino-N-(4-(1-(2-oxo-2-
(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-
yl)butyl)hexanamide bis(hydrotrifluoroacetate) (94) Purification by preparative HPLC 
(gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-70:30, tR = 11 min) yielded 94 as a 
white fluffy solid (22 mg, 0.022 mmol, 30%). Ratio of configurational isomers evident in the 
NMR spectra: 1.1:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.24-1.55 (m, 11H), 1.55-1.70 
(m, 3H), 1.79-1.93 (m, 2.4H), 1.94 (s, 3H), 1.95-1.99 (0.6H), 2.82-3.09 (m, 7H), 3.10-3.17 
(m, 1H), 3.40-3.48 (m, 1H), 3.67-3.82 (m, 2H), 4.23 (dd, 1H, J 9.8, 4.5 Hz), 4.35-4.46 (m, 
2H), 6.71 (d, 2H, J 8.5 Hz), 7.07 (d, 2H, J 8.6 Hz), 7.24-7.31 (m, 0.8H), 7.32-7.35 (m, 1.2H), 
7.36-7.41 (m, 0.4H), 7.45-7.55 (m, 2.2H), 7.60-7.71 (m, 2H), 7.72-7.78 (m, 0.4H), 7.90 (d, 
0.6H, J 8.2 Hz), 7.97 (d, 0.4H, J 8.2 Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ (ppm) 22.37, 
22.63, 24.59, 27.89, 30.31, 30.48, 32.30, 34.34, 36.27, 37.65, 40.22, 40.47, 54.29, 55.01, 
55.38, 57.09, 58.01, 116.35, 123.08, 123.66, 126.86, 127.54, 127.88, 128.49, 131.33, 
134.94, 135.47, 135.71, 137.00, 141.01, 142.68, 157.44, 162.80, 164.97, 165.47, 168.59, 
168.84, 173.56, 174.23. HRMS (ESI): m/z [M+H]+ calcd for [C41H54N7O6]+ 740.4136, found 
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740.4147. RP-HPLC (220 nm): 99% (tR = 11.1 min, k = 11.1). C41H53N7O6 · C4H2F6O4 
(739.92 + 228.04). 
(S)-2-((S)-2-((S)-2-Acetamido-3-(4-hydroxyphenyl)propanamido)propanamido)-6-
amino-N-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-
yl)ethyl)piperidin-4-yl)butyl)hexanamide bis(hydrotrifluoroacetate) (95) Purification by 
preparative HPLC (gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-67:33, tR = 11 min) 
yielded 95 as a white fluffy solid (24 mg, 0.023 mmol, 49%). Ratio of configurational isomers 
evident in the NMR spectra: 1.2:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.25-1.33 (m, 
4H), 1.35 (d, 3H, J 7.2 Hz), 1.37-1.54 (m, 7H), 1.62-1.74 (m, 3H), 1.80-1.90 (m, 2H), 1.92 
(s, 3H), 1.93-1.96 (m, 1H), 2.79-2.85 (m, 1H), 2.85-2.95 (m, 3H), 2.97-3.07 (m, 2H), 3.18 (t, 
2H, J 6.9 Hz), 3.39-3.48 (m, 1H), 3.67-3.82 (m, 2H), 4.19-4.27 (m, 2H), 4.35-4.45 (m, 2H), 
6.70 (d, 2H, J 8.7 Hz), 7.06 (d, 2H, J 8.5 Hz), 7.24-7.31 (m, 0.8H), 7.32-7.36 (m, 1.2H), 
7.36-7.40 (m, 0.4H), 7.45-7.55 (m, 2.2H), 7.61-7.71 (m, 2H), 7.73-7.77 (m, 0.4H), 7.90 (d, 
0.6H, J 7.8 Hz), 7.97 (d, 0.4H, J 7.7 Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ (ppm) 17.38, 
22.51, 23.81, 24.53, 27.92, 30.21, 30.46, 32.22, 34.35, 36.26, 37.61, 40.18, 40.49, 51.09, 
54.53, 55.02, 55.39, 57.08, 57.94, 58.03, 116.28, 123.09, 123.66, 126.86, 127.53, 127.88, 
128.48, 128.87, 129.44, 130.11, 130.55, 130.88, 131.24, 131.71, 131.96, 132.35, 133.01, 
133.43, 134.58, 134.93, 135.47, 135.72, 137.02, 141.01, 142.68, 157.39, 164.97, 165.47, 
168.57, 168.84, 173.72, 173.90, 174.39, 174.94. HRMS (ESI): m/z [M+H]+ calcd for 
[C44H59N8O7]+ 811.4507, found 811.4508. RP-HPLC (220 nm): 99% (tR = 13.3 min, k = 13.5). 
C44H58N8O7 · C4H2F6O4 (811.00 + 228.04). 
(S)-2-Acetamido-6-amino-N-((S)-5-guanidino-1-oxo-1-((4-(1-(2-oxo-2-(11-oxo-10,11-
dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)amino)pentan-2-
yl)hexanamide tris(hydrotrifluoroacetate) (96) Purification by preparative HPLC 
(gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-70:30, tR = 8 min) yielded 96 as a white 
fluffy solid (33 mg, 0.031 mmol, 67%). Ratio of configurational isomers evident in the NMR 
spectra: 1.8:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.25-1.38 (m, 4H), 1.39-1.56 (m, 
7H), 1.57-1.74 (m, 6H), 1.76-1.97 (m, 4H), 1.99 (s, 3H), 2.86-2.97 (m, 3H), 2.99-3.09 (m, 
1H), 3.11-3.24 (m, 4H), 3.40-3.50 (m, 1H), 3.67-3.83 (m, 2H), 4.21-4.26 (m, 1H), 4.29-4.34 
(m, 1H), 4.37-4.48 (m, 1H), 4.40 (d, 0.6H, J 17 Hz), 4.44 (d, 0.4H, J 17 Hz), 7.24-7.31 (m, 
0.8H), 7.31-7.36 (m, 1.2H), 7.36-7.40 (m, 0.4H), 7.44-7.56 (m, 2.2H), 7.60-7.72 (m, 2.2H), 
7.73-7.78 (m, 0.4H), 7.90 (dd, 0.6H, J 1.7 7.7 Hz), 7.97 (d, 0.4H, J 7.7 Hz). 13C-NMR (150.9 
MHz, MeOH-d4): δ (ppm) 22.44, 23.84, 24.64, 26.36, 28.07, 30.28, 30.36, 30.44, 32.06, 
34.38, 36.32, 40.25, 40.45, 41.89, 54.17, 55.00, 55.08, 55.36, 57.95, 58.01, 123.01, 123.66, 
126.85, 127.54, 127.89, 128.48, 128.89, 129.44, 130.12, 130.55, 130.89, 131.20, 131.71, 
131.95, 132.34, 132.99, 133.45, 134.58, 134.94, 135.47, 135.72, 137.00, 141.01, 142.70, 
158.66, 164.99, 165.50, 168.58, 168.85, 173.67, 173.79, 174.46. HRMS (ESI): m/z [M+H]+ 
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calcd for [C38H57N10O5]+ 733.4513, found 733.4512. RP-HPLC (220 nm): 99% (tR = 6.9 min, 
k = 6.5). C38H56N10O5 · C6H3F9O6 (732.93 + 342.07).  
(S)-2-Acetamido-6-amino-N-((S)-1-(((S)-5-guanidino-1-oxo-1-((4-(1-(2-oxo-2-(11-oxo-
10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-
yl)butyl)amino)pentan-2-yl)amino)-1-oxopropan-2-yl)hexanamide 
tris(hydrotrifluoroacetate) (97) Purification by preparative HPLC (gradient: 0-25 min: 
0.1% aq TFA/acetonitrile 90:10-70:30, tR = 8 min) yielded 97 as a white fluffy solid (24 mg, 
0.021 mmol, 60%). Ratio of configurational isomers evident in the NMR spectra: 1.9:1. 1H-
NMR (600 MHz, MeOH-d4): δ (ppm) 1.26-1.36 (m, 4H), 1.37 (d, 3H, J 7.1 Hz), 1.38-1.56 
(m, 7H), 1.56-1.77 (m, 6H), 1.77-1.97 (m, 4H), 1.98-2.01 (m, 3H), 2.93 (t, 3H, J 7.6 Hz), 
3.00-3.08 (m, 1H), 3.12-3.24 (m, 4H), 3.41-3.49 (m, 1H), 3.68-3.83 (m, 2H), 4.19-4.24 (m, 
1H), 4.24-4.30 (m, 2H) 4.40 (d, 0.6H, J 17 Hz), 4.44 (d, 0.4H, J 17 Hz), 7.24-7.31 (m, 0.8H), 
7.31-7.36 (m, 1.2H), 7.36-7.41 (m, 0.4H), 7.45-7.55 (m, 2.2H), 7.60-7.71 (m, 2H), 7.72-7.78 
(m, 0.4H), 7.90 (dd, 0.6H, J 1.4 7.9 Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ (ppm) 17.48, 
22.53, 23.77, 24.55, 26.32, 28.11, 30.18, 30.23, 30.46, 32.11, 34.38, 36.26, 40.15, 40.44, 
41.90, 51.01, 54.35, 55.01, 55.28, 55.37, 58.02, 118.96, 123.08, 123.67, 126.86, 127.54, 
127.89, 128.49, 128.89, 129.44, 130.12, 130.55, 130.89, 131.20, 131.71, 131.95, 132.34, 
133.00, 133.44, 134.58, 134.94, 135.47, 135.72, 137.01, 141.01, 142.69, 158.65, 165.00, 
165.50, 168.57, 168.84, 173.66, 173.95, 174.64, 175.12. HRMS (ESI): m/z [M+2H]2+ calcd 
for [C41H63N11O6]2+ 402.7481, found 402.7484. RP-HPLC (220 nm): 99% (tR = 7.5 min, k = 
7.2). C41H61N11O6 · C6H3F9O6 (804.01 + 342.07). 
(S)-2-Acetamido-N-((S)-1-oxo-1-((2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-1-
yl)ethyl)amino)propan-2-yl)propanamide tris(hydrotrifluoroacetate) (98) Purification 
by preparative HPLC (gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-77:23, tR = 9 min) 
yielded 98 as a white fluffy solid (16 mg, 0.015 mmol, 39%). Ratio of configurational isomers 
evident in the NMR spectra: 1.6:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.30-1.63 (m, 
13H), 1.66-1.76 (m, 2H), 1.86-1.99 (m, 2H), 2.00 (s, 3H), 2.41-2.81 (m, 1H), 2.81-3.23 (m, 
10H), 3.32-3.51 (m, 6H), 3.68-3.83 (m, 2H), 4.14-4.27 (m, 2H), 4.40 (d, 0.6H, J 17 Hz), 4.44 
(d, 0.4H, J 17 Hz), 7.23-7.31 (m, 0.8H), 7.31-7.36 (m, 1.2H), 7.36-7.41 (m, 0.4H), 7.45-7.56 
(m, 2.2H), 7.60-7.71 (m, 2H), 7.72-7.79 (m, 0.4H), 7.90 (dd, 0.6H, J 1.6 8.0 Hz), 7.97 (dd, 
0.4H, J 1.1 7.8 Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ (ppm) 17.41, 17.56, 22.39, 22.53, 
24.54, 25.27, 30.41, 34.32, 36.16, 36.68, 50.91, 50.96, 51.48, 52.12, 54.94, 55.30, 57.18, 
57.76, 58.04, 123.09, 123.65, 126.86, 127.52, 127.87, 128.49, 128.88, 129.45, 130.11, 
130.55, 130.89, 131.22, 131.71, 131.97, 132.35, 133.01, 133.41, 134.58, 134.94, 135.46, 
135.73, 137.04, 141.01, 142.68, 164.96, 165.45, 168.58, 168.83, 173.91, 175.50, 175.69. 
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HRMS (ESI): m/z [M+H]+ calcd for [C38H55N8O5]+ 703.4295, found 703.4296. RP-HPLC (220 
nm): 95% (tR = 7.4 min, k = 7.0). C38H54N8O5 · C4H2F6O4 (702.90 + 228.04). 
(S)-2-Acetamido-N-((S)-3-(4-hydroxyphenyl)-1-oxo-1-((2-(4-(4-(1-(2-oxo-2-(11-oxo-
10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-
1-yl)ethyl)amino)propan-2-yl)-3-(1H-indol-3-yl)propanamide 
tris(hydrotrifluoroacetate) (99) Purification by preparative HPLC (gradient: 0-25 min: 
0.1% aq TFA/acetonitrile 90:10-50:50, tR = 12 min) yielded 99 as a white fluffy solid (24 mg, 
0.019 mmol, 53%). Ratio of configurational isomers evident in the NMR spectra: 1.8:1. 1H-
NMR (600 MHz, MeOH-d4): δ (ppm) 1.25-1.55 (m, 8H), 1.60-1.69 (m, 2H), 1.80-1.89 (m, 
1H), 1.91 (s, 3H), 1.92-1.96 (m, 1H), 2.74-2.95 (m, 6H), 2.95-3.24 (m, 10H), 3.32-3.47 (m, 
4H), 3.67-3.80 (m, 2H), 4.30 (t, 1H, J 7.3 Hz), 4.39 (d, 0.6H, J 17 Hz), 4.43 (d, 0.4H, J 17 
Hz), 4.52 (t, 1H, J 7.0 Hz), 6.70 (d, 2H, J 8.5 Hz), 6.95 (d, 2H, J 8.5 Hz), 7.02 (t, 1H, J 7.5 
Hz), 7.07-7.12 (m, 2H), 7.24-7.31 (m, 0.8H), 7.32-7.36 (m, 2.2H), 7.36-7.40 (m, 0.4H), 7.46-
7.55 (m, 3.2H), 7.60-7.71 (m, 2H), 7.73-7.78 (m, 0.4H), 7.91 (d, 0.6H, J 8.2 Hz), 7.98 (d, 
0.4H, J 7.9 Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ (ppm) 22.57, 24.44, 25.04, 28.45, 
30.37, 34.27, 36.07, 36.28, 37.18, 50.66, 51.61, 54.91, 55.27, 56.37, 56.81, 57.05, 57.70, 
57.94, 58.04, 110.75, 112.48, 116.34, 119.26, 119.96, 122.61, 123.10, 123.64, 124.67, 
126.86, 127.52, 127.87, 128.48, 128.56, 128.73, 128.88, 129.44, 130.12, 130.56, 130.88, 
131.23, 131.36, 131.72, 131.97, 132.35, 133.02, 133.40, 134.58, 134.93, 135.47, 135.72, 
137.03, 138.01, 141.00, 142.67, 157.47, 164.94, 165.92, 168.59, 168.83, 173.78, 173.93, 
174.93. HRMS (ESI): m/z [M+H]+ calcd for [C52H64N9O6]+ 910.4980, found 910.4972. RP-
HPLC (220 nm): 97% (tR = 14.9 min, k = 15.2). C52H63N9O6 · C4H2F6O4 (910.13 + 228.04).  
(S)-2-Acetamido-N-((S)-1-(((S)-3-(4-hydroxyphenyl)-1-oxo-1-((2-(4-(4-(1-(2-oxo-2-(11-
oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-
yl)butyl)piperazin-1-yl)ethyl)amino)propan-2-yl)amino)-1-oxopropan-2-yl)-3-(1H-
indol-3-yl)propanamide tris(hydrotrifluoroacetate) (100) Purification by preparative 
HPLC (gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-50:50, tR = 12 min) yielded 100 
as a white fluffy solid (13 mg, 0.010 mmol, 27%). Ratio of configurational isomers evident 
in the NMR spectra: 1.6:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.13 (d, 3H, J 7.4 Hz), 
1.26-1.54 (m, 7H), 1.60-1.68 (m, 1H), 1.81-1.97 (m, 2H), 2.01 (s, 3H), 2.80-2.95 (m, 4H), 
2.95-3.29 (m, 13H), 3.32-3.49 (m, 4H), 3.66-3.81 (m, 2H), 4.02 (q, 1H, J 7.2 Hz), 4.28-4.32 
(m, 1H), 4.39 (d, 0.6H, J 17 Hz), 4.43 (d, 0.4H, J 17 Hz), 4.50 (t, 1H, J 7.0 Hz), 6.69 (d, 2H, 
J 8.5 Hz), 6.99-7.03 (m, 3H), 7.10 (t, 1H, J 7.5 Hz), 7.27 (br s, 1H), 7.25-7.31 (m, 0.8H), 
7.31-7.36 (m, 2.2H), 7.37-7.41 (m, 0.4H), 7.46-7.57 (m, 3.2H), 7.62-7.71 (m, 2H), 7.73-7.78 
(m, 0.4H), 7.91 (d, 0.6H, J 8.7 Hz), 7.98 (d, 0.4H, J 7.9 Hz). 13C-NMR (150.9 MHz, MeOH-
d4): δ (ppm) 16.97, 22.69 24.49, 25.15, 28.42, 30.37, 34.29, 36.12, 36.33, 37.13, 50.64, 
51.59, 51.92, 54.92, 55.28, 56.80, 57.04, 57.13, 57.71, 57.96, 58.04, 110.62, 112.53, 
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116.29, 119.26, 119.96, 122.64, 123.09, 123.65, 124.78, 126.87, 127.52, 127.86, 128.48, 
128.80, 128.88, 128.94, 129.44, 130.12, 130.57, 130.88, 131.18, 131.24, 131.98, 132.36, 
133.02, 133.40, 134.58, 134.93, 135.47, 135.72, 137.04, 138.04, 141.01, 142.66, 157.41, 
164.94, 165.42, 168.59, 168.84,174.16, 174.20, 175.29, 175.47. HRMS (ESI): m/z [M+H]+ 
calcd for [C55H69N10O7]+ 981.5351, found 981.5366. RP-HPLC (220 nm): 99% (tR = 14.9 min, 
k = 15.2). C55H68N10O7 · C4H2F6O4 (981.21 + 228.04). 
(S)-2-Acetamido-N1-((S)-3-methyl-1-oxo-1-((2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-
5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-1-
yl)ethyl)amino)butan-2-yl)pentanediamide tris(hydrotrifluoroacetate) (101) 
Purification by preparative HPLC (gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-72:28, 
tR = 11 min) yielded 101 as a white fluffy solid (23 mg, 0.020 mmol, 56%). Ratio of 
configurational isomers evident in the NMR spectra: 1.8:1. 1H-NMR (600 MHz, MeOH-d4): 
δ (ppm) 0.91 (d, 3H, J 6.5 Hz), 0.96 (d, 3H, J 6.5 Hz), 1.30-1.77 (m, 12H), 1.86-1.98 (m, 
3H), 2.00 (s, 3H), 2.01-2.09 (m, 1H), 2.33 (t, 2H, J 7.5 Hz), 2.88-2.98 (m, 1H), 2.99-3.10 (m, 
3H), 3.12-3.18 (m, 2H), 3.21-3.30 (m, 2H), 3.32-3.39 (m, 2H), 3.39-3.59 (m, 7H), 3.69-3.83 
(m, 2H), 4.22-4.29 (m, 2H), 4.40 (d, 0.6H, J 17 Hz), 4.44 (d, 0.4H, J 17 Hz), 7.24-7.31 (m, 
0.8H), 7.31-7.36 (m, 1.2H), 7.36-7.41 (m, 0.4H), 7.45-7.55 (m, 2.2H), 7.59-7.72 (m, 2H), 
7.72-7.78 (m, 0.4H), 7.90 (dd, 0.6H, J 1.7 7.7 Hz), 7.97 (d, 0.4H, J 7.9 Hz). 13C-NMR (150.9 
MHz, MeOH-d4): δ (ppm) 21.85, 22.54, 23.33, 24.45, 25.09, 25.88, 28.46, 30.39, 32.39, 
34.28, 36.10, 36.20, 41.10, 50.71, 51.35, 53.90, 54.93, 55.08, 55.29, 57.37, 57.74, 57.94, 
58.03, 123.08, 123.65, 126.85, 127.52, 127.87, 128.49, 128.88, 129.44, 130.11, 130.55, 
130.88, 131.21, 131.71, 131.96, 132.35, 133.00, 133.41, 134.58, 134.94, 135.46, 135.72, 
137.03, 141.01, 142.68, 164.97, 165.45, 168.58, 168.83, 173.89, 174.72, 175.52, 177.57. 
HRMS (ESI): m/z [M+H]+ calcd for [C43H64N9O6]+ 802.4980, found 802.4982. RP-HPLC (220 
nm): 97% (tR = 9.6 min, k = 9.4). C43H63N9O6 · C4H2F6O4 (802.03 + 228.04). 
(S)-2-Acetamido-N1-((S)1-(((S)-4-methyl-1-oxo-1-((2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-
dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-1-
yl)ethyl)amino)pentan-2-yl)amino)-1-oxopropan-2-yl)pentanediamide 
tris(hydrotrifluoroacetate) (102) Purification by preparative HPLC (gradient: 0-25 min: 
0.1% aq TFA/acetonitrile 90:10-72:28, tR = 11 min) yielded 102 as a white fluffy solid (25 
mg, 0.021 mmol, 66%). Ratio of configurational isomers evident in the NMR spectra: 1.8:1. 
1H-NMR (600 MHz, MeOH-d4): δ (ppm) 0.91 (d, 3H, J 6.5 Hz), 0.96 (d, 3H, J 6.4 Hz), 1.33-
1.76 (m, 15H), 1.87-1.99 (m, 3H), 2.01 (s, 3H), 2.03-2.12 (m, 1H), 2.34 (t, 2H, J 7.5 Hz), 
2.88-2.98 (m, 1H), 3.00-3.12 (m, 3H), 3.12-3.18 (m, 2H), 3.22-3.30 (m, 2H), 3.32-3.40 (m, 
2H), 3.41-3.57 (m, 7H), 3.68-3.84 (m, 2H), 4.18-4.26 (m, 3H), 4.40 (d, 0.6H, J 17 Hz), 4.44 
(d, 0.4H, J 17 Hz), 7.24-7.31 (m, 0.8H), 7.31-7.36 (m, 1.2H), 7.36-7.40 (m, 0.4H), 7.45-7.55 
(m, 2.2H), 7.60-7.72 (m, 2H), 7.72-7.78 (m, 0.4H), 7.90 (dd, 0.6H, J 1.7 8.0 Hz), 7.97 (d, 
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0.4H, J 8.1 Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ (ppm) 17.28, 21.80, 22.58, 23.33, 
24.47, 25.11, 25.94, 28.27, 30.39, 32.33, 34.29, 36.11, 36.26, 40.95, 50.71, 51.38, 51.73, 
54.02, 54.93, 55.29, 55.37, 57.23, 57.72, 57.94, 58.03, 123.08, 123.65, 126.85, 127.52, 
127.87, 128.48, 128.88, 129.44, 130.11, 130.55, 130.88, 131.21, 131.71, 131.96, 132.35, 
133.01, 133.41, 134.58, 134.94, 135.46, 135.72, 137.03, 141.01, 142.68, 164.97, 165.45, 
168.57, 168.83, 174.05, 174.79, 175.53, 175.93, 177.56. HRMS (ESI): m/z [M+H]+ calcd for 
[C46H69N10O7]+ 873.5351, found 873.5346. RP-HPLC (220 nm): 96% (tR = 10.1 min, k = 
10.0). C46H68N10O7 · C4H2F6O4 (873.11 + 228.04). 
(S)-2-Acetamido-6-amino-N-((S)-3-(4-hydroxyphenyl)-1-oxo-1-((2-(4-(4-(1-(2-oxo-2-
(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-
yl)butyl)piperazin-1-yl)ethyl)amino)propan-2-yl)hexanamide 
tetrakis(hydrotrifluoroacetate) (103) Purification by preparative HPLC (gradient: 0-25 
min: 0.1% aq TFA/acetonitrile 90:10-72:28, tR = 9 min) yielded 103 as a white fluffy solid 
(22 mg, 0.017 mmol, 47%). Ratio of configurational isomers evident in the NMR spectra: 
1.1:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.22-1.76 (m, 16H), 1.86-1.98 (m, 2H), 1.99 
(s, 3H), 2.72-3.16 (m, 14H), 3.32-3.49 (m, 6H), 3.68-3.82 (m, 2H), 4.13-4.17 (m, 1H), 4.37-
4.49 (m, 2H), 6.71 (d, 2H, J 8.5 Hz), 7.04 (d, 2H, J 8.5 Hz), 7.24-7.31 (m, 0.8H), 7.31-7.36 
(m, 1.2H), 7.36-7.40 (m, 0.4H), 7.45-7.55 (m, 2.2H), 7.60-7.71 (m, 2H), 7.73-7.77 (m, 0.4H), 
7.90 (dd, 0.6H, J 1.5 7.7 Hz), 7.97 (d, 0.4H, J 7.9 Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ 
(ppm) 22.56, 23.59, 24.48, 25.11, 28.12, 30.39, 32.01, 34.29, 36.11, 36.65, 37.55, 40.42, 
50.70, 51.93, 54.93, 55.28, 55.37, 56.50, 56.92, 57.73, 58.02, 116.31, 123.08, 123.65, 
126.85, 127.52, 127.88, 128.49, 128.88, 128.96, 129.45, 130.10, 130.54, 130.88, 131.20, 
131.39, 131.70, 131.95, 132.34, 133.00, 133.41, 134.57, 134.94, 135.46, 135.72, 137.02, 
141.00, 142.68, 157.33, 164.96, 165.44, 168.57, 168.83, 173.91, 174.00, 174.24. HRMS 
(ESI): m/z [M+H]+ calcd for [C47H66N9O6]+ 852.5136, found 852.5145. RP-HPLC (220 nm): 
97% (tR = 7.9 min, k = 7.6). C47H65N9O6 · C6H3F9O6 (852.09 + 342.07). 
(S)-2-Acetamido-6-amino-N-((S)-1-(((S)-3-(4-hydroxyphenyl)-1-oxo-1-((2-(4-(4-(1-(2-
oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-
yl)butyl)piperazin-1-yl)ethyl)amino)propan-2-yl)amino)-1-oxopropan-2-
yl)hexanamide tetrakis(hydrotrifluoroacetate) (104) Purification by preparative HPLC 
(gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-72:28, tR = 9 min) yielded 104 as a 
white fluffy solid (27 mg, 0.020 mmol, 54%). Ratio of configurational isomers evident in the 
NMR spectra: 1.7:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.29 (d, 3H, J 7.2 Hz), 1.31-
1.60 (m, 10H), 1.63-1.83 (m, 6H), 1.86-2.00 (m, 2H), 2.02 (s, 3H), 2.73-3.17 (m, 14H), 3.26-
3.50 (m, 6H), 3.66-3.83 (m, 2H), 4.19-4.27 (m, 2H), 4.35-4.47 (m, 2H), 6.70 (d, 2H, J 8.5 
Hz), 7.04 (d, 2H, J 8.5 Hz), 7.24-7.31 (m, 0.8H), 7.31-7.36 (m, 1.2H), 7.36-7.41 (m, 0.4H), 
7.46-7.55 (m, 2.2H), 7.60-7.71 (m, 2H), 7.73-7.78 (m, 0.4H), 7.90 (dd, 0.6H, J 1.4 8.5 Hz), 
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7.97 (d, 0.4H, J 7.8 Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ (ppm) 17.50, 22.55, 23.76, 
24.49, 25.12, 28.13, 30.40, 32.15, 34.30, 36.12, 36.64, 37.65, 40.47, 50.72, 51.11, 51.95, 
54.93, 55.18, 55.29, 56.82, 56.97, 57.34, 58.04, 116.31, 123.09, 123.65, 126.86, 127.52, 
127.87, 128.48, 128.88, 128.91, 129.44, 130.11, 130.55, 130.88, 131.22, 131.26, 131.36, 
131.71, 131.97, 132.35, 133.01, 133.41, 134.58, 134.94, 135.46, 135.72, 137.04, 141.01, 
142.68, 157.38, 164.96, 165.44, 168.58, 168.83, 173.85, 173.88, 174.62, 175.09. HRMS 
(ESI): m/z [M+H]+ calcd for [C50H71N10O7]+ 923.5507, found 923.5505. RP-HPLC (220 nm): 
95% (tR = 8.1 min, k = 7.8). C50H70N10O7 · C6H3F9O6 (924.18 + 342.07). 
(S)-2-((S)-2-Acetamido-3-(4-hydroxyphenyl)propanamido)-6-amino-N-(2-(4-(4-(1-(2-
oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-
yl)butyl)piperazin-1-yl)ethyl)hexanamide tetrakis(hydrotrifluoroacetate) (105) 
Purification by preparative HPLC (gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-72:28, 
tR = 10 min) yielded 105 as a white fluffy solid (23 mg, 0.017 mmol, 49%). Ratio of 
configurational isomers evident in the NMR spectra: 1.3:1. 1H-NMR (600 MHz, MeOH-d4): 
δ (ppm) 1.28-1.74 (m, 15H), 1.80-1.94 (m, 2.5H), 1.95 (s, 3H), 1.96-1.99 (m, 0.5H), 2.83-
3.27 (m, 14H), 3.33-3.51 (m, 6H), 3.68-3.83 (m, 2H), 4.18-4.22 (m, 1H), 4.37-4.47 (m, 2H), 
6.73 (d, 2H, J 8.5 Hz), 7.09 (d, 2H, J 8.5 Hz), 7.24-7.31 (m, 0.8H), 7.31-7.36 (m, 1.2H), 
7.36-7.40 (m, 0.4H), 7.45-7.56 (m, 2.2H), 7.59-7.72 (m, 2H), 7.72-7.78 (m, 0.4H), 7.90 (dd, 
0.6H, J 1.6 8.2 Hz), 7.97 (d, 0.4H, J 7.8 Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ (ppm) 
22.42, 23.70, 24.46, 25.07, 27.94, 30.38, 31.82, 34.29, 36.09, 36.45, 37.64, 40.45, 50.73, 
51.67, 54.68, 54.93, 55.28, 57.11, 57.36, 57.23, 58.03, 116.37, 123.65, 126.85, 127.52, 
127.88, 128.49, 128.73, 128.88, 129.45, 130.10, 130.54. 130.88, 131.21, 121.38, 131.70, 
131.95, 132.34, 133.00, 133.41, 134.57, 134.94, 135.46, 135.71, 137.02, 141.00, 142.68, 
157.43, 164.96, 165.44, 168.58, 168.83, 173.74, 174.37, 174.62. HRMS (ESI): m/z 
[M+3H]3+ calcd for [C47H68N9O6]3+ 284.8431, found 284.8434. RP-HPLC (220 nm): 98% (tR 
= 8.2 min, k = 7.9). C47H65N9O6 · C6H3F9O6 (852.09 + 342.07). 
(S)-2-((S)-2-((S)-2-Acetamido-3-(4-hydroxyphenyl)propanamido)propanamido)-6-
amino-N-(2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-
yl)ethyl)piperidin-4-yl)butyl)piperazin-1-yl)ethyl)hexanamide 
tetrakis(hydrotrifluoroacetate) (106) Purification by preparative HPLC (gradient: 0-25 
min: 0.1% aq TFA/acetonitrile 90:10-72:28, tR = 10 min) yielded 106 as a white fluffy solid 
(28 mg, 0.020 mmol, 56%). Ratio of configurational isomers evident in the NMR spectra: 
1.6:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.30-1.36 (m, 4H), 1.37 (d, 3H, J 7.2 Hz), 
1.39-1.58 (m, 6H), 1.64-1.79 (m, 5H), 1.82-1.94 (m, 2.5H), 1.95 (s, 3H), 1.96-1.98 (m, 0.5H), 
2.85-3.22 (m, 14H), 3.34-3.56 (m, 6H), 3.69-3.83 (m, 2H), 4.16-4.22 (m, 2H), 4.35-4.47 (m, 
2H), 6.71 (d, 2H J 8.5 Hz), 7.06 (d, 2H, J 8.5 Hz), 7.24-7.31 (m, 0.8H), 7.31-7.36 (m, 1.2H), 
7.36-7.41 (m, 0.4H), 7.45-7.55 (m, 2.2H), 7.61-7.71 (m, 2H), 7.73-7.78 (m, 0.4H), 7.90 (dd, 
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0.6H, J 1.5 8.2 Hz), 7.97 (d, 0.4H, J 7.9 Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ (ppm) 
17.14 22.55, 23.82, 24.50, 25.17, 27.97, 30.40, 31.69, 34.31, 36.13, 36.43, 37.61, 40.45, 
50.76, 51.59, 51.70, 54.93, 55.14, 55.29, 56.93, 57.66, 57.77, 58.03, 116.31, 123.08, 
123.65, 126.86, 127.52, 127.87, 128.48, 128.75, 128.88, 129.44, 130.11, 130.55, 130.88, 
131.22, 131.28, 131.71, 131.97, 132.35, 133.01, 133.41, 134.57, 134.94, 135.46, 135.72, 
137.04, 141.01, 142.68, 157.44, 164.96, 165.44, 168.59, 168.83, 173.94, 174.66, 174.78, 
175.65. HRMS (ESI): m/z [M+3H]3+ calcd for [C50H73N10O7]3+ 308.5221, found 308.5224. 
RP-HPLC (220 nm): 98% (tR = 8.3 min, k = 8.0). C50H70N10O7 · C6H3F9O6 (923.17 + 342.07). 
(S)-2-Acetamido-6-amino-N-((S)-5-guanidino-1-oxo-1-((2-(4-(4-(1-(2-oxo-2-(11-oxo-
10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-
1-yl)ethyl)amino)pentan-2-yl)hexanamide pentakis(hydrotrifluoroacetate) (107) 
Purification by preparative HPLC (gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-78:22, 
tR = 8 min) yielded 107 as a white fluffy solid (27 mg, 0.019 mmol, 53%). Ratio of 
configurational isomers evident in the NMR spectra: 1.8:1. 1H-NMR (600 MHz, MeOH-d4): 
δ (ppm) 1.30-1.77 (m, 18H), 1.78-1.99 (m, 4H), 2.00 (s, 3H), 2.84-2.98 (m, 5H), 2.99-3.26 
(m, 9H), 3.35-3.50 (m, 6H), 3.69-3.83 (m, 2H), 4.20-4.24 (m, 1H), 4.27-4.31 (m, 1H), 4.40 
(d, 0.6H, J 17 Hz), 4.44 (d, 0.4H, J 17 Hz), 7.24-7.31 (m, 0.8H), 7.32-7.36 (m, 1.2H), 7.37-
7.41 (m, 0.4H), 7.46-7.55 (m, 2.2H), 7.61-7.71 (m, 2H), 7.73-7.78 (m, 0.4H), 7.90 (dd, 0.6H, 
J 1.6 8.0 Hz), 7.97 (m, 0.4H, J 8.0 Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ (ppm) 22.49, 
23.89, 24.49, 25.14, 26.37, 28.09, 29.89, 30.39, 32.02, 34.30, 36.12, 36.69, 40.46, 41.89, 
50.79, 51.92, 54.47, 54.93, 55.28, 55.35, 57.08, 57.73, 58.03, 123.08, 123.65, 126.85, 
127.52, 127.88, 128.49, 128.88, 129.45, 130.10, 130.55, 130.88, 131.21, 131.71, 131.96, 
132.34, 133.00, 133.41, 134.57, 134.94, 135.46, 135.72, 137.03, 141.01, 142.68, 158.67, 
164.96, 165.45, 168.58, 168.83, 173.93, 174.29, 174.83. HRMS (ESI): m/z [M+3H]3+ calcd 
for [C44H71N12O5]3+ 282.5223, found 282.5232. RP-HPLC (220 nm): 98% (tR = 5.9 min, k = 
5.4). C44H68N12O5 · C8H4F12O8 (845.11 + 456.09). 
(S)-2-Acetamido-6-amino-N-((S)-1-(((S)-5-guanidino-1-oxo-1-((2-(4-(4-(1-(2-oxo-2-(11-
oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-
yl)butyl)piperazin-1-yl)ethyl)amino)pentan-2-yl)amino)-1-oxopropan-2-
yl)hexanamide pentakis(hydrotrifluoroacetate) (108) Purification by preparative HPLC 
(gradient: 0-25 min: 0.1% aq TFA/acetonitrile 90:10-78:22, tR = 8 min) yielded 108 as a 
white fluffy solid (35 mg, 0.023 mmol, 65%). Ratio of configurational isomers evident in the 
NMR spectra: 1.8:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.31-1.57 (m, 12H), 1.58-1.99 
(m, 13H), 2.01 (s, 3H), 2.84-2.97 (m, 5H), 3.00-3.25 (m, 9H), 3.35-3.53 (m, 6H), 3.68-3.83 
(m, 2H), 4.18-4.22 (m, 1H), 4.23-4.30 (m, 2H), 4.40 (d, 0.6H, J 17 Hz), 4.44 (d, 0.4H, J 17 
Hz), 7.23-7.31 (m, 0.8H), 7.32-7.36 (m, 1.2H), 7.36-7.41 (m, 0.4H), 7.45-7.55 (m, 2.2H), 
7.61-7.71 (m, 2H), 7.73-7.78 (m, 0.4H), 7.90 (dd, 0.6H, J 1.7 7.6 Hz), 7.97 (d, 0.4H, J 7.9 
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Hz). 13C-NMR (150.9 MHz, MeOH-d4): δ (ppm) 17.34, 22.57, 23.83, 24.50, 25.16, 26.31, 
28.14, 29.72, 30.40, 32.04, 34.31, 36.14, 36.71, 40.44, 41.90, 50.81, 51.25, 52.00, 54.68, 
54.92, 55.29, 55.51, 57.06, 57.74, 58.03, 123.09, 123.65, 126.86, 127.52, 127.87, 128.48, 
128.88, 129.44, 130.11, 130.55, 130.88, 131.21, 131.71, 131.97, 132.35, 133.01, 133.42, 
134.58, 134.94, 135.46, 135.72, 137.04, 141.01, 142.68, 158.67, 164.96, 165.44, 168.58, 
168.84, 174.09, 174.28, 174.84, 175.56. HRMS (ESI): m/z [M+3H]3+ calcd for 
[C47H76N13O6]3+ 306.2014, found 306.2017. RP-HPLC (220 nm): 98% (tR = 5.9 min, k = 5.4). 
C47H73N13O6 · C8H4F12O8 (916.19 + 456.09). 
 
4.4.4 Cell Culture  
CHO-K9 cell lines stably expressing the human M1-M5 muscarinic receptors were obtained 
from the Missouri S&T cDNA Resource Center (Rolla, MO). Cells were cultured in HAM’s 
F12 medium supplemented with fetal calf serum (Biochrom, Berlin, Germany) (10%) and 
G418 (Biochrom) (750 µg/mL).  
 
4.4.5 Radioligand competition binding  
Radioligand competition binding experiments at live CHO-hMxR cells (x = 1-5) were 
performed in white 96-well plates with clear bottom (Corning Life Sciences, Tewksbury, MA; 
Corning cat. no. 3610) at 23 ± 1 °C using the protocol of previously described MR binding 
studies with [3H]NMS.23 Leibovitz L-15 medium (Gibco, Life Technologies GmbH, 
Darmstadt, Germany) supplemented with 1% BSA (Serva, Heidelberg, Germany) was used 
as binding buffer. The concentration of [3H]NMS was 0.2 nM (M1, M2, M3), 0.1 nM (M4) or 
0.3 nM (M5) and the incubation time was 3 h throughout. Unspecific binding was determined 
in the presence of atropine (2) (500-fold excess to [3H]NMS).  
 
4.4.6 Data processing  
Total binding data (DPM) from radioligand competition binding experiments (determination 
of the effect of compounds 85 and 87-108 on the equilibrium binding of [3H]NMS) were 
plotted against log(concentration competitor) and analyzed by a four-parameter logistic 
equation (log(inhibitor) vs. response-variable slope) (GraphPad Prism Software 6.0, 
GraphPad Software, San Diego, CA) followed by normalization (100% = ‘top’ of the four-
parameter logistic fit, 0% = unspecifically bound radioligand (DPM) determined in the 
presence of 2) and analysis of the normalized data by a four-parameter logistic equation 
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fused to the Cheng-Prusoff equation (logarithmic form) (equation 1) to obtain pIC50 and pKi 
values. 
 
(equation 1) 
 
𝑌 =
𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚
1 + 10(𝐿𝑜𝑔𝐼𝐶50−𝑋)∗𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒
+  𝐵𝑜𝑡𝑡𝑜𝑚 
𝑙𝑜𝑔𝐼𝐶50 = log (10𝑙𝑜𝑔𝐾𝑖 ∗ (1 +
𝐻𝑜𝑡𝑁𝑀
𝐻𝑜𝑡𝐾𝑑𝑁𝑀
)) 
 
HotNM = radioligand concentration in nM, HotKdNM = Dissociation constant (Kd) of the 
radioligand in nM. 
  
  
DIBA-peptide conjugates 
149 
4.5. References 
(1) Eglen, R. M. Overview of muscarinic receptor subtypes. Handb. Exp. Pharmacol. 
2012, 3-28. 
(2) Gregory, K. J.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of muscarinic 
acetylcholine receptors. Curr. Neuropharmacol. 2007, 5, 157-167. 
(3) Eglen, R. M.; Choppin, A.; Watson, N. Therapeutic opportunities from muscarinic 
receptor research. Trends Pharmacol. Sci. 2001, 22, 409-414. 
(4) Sheardown, M. J. Muscarinic M1receptor agonists and M2 receptor antagonists as 
therapeutic targets in Alzheimer’s disease. Expert Opin. Ther. Pat. 2002, 12, 863-870. 
(5) Clader, J. W.; Wang, Y. Muscarinic receptor agonists and antagonists in the 
treatment of Alzheimer's disease. Curr. Pharm. Des. 2005, 11, 3353-3361. 
(6) Citron, M. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug 
Discovery 2010, 9, 387-398. 
(7) Kruse, A. C.; Ring, A. M.; Manglik, A.; Hu, J.; Hu, K.; Eitel, K.; Hubner, H.; Pardon, 
E.; Valant, C.; Sexton, P. M.; Christopoulos, A.; Felder, C. C.; Gmeiner, P.; Steyaert, J.; 
Weis, W. I.; Garcia, K. C.; Wess, J.; Kobilka, B. K. Activation and allosteric modulation of a 
muscarinic acetylcholine receptor. Nature 2013, 504, 101-106. 
(8) Teller, H.; Straub, A.; Brechmann, M.; Mueller, T.; Meininghaus, M.; Nowak-Reppel, 
K.; Tinel, H.; Muenter, K.; Fliegner, D.; Mondritzki, T.; Boultadakis Arapinis, M.; Marquardt, 
T.; Vakalopoulos, A.; Rebstock, A.-S.; Wittwer, M. Naphthyridinecarboxamides as positive 
allosteric modulators of muscarinic M2 receptor and their preparation. 2016-EP62737 
2016198342, 20160606., 2016. 
(9) Miao, Y.; Goldfeld, D. A.; Von Moo, E.; Sexton, P. M.; Christopoulos, A.; 
McCammon, J. A.; Valant, C. Accelerated structure-based design of chemically diverse 
allosteric modulators of a muscarinic G protein-coupled receptor. Proc. Natl. Acad. Sci. U. 
S. A. 2016, 113, E5675-E5684. 
(10) Kruse, A. C.; Kobilka, B. K.; Gautam, D.; Sexton, P. M.; Christopoulos, A.; Wess, J. 
Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat. Rev. 
Drug Discovery 2014, 13, 549-560. 
(11) Birdsall, N. J. M.; Lazareno, S. Allosterism at muscarinic receptors: ligands and 
mechanisms. Mini-Rev. Med. Chem. 2005, 5, 523-543. 
(12) Antony, J.; Kellershohn, K.; Mohr-Andra, M.; Kebig, A.; Prilla, S.; Muth, M.; Heller, 
E.; Disingrini, T.; Dallanoce, C.; Bertoni, S.; Schrobang, J.; Trankle, C.; Kostenis, E.; 
Christopoulos, A.; Holtje, H. D.; Barocelli, E.; De Amici, M.; Holzgrabe, U.; Mohr, K. 
Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. 
FASEB J. 2009, 23, 442-450. 
Chapter 4 
150 
(13) De Amici, M.; Dallanoce, C.; Holzgrabe, U.; Trankle, C.; Mohr, K. Allosteric ligands 
for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities. 
Med. Res. Rev. 2010, 30, 463-549. 
(14) Valant, C.; Robert Lane, J.; Sexton, P. M.; Christopoulos, A. The best of both 
worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. Annu. Rev. 
Pharmacool. Toxicol. 2012, 52, 153-178. 
(15) Lane, J. R.; Sexton, P. M.; Christopoulos, A. Bridging the gap: bitopic ligands of G-
protein-coupled receptors. Trends Pharmacol. Sci. 2013, 34, 59-66. 
(16) Christopoulos, A. Advances in G protein-coupled receptor allostery: from function to 
structure. Mol. Pharmacol. 2014, 86, 463-478. 
(17) Gitler, M. S.; Reba, R. C.; Cohen, V. I.; Rzeszotarski, W. J.; Baumgold, J. A novel 
M2-selective muscarinic antagonist: binding characteristics and autoradiographic 
distribution in rat brain. Brain Res. 1992, 582, 253-260. 
(18) Martin, J.; Deagostino, A.; Perrio, C.; Dauphin, F.; Ducandas, C.; Morin, C.; 
Desbene, P. L.; Lasne, M. C. Syntheses of R and S isomers of AF-DX 384, a selective 
antagonist of muscarinic M2 receptors. Bioorg. Med. Chem. 2000, 8, 591-600. 
(19) Keller, M.; Trankle, C.; She, X.; Pegoli, A.; Bernhardt, G.; Buschauer, A.; Read, R. 
W. M2 Subtype preferring dibenzodiazepinone-type muscarinic receptor ligands: Effect of 
chemical homo-dimerization on orthosteric (and allosteric?) binding. Bioorg Med Chem 
2015, 23, 3970-3990. 
(20) Chiarini, A.; Burdriesi, R.; Bolognsei, M. L.; Minarini, A.; Melchiorre, C. In vitro 
characterization of tripitramine, a polymethylene tetraamine displaying high selectivity and 
affinity for muscarinic M2 receptors. Br. J. Pharmacol. 1995, 114, 1507-1517. 
(21) Trankle, C.; Andresen, I.; Lambrecht, G.; Mohr, K. M2 receptor binding of the 
selective antagonist AF-DX 384: possible involvement of the common allosteric site. Mol. 
Pharmacol. 1998, 53, 304-312. 
(22) Doerje, F.; Wess, J.; Lambrecht, G.; Tacke, R.; Mutschler, E.; Brann, M. R. 
Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J. 
Pharmacol. Exp. Ther. 1991, 256, 727-733. 
(23) Keller, M.; Trankle, C.; She, X.; Pegoli, A.; Bernhardt, G.; Buschauer, A.; Read, R. 
W. M2 Subtype preferring dibenzodiazepinone-type muscarinic receptor ligands: Effect of 
chemical homo-dimerization on orthosteric (and allosteric?) binding. Bioorg. Med. Chem. 
2015, 23, 3970-3990. 
(24) Doods, H. N.; Quirion, R.; Mihm, G.; Engel, W.; Rudolf, K.; Entzeroth, M.; Schiavi, 
G. B.; Ladinsky, H.; Bechtel, W. D.; et al. Therapeutic potential of CNS-active M2 
antagonists: novel structures and pharmacology. Life Sci. 1993, 52, 497-503. 
DIBA-peptide conjugates 
151 
(25) Maggio, R.; Barbier, P.; Bolognesi, M. L.; Minarini, A.; Tedeschi, D.; Melchiorre, C. 
Binding profile of the selective muscarinic receptor antagonist tripitramine. Eur. J. 
Pharmacol. 1994, 268, 459-462. 
(26) McCombie, S. W.; Lin, S. I.; Tagat, J. R.; Nazareno, D.; Vice, S.; Ford, J.; Asberom, 
T.; Leone, D.; Kozlowski, J. A.; Zhou, G.; Ruperto, V. B.; Duffy, R. A.; Lachowicz, J. E. 
Synthesis and structure-activity relationships of M(2)-selective muscarinic receptor ligands 
in the 1-[4-(4-arylsulfonyl)-phenylmethyl]-4-(4-piperidinyl)-piperazine family. Bioorg. Med. 
Chem. Lett. 2002, 12, 795-798. 
(27) Bohme, T. M.; Keim, C.; Kreutzmann, K.; Linder, M.; Dingermann, T.; Dannhardt, 
G.; Mutschler, E.; Lambrecht, G. Structure-activity relationships of dimethindene derivatives 
as new M2-selective muscarinic receptor antagonists. J. Med. Chem. 2003, 46, 856-867. 
(28) She, X. Synthesis and pharmacological characterization of dibenzodiazepinone-
type heterodimeric and fluorescently labeled muscarinic receptor ligands. Doctoral thesis, 
University of Regensburg, Regensburg, Germany, 2017. 
(29) Keller, M.; Kuhn, K. K.; Einsiedel, J.; Hubner, H.; Biselli, S.; Mollereau, C.; Wifling, 
D.; Svobodova, J.; Bernhardt, G.; Cabrele, C.; Vanderheyden, P. M.; Gmeiner, P.; 
Buschauer, A. Mimicking of Arginine by Functionalized N(omega)-Carbamoylated Arginine 
As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity 
Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As 
Examples. J Med Chem 2016, 59, 1925-1945. 
(30) Joullie, M. M.; Lassen, K. M. Evolution of amide bond formation. ARKIVOC 
(Gainesville, FL, United States) 2010, 189-250. 
(31) Haga, K.; Kruse, A. C.; Asada, H.; Yurugi-Kobayashi, T.; Shiroishi, M.; Zhang, C.; 
Weis, W. I.; Okada, T.; Kobilka, B. K.; Haga, T.; Kobayashi, T. Structure of the human M2 
muscarinic acetylcholine receptor bound to an antagonist. Nature 2012, 482, 547-551. 
(32) Dror, R. O.; Green, H. F.; Valant, C.; Borhani, D. W.; Valcourt, J. R.; Pan, A. C.; 
Arlow, D. H.; Canals, M.; Lane, J. R.; Rahmani, R.; Baell, J. B.; Sexton, P. M.; Christopoulos, 
A.; Shaw, D. E. Structural basis for modulation of a G-protein-coupled receptor by allosteric 
drugs. Nature 2013, 503, 295-299. 
(33) Birdsall, N. J. M.; Brown, D. A.; Buckley, N. J.; Christopoulos, A.; Eglen, R. M.; 
Ehlert, F.; Hammer, R.; Kilbinger, H. J.; Lambrecht, G.; Mitchelson, F.; Mutschler, E.; 
Nathanson, N. M.; Schwarz, R. D.; Tobin, A. B.; Wess, J. Acetylcholine receptors 
(muscarinic): M2 receptor. 
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=14. 
(Accessed on 13/03/2017).
 152 
 
 
 
 153 
 
Chapter 5 
Summary
Chapter 5 
154 
In humans, the family of muscarinic acetylcholine receptors (mAChR, MRs) comprises five subtypes 
(M1R-M5R), which are members of the class A GPCR superfamily and mediate the action of the 
neurotransmitter acetylcholine in the central and peripheral nervous system. For instance, the M2R, 
which binds to Gi/o heterotrimeric G-proteins, acts as a presynaptic autoreceptor in the brain and in 
the periphery. Accordingly, selective M2R antagonism in the CNS results in an enhanced cholinergic 
transmission, representing a potential therapeutic approach to increase cholinergic function in 
Alzheimer patients. The development of high affinity and selective MR ligands has been hampered 
by the high conservation of the orthosteric (acetylcholine) binding site within the five MR subtypes. 
Therefore, highly selective molecular tools and therapeutic agents, acting at MRs, are lacking. MRs 
possess various accessory (allosteric) binding sites, which are less conserved. This prompted the 
design of numerous allosteric MR ligands. However, allosteric modulators with high MR affinity (Ki < 
0.1 µM) are not described to date. The dualsteric ligand approach, that means, the design of ligands, 
which simultaneously bind to the orthosteric pocket and an allosteric site, was suggested as a 
promising strategy to develop high-affinity and highly selective MR ligands. 
In order to investigate the binding mode of dibenzodiazepinone-type MR antagonists at the M2R, 
three radiolabeled compounds, a monomeric ([3H]19) and two homodimeric ([3H]33, [3H]47) 
derivatives, were prepared. The results from various detailed experiments performed with [3H]19 and 
[3H]33, in particular saturation binding studies in the absence and in the presence of reported 
allosteric M2R ligands, strongly suggested that the studied type of M2R antagonists bind 
dualsterically to the M2R, interacting simultaneously with both, the orthosteric and the ‘common’ 
allosteric binding site. The results from molecuclar dynamics (MD) simulations, performed with the 
M2R (inactive state) bound to 19 or 33, were consistent with the conclusions drawn from radioligand 
binding studies. Interestingly, the homodimeric ligand 33, in contrast to the monomeric ligand 19, 
showed a long residence time at the M2R, which might be attributed, as also suggested by MD 
simulations, to additional contacts of 33 with amino acids constituting the allosteric vestibule. 
Moreover, five fluorescently labeled dibenzodiazepinone-type MR ligands (including two 
homodimeric and one heterodimeric derivative) were prepared using red-emitting cyanine dyes. 
Equilibrium competition binding studies with the orthosteric antagonist [3H]NMS revealed high M2R 
affinities for all fluorescent ligands (pKi = 8.85-9.59). Flow cytometric and high-content imaging-
based binding experiments with a monomeric (62) and a homodimeric (64) fluorescent ligand in the 
presence of the reported allosteric modulator W84 (8) suggested that the fluorescent 
dibenzodiazepinone-type MR ligands bind dualsterically to the M2R, as also concluded for the tritium-
labeled analogs [3H]19 and [3H]33. Confocal microscopy with 62 and 64 at CHO-hM2R cells revealed 
that binding of the fluorescent probes occurred mainly at the cell membrane, and an increase of 
intracellular fluorescence was not observed with increasing incubation time. 
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Finally, aiming at MR ligands with improved M2R selectivity, the dibenzodiazepinone pharmacophore 
was conjugated to several di- and tripeptides via two different linkers yielding a series of non-
peptide/peptide hybrid ligands (DIBA-peptide conjugates). The affinity and the selectivity profile of 
these compounds was assessed by radioligand competition binding at CHO-hMxR cells (x = 1-5) 
using [3H]NMS. The introduction of two basic amino acids (Arg, Lys) yielded the DIBA-peptide 
conjugates with the highest M2R selectivity (compound 96 (aliphatic linker, peptide sequence Lys-
Arg): Ki M1R:M2R:M3R:M4R:M5R = 58:1:6900:99:300; compound 108 (basic linker, peptide sequence 
Lys-Ala-Arg): Ki M1R:M2R:M3R:M4R:M5R = 49:1:1800:70:3500). The DIBA-peptide conjugates 96 
and 108 represent the most selective M2R antagonists reported to date with M2R binding constants 
in the low nanomolar (96, pKi = 9.00) and in the picomolar (108, pKi = 10.21) range. Thus, this new 
class of compounds represents a valuable basis for the development of high affinity and highly 
selective M2R antagonists. 
Taken together, the present work afforded new radio- and fluorescence labeled molecular tools, 
which bind with high affinity to the M2R. Moreover, the conjugation of the dibenzodiazepinone 
pharmacophore to short peptides yielded high affinity M2R ligands with improved M2R selectivity 
compared to previously reported M2 subtype preferring MR ligands. 
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6.1 NMR spectra 
 
1H-NMR spectrum (600 MHz, MeOH-d4) of compound 31. 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 31. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 33. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 33. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 46. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 46. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 47. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 47. 
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1H-NMR spectrum (400 MHz, MeOH-d4) of compound 50. 
 
 
 
13C-NMR spectrum (100 MHz, MeOH-d4) of compound 50. 
Appendix 
163 
 
1H-NMR spectrum (600 MHz, MeOH-d4) of compound 52. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 52. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 85. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 85 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 87. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 87. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 88. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 88. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 89. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 89. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 90. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 90. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 91. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 91. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 92. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 92 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 93. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 93. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 94 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 94. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 95. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 95. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 96. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 96. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 97. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 97. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 98. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 98. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 99. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 99. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 100. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 100. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 101 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 101. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 102. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 102. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 103. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 103. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 104. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 104. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 105. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 105. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 106. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 106. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 107. 
 
 
13C-NMR spectrum (150 MHz, MeOH-d4) of compound 107. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 108. 
 
 
1H-NMR spectrum (600 MHz, MeOH-d4) of compound 108.  
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6.2 Chromatograms 
6.2.1 Chapter 2 
 
 
RP-HPLC analysis (purity control) of 31 (A), 33 (B), 46 (C), 47 (D), 50, (E) and 52 (F). 
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6.2.2 Chapter 3 
 
 
RP-HPLC analysis (purity control) of 61 (A), 62 (B), 63 (C), 64 (D), 65, (E). 
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6.2.3  Chapter 4 
 
 
RP-HPLC analysis (purity control) of 98 (A), 99 (B), 100 (C), 101 (D), 102, (E) and 103 (F) 
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RP-HPLC analysis (purity control) of 92 (A), 93 (B), 94 (C), 95 (D), 96, (E) and 97 (F) 
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RP-HPLC analysis (purity control) of 98 (A), 99 (B), 100 (C), 101 (D), 102, (E) and 103 (F) 
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RP-HPLC analysis (purity control) of 104 (A), 105 (B), 106 (C), 107 (D), 108 (E). 
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6.3 Abbreviations 
α  cooperativity factor 
AA  amino acid(s) 
aq.  aqueous 
atm  atmoshpere 
BBB  blood brain barrier 
Bmax  maximum number of binding sites 
Boc  tert-butoxycarbonyl 
Bq  Becquerel 
bs  broad singulet 
BSA  bovine serum albumin 
tBu  tert-butyl 
c  concentration 
CH2Cl2  methylene chloride 
(CH3)2S.BH3 borane dimethyl sulfide complex 
CHO  chinese hamster ovary 
Ci  curie 
CI  chemical ionization 
CNS  central nervous system 
CMAP  (grid-based) correction map 
COSY  correlated spectroscopy 
d  doublet 
δ  chemical shift 
CBr4  tetrabromomethane 
CDCl3  deuterated chloroform 
DAPI  4',6-diamino-2-phenylindole 
DIPEA  N,N-diisopropyl-ethylamine 
DMF  N,N-dimethylformamide 
DMSO  dimethylsulfoxide 
DMSO-d6 per-deuterated dimethylsulfoxide 
DPM  disintegration per minute 
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dr  diastereomeric ratio 
EC50  agonist concentration which induces 50% of the maximum response 
EGFP  enhanced green fluorescent protein 
EI  electron impact ionization 
EtOAc  ethyl acetate 
EtOH  ethanol 
eq.  equivalent(s) 
ESI  electrospray ionization 
FACS  fluorescence activated cell sorter 
FCS  fetal calf serum 
Fmoc  9-fluorenylmethoxycarbonyl 
GPCR  G-protein coupled receptor 
h  hour(s) 
HBSS  Hanks’ balanced salt solution 
HBTU  2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
HMBC  heteronuclear multiple bond correlation 
HOBt  1-hydroxybenzotriazole (monohydrate) 
HR-MS high resolution mass spectrometry 
HSQC  heteronuclear multiple bond correlation 
IC50  inhibitor/antagonist concentration which suppresses 50 % of an agonist 
induced effect or displaces 50 % of a labeled ligand from the binding site 
IP1  inositol monophosphate 
J  coupling constant 
k  retention (capacity) factor 
K2CO3  potassium carbonate 
Kb  dissociation constant derived from functional assay 
Kd  dissociation constant derived from saturation experiments 
Ki  dissociation constant derived from competition binding assay 
LiAlH4  lithiumaluminium hydride 
Kobs  observed/macroscopic association rate constant 
Koff  dissociation rate constant 
Kon  association rate constant 
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m  multiplet 
M  molar (mol/L) 
MeOH  methanol 
MeCN  acetonitrile 
MeOH-d4 per-deuterated methanol 
mol  mole(s) 
mp  melting point 
MRs  muscarinic receptors 
Mx  muscarinic receptors subtypes, n = 1, 2, 3, 4, 5 
NaN3  sodium azide 
Net3  triethylamine 
NHS  N-hydroxysuccinimide 
NPT  constant number of particles, pressure and temperature 
NVT  constant number of particles, volume and temperature 
PBS  phosphate buffer saline 
Pd/C  palladium on carbon 
PE  petroleum ether 
pIC50  negative logarithm of the IC50 in M 
pKd  negative logarithm of the Kd in M 
pKd  negative logarithm of the Ki in M 
PNS  peripheral nervous system 
Ph  phenyl 
POPC  palmitoyloleoylphosphatidylcholine 
ppm  parts per million 
q  quartet 
RP  reverse-phase 
rt  room temperature 
s  (1) singulet, (2) second(s) 
sat.  saturated 
SEM  standard error of the mean 
SOCl2  thionyl chloride 
t  (1) time, (2) triplet 
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t0  hold-up time (also referred as dead time) 
TBTU  2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate 
TFA  trifluoroacetic acid 
TLC  thin-layer chromatography 
TM  transmembrane 
THF  tetrahydrofurane 
tR  retention time 
UV  ultraviolet 
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